	data source	chemical name	disease name	gene symbol	variant	label
0	civic	Daunorubicin	Acute Myeloid Leukemia	DNMT3A	R882	Resistance
1	civic	Selumetinib	Melanoma	MAP2K1	P124S	Resistance
2	civic	Selumetinib	Melanoma	MAP2K1	Q56P	Resistance
3	civic	Vemurafenib	Melanoma	NRAS	Q61	Resistance
4	civic	Imatinib	Gastrointestinal Stromal Tumor	PDGFRA	D842V	Resistance
5	civic	Imatinib	Gastrointestinal Stromal Tumor	PDGFRA	D842V	Resistance
6	civic	Sorafenib	Lung Non-small Cell Carcinoma	ARAF	S214C	Sensitivity/Response
7	civic	Idarubicin	Acute Myeloid Leukemia	DNMT3A	R882	Sensitivity/Response
8	civic	Peginterferon Alfa-2b	Polycythemia Vera	JAK2	V617F	Sensitivity/Response
9	civic	Fedratinib	Polycythemia Vera	JAK2	V617F	Sensitivity/Response
10	civic	Tanespimycin	Melanoma	NRAS	G13D	Sensitivity/Response
11	civic	Temozolomide	Melanoma	NRAS	Q61L	Sensitivity/Response
12	civic	Temozolomide	Melanoma	NRAS	Q61R	Sensitivity/Response
13	civic	Crizotinib	Inflammatory Myofibroblastic Tumor	ALK	F1174L	Resistance
14	civic	Crizotinib	Lung Non-small Cell Carcinoma	ALK	F1174L	Resistance
15	civic	Sorafenib,Imatinib,Nilotinib	Melanoma	KIT	L576P	Resistance
16	civic	Erlotinib,Gefitinib	Lung Non-small Cell Carcinoma	KRAS	G12/G13	Resistance
17	civic	Chemotherapy,Cetuximab	Colorectal Cancer	NRAS	Q61	Resistance
18	civic	Alectinib	Neuroblastoma	ALK	F1174L	Sensitivity/Response
19	civic	Crizotinib	Neuroblastoma	ALK	F1174L	Sensitivity/Response
20	civic	TAE684	Neuroblastoma	ALK	R1275Q	Sensitivity/Response
21	civic	Sorafenib	Lung Non-small Cell Carcinoma	ARAF	S214C	Sensitivity/Response
22	civic	Trametinib	Lung Non-small Cell Carcinoma	ARAF	S214C	Sensitivity/Response
23	civic	Dasatinib	Melanoma	KIT	L576P	Sensitivity/Response
24	civic	Crenolanib	Gastrointestinal Stromal Tumor	PDGFRA	D842I	Sensitivity/Response
25	civic	Crenolanib	Gastrointestinal Stromal Tumor	PDGFRA	D842V	Sensitivity/Response
26	civic	Crenolanib	Gastrointestinal Stromal Tumor	PDGFRA	D842Y	Sensitivity/Response
27	civic	Crenolanib	Gastrointestinal Stromal Tumor	PDGFRA	I843DEL	Sensitivity/Response
28	civic	Crenolanib	Gastrointestinal Stromal Tumor	PDGFRA	D842_I843delinsVM	Sensitivity/Response
29	civic	TAE684	Neuroblastoma	ALK	R1275Q	Resistance
30	civic	Imatinib	Melanoma	KIT	Exon 11 Mutation	Sensitivity/Response
31	civic	Motesanib	Thyroid Gland Medullary Carcinoma	RET	C634W	Resistance
32	civic	Motesanib	Thyroid Gland Medullary Carcinoma	RET	M918T	Resistance
33	civic	JAK2 Inhibitor AZD1480	Thyroid Gland Medullary Carcinoma	RET	M918T	Sensitivity/Response
34	civic	Regorafenib	Colorectal Cancer	PIK3CA	E542K	Resistance
35	civic	Trametinib,Mirdametinib	Melanoma	BRAF	V600E	Resistance
36	civic	Regorafenib	Colorectal Cancer	KRAS	Exon 2 Mutation	Sensitivity/Response
37	civic	Panitumumab	Colorectal Cancer	BRAF	V600	Resistance
38	civic	Panitumumab,Sorafenib	Colorectal Cancer	BRAF	V600E	Sensitivity/Response
39	civic	Vemurafenib	Melanoma	BRAF	V600E	Resistance
40	civic	Dabrafenib	Lung Non-small Cell Carcinoma	BRAF	V600E	Resistance
41	civic	Dabrafenib,Trametinib	Melanoma	BRAF	V600	Sensitivity/Response
42	civic	Dabrafenib	Melanoma	BRAF	V600D	Sensitivity/Response
43	civic	Dabrafenib,Trametinib	Melanoma	BRAF	V600E	Sensitivity/Response
44	civic	PLX4720,Pictilisib Bismesylate	Colorectal Cancer	BRAF	V600E	Sensitivity/Response
45	civic	Nutlin-3,PLX4720	Colorectal Cancer	BRAF	V600E	Sensitivity/Response
46	civic	Bevacizumab,Vemurafenib,Capecitabine	Colorectal Cancer	BRAF	V600E	Sensitivity/Response
47	civic	Vemurafenib	Colorectal Cancer	BRAF	V600E	Sensitivity/Response
48	civic	Tretinoin	Acute Myeloid Leukemia	CEBPA	Mutation	Sensitivity/Response
49	civic	Chemotherapy,Cetuximab	Colorectal Cancer	PIK3CA	Exon 10 Mutation	Resistance
50	civic	Cetuximab	Colorectal Cancer	NRAS	Q61	Resistance
51	civic	Crizotinib	Neuroblastoma	ALK	F1174L	Resistance
52	civic	Cetuximab	Colorectal Cancer	BRAF	V600E	Resistance
53	civic	Tretinoin	Acute Myeloid Leukemia	FLT3	ITD	Resistance
54	civic	Daunorubicin	Acute Myeloid Leukemia	FLT3	ITD	Resistance
55	civic	SU5614	Acute Myeloid Leukemia	FLT3	ITD	Resistance
56	civic	Chemotherapy,Cetuximab	Colorectal Cancer	KRAS	G12/G13	Resistance
57	civic	Cetuximab	Colorectal Cancer	KRAS	G12/G13	Resistance
58	civic	Cetuximab	Colorectal Cancer	KRAS	G12V	Resistance
59	civic	Tretinoin	Acute Myeloid Leukemia	NPM1	EXON 12 MUTATION	Sensitivity/Response
60	civic	Chemotherapy,Cetuximab	Colorectal Cancer	PIK3CA	Exon 21 Mutation	Resistance
61	civic	Daunorubicin,Cytarabine	Acute Myeloid Leukemia	WT1	Exon 7 Mutation	Resistance
62	civic	TAE684	Neuroblastoma	ALK	F1174L	Sensitivity/Response
63	civic	Crizotinib	Neuroblastoma	ALK	R1275Q	Sensitivity/Response
64	civic	PD173074	Bladder Carcinoma	FGFR3	FGFR3::BAIAP2L1	Sensitivity/Response
65	civic	Cetuximab	Colorectal Cancer	KRAS	G13D	Sensitivity/Response
66	civic	Tretinoin	Acute Myeloid Leukemia	NPM1	EXON 12 MUTATION	Sensitivity/Response
67	civic	Daunorubicin	Acute Myeloid Leukemia	NPM1	EXON 12 MUTATION	Sensitivity/Response
68	civic	Valproic Acid	Acute Myeloid Leukemia	NPM1	EXON 12 MUTATION	Sensitivity/Response
69	civic	Tretinoin,NSC348884	Acute Myeloid Leukemia	NPM1	EXON 12 MUTATION	Sensitivity/Response
70	civic	Anti-CD123,Anti-CD33	Acute Myeloid Leukemia	NPM1	EXON 12 MUTATION	Sensitivity/Response
71	civic	Anti-CD33	Acute Myeloid Leukemia	NPM1	EXON 12 MUTATION	Sensitivity/Response
72	civic	NSC348884	Acute Myeloid Leukemia	NPM1	W288FS	Sensitivity/Response
73	civic	Daunorubicin,Cytarabine,Etoposide	Acute Myeloid Leukemia	NPM1	W288FS	Sensitivity/Response
74	civic	Sirolimus	Lung Non-small Cell Carcinoma	TSC1	Frameshift Truncation	Sensitivity/Response
75	civic	Everolimus	Bladder Carcinoma	TSC1	Loss-of-function	Sensitivity/Response
76	civic	Olaparib	Ovarian Cancer	BRCA1	Loss-of-function	Sensitivity/Response
77	civic	Olaparib	Ovarian Cancer	BRCA2	Loss-of-function	Sensitivity/Response
78	civic	Gefitinib,Erlotinib	Lung Non-small Cell Carcinoma	EGFR	L858R	Sensitivity/Response
79	civic	Akt Inhibitor MK2206	Breast Cancer	AKT1	E17K	Sensitivity/Response
80	civic	Imatinib	Acute Myeloid Leukemia	ABL1	BCR::ABL	Resistance
81	civic	Erlotinib	Lung Non-small Cell Carcinoma	EGFR	T790M	Resistance
82	civic	Gefitinib	Lung Non-small Cell Carcinoma	EGFR	T790M	Resistance
83	civic	Dacomitinib	Lung Non-small Cell Carcinoma	EGFR	T790M	Resistance
84	civic	Lapatinib	Breast Cancer	ERBB2	L755S	Resistance
85	civic	Hormone Therapy	Breast Cancer	ESR1	L536Q	Resistance
86	civic	Hormone Therapy	Breast Cancer	ESR1	D538G	Resistance
87	civic	Hormone Therapy	Breast Cancer	ESR1	Y537C	Resistance
88	civic	Hormone Therapy	Breast Cancer	ESR1	Y537N	Resistance
89	civic	Hormone Therapy	Breast Cancer	ESR1	Y537S	Resistance
90	civic	Sorafenib	Acute Myeloid Leukemia	FLT3	TKD MUTATION	Resistance
91	civic	Imatinib	Gastrointestinal Stromal Tumor	KIT	V654A	Resistance
92	civic	Cetuximab	Colorectal Cancer	KRAS	Exon 2 Mutation	Resistance
93	civic	Erlotinib,Gefitinib	Lung Adenocarcinoma	KRAS	G12A	Resistance
94	civic	Cetuximab,Panitumumab	Colorectal Cancer	PIK3CA	H1047R	Resistance
95	civic	Imatinib	Acute Myeloid Leukemia	ABL1	BCR::ABL	Sensitivity/Response
96	civic	Imatinib	Chronic Myeloid Leukemia	ABL1	BCR::ABL	Sensitivity/Response
97	civic	Dasatinib,Nilotinib	Chronic Myeloid Leukemia	ABL1	BCR::ABL	Sensitivity/Response
98	civic	Crizotinib	Lung Non-small Cell Carcinoma	ALK	EML4::ALK	Sensitivity/Response
99	civic	Palbociclib	T-cell Lymphoblastic Leukemia/lymphoma	CCND3	Loss	Sensitivity/Response
100	civic	Alpelisib	Estrogen-receptor Positive Breast Cancer	CDK4	EXPRESSION	Sensitivity/Response
101	civic	Dasatinib	Lung Non-small Cell Carcinoma	DDR2	G253C	Sensitivity/Response
102	civic	Dasatinib	Lung Non-small Cell Carcinoma	DDR2	G505S	Sensitivity/Response
103	civic	Dasatinib	Lung Non-small Cell Carcinoma	DDR2	G774V	Sensitivity/Response
104	civic	Dasatinib	Lung Non-small Cell Carcinoma	DDR2	I638F	Sensitivity/Response
105	civic	Dasatinib	Lung Non-small Cell Carcinoma	DDR2	L239R	Sensitivity/Response
106	civic	Dasatinib	Lung Non-small Cell Carcinoma	DDR2	L63V	Sensitivity/Response
107	civic	Dasatinib,Erlotinib	Lung Non-small Cell Carcinoma	DDR2	S768R	Sensitivity/Response
108	civic	Gefitinib	Lung Non-small Cell Carcinoma	EGFR	Exon 19 Deletion	Sensitivity/Response
109	civic	Gefitinib	Lung Non-small Cell Carcinoma	EGFR	G719S	Sensitivity/Response
110	civic	Gefitinib,Erlotinib	Lung Non-small Cell Carcinoma	EGFR	L858R	Sensitivity/Response
111	civic	Gefitinib	Lung Non-small Cell Carcinoma	EGFR	L858R	Sensitivity/Response
112	civic	Pemetrexed,Erlotinib	Lung Non-small Cell Carcinoma	EGFR	T790M	Sensitivity/Response
113	civic	Staurosporine	Lung Non-small Cell Carcinoma	EGFR	T790M	Sensitivity/Response
114	civic	Neratinib,Lapatinib	Breast Cancer	ERBB2	D769H	Sensitivity/Response
115	civic	Neratinib	Breast Cancer	ERBB2	D769Y	Sensitivity/Response
116	civic	Neratinib	Breast Cancer	ERBB2	L755_T759del	Sensitivity/Response
117	civic	Neratinib	Breast Cancer	ERBB2	G309A	Sensitivity/Response
118	civic	Neratinib	Breast Cancer	ERBB2	L755S	Sensitivity/Response
119	civic	Neratinib	Breast Cancer	ERBB2	L755W	Sensitivity/Response
120	civic	Neratinib	Breast Cancer	ERBB2	P780INS	Sensitivity/Response
121	civic	Lapatinib,Neratinib	Breast Cancer	ERBB2	R678Q	Sensitivity/Response
122	civic	Neratinib	Breast Cancer	ERBB2	R896C	Sensitivity/Response
123	civic	Neratinib	Breast Cancer	ERBB2	V777L	Sensitivity/Response
124	civic	Neratinib	Breast Cancer	ERBB2	V842I	Sensitivity/Response
125	civic	Tamoxifen,Fulvestrant	Breast Cancer	ESR1	L536Q	Sensitivity/Response
126	civic	Fulvestrant,Tamoxifen	Breast Cancer	ESR1	D538G	Sensitivity/Response
127	civic	Tamoxifen,Fulvestrant	Breast Cancer	ESR1	Y537C	Sensitivity/Response
128	civic	Fulvestrant,Tamoxifen	Breast Cancer	ESR1	Y537N	Sensitivity/Response
129	civic	Tamoxifen,Fulvestrant	Breast Cancer	ESR1	Y537S	Sensitivity/Response
130	civic	Ponatinib	Cholangiocarcinoma	FGFR2	FGFR2::MGEA5	Sensitivity/Response
131	civic	Ponatinib,Pazopanib	Cholangiocarcinoma	FGFR2	FGFR2::TACC3	Sensitivity/Response
132	civic	Lestaurtinib	Acute Myeloid Leukemia	FLT3	ITD	Sensitivity/Response
133	civic	Sorafenib	Acute Myeloid Leukemia	FLT3	ITD	Sensitivity/Response
134	civic	Tyrphostin AG 1296	Acute Myeloid Leukemia	FLT3	ITD	Sensitivity/Response
135	civic	Bortezomib,Fasudil	Lung Adenocarcinoma	GATA2	EXPRESSION	Sensitivity/Response
136	civic	Imatinib	Malignant Anus Melanoma	KIT	Internal Duplication	Sensitivity/Response
137	civic	Nilotinib,Imatinib,Dasatinib	Lung Non-small Cell Carcinoma	KIT	L576P	Sensitivity/Response
138	civic	Sunitinib	Gastrointestinal Stromal Tumor	KIT	V654A	Sensitivity/Response
139	civic	Selumetinib,Dactolisib	Lung Non-small Cell Carcinoma	KRAS	G12D	Sensitivity/Response
140	civic	Cetuximab	Colorectal Cancer	KRAS	G13D	Sensitivity/Response
141	civic	Temozolomide	Glioblastoma	MGMT	Promoter Methylation	Sensitivity/Response
142	civic	Carmustine	Glioblastoma	MGMT	Promoter Methylation	Sensitivity/Response
143	civic	O6-Benzylguanine	Glioblastoma	MGMT	Promoter Methylation	Sensitivity/Response
144	civic	PI3K-alpha Inhibitor MEN1611	Breast Cancer	PIK3CA	E542K	Sensitivity/Response
145	civic	Sirolimus	Breast Cancer	PIK3CA	E542K	Sensitivity/Response
146	civic	PI3K-alpha Inhibitor MEN1611	Breast Cancer	PIK3CA	H1047R	Sensitivity/Response
147	civic	Tretinoin	Acute Promyelocytic Leukemia	PML	PML::RARA	Sensitivity/Response
148	civic	MTOR Inhibitor	Breast Cancer	PTEN	R233*	Sensitivity/Response
149	civic	Doxorubicin	Breast Cancer	TP53	R175H	Sensitivity/Response
150	civic	Everolimus	Invasive Bladder Transitional Cell Carcinoma	TSC1	Frameshift Truncation	Sensitivity/Response
151	civic	Imatinib	Chronic Myeloid Leukemia	ABL1	BCR::ABL	Sensitivity/Response
152	civic	Panitumumab,Cetuximab	Colorectal Cancer	PIK3CA	E545K	Resistance
153	civic	Cetuximab,Panitumumab	Colorectal Cancer	PIK3CA	H1047R	Resistance
154	civic	Doxorubicin	Breast Cancer	TP53	R249	Sensitivity/Response
155	civic	Imatinib,GW-2580	Acute Lymphoblastic Leukemia	CSF1R	MEF2D::CSF1R	Sensitivity/Response
156	civic	Cytarabine	Acute Myeloid Leukemia	RUNX1	Mutation	Resistance
157	civic	Linsitinib	Prostate Cancer	IGF2	Overexpression	Sensitivity/Response
158	civic	Gefitinib,Erlotinib	Lung Non-small Cell Carcinoma	EGFR	Exon 19 Deletion	Sensitivity/Response
159	civic	Cabazitaxel,Linsitinib,Docetaxel	Prostate Cancer	IGF2	Overexpression	Sensitivity/Response
160	civic	Ibrutinib	Chronic Lymphocytic Leukemia	BTK	C481S	Resistance
161	civic	Vemurafenib	Melanoma	AKT1	Q79K	Resistance
162	civic	JW55	Colon Carcinoma	APC	Mutation	Sensitivity/Response
163	civic	G007-LK	Colorectal Cancer	APC	Mutation	Sensitivity/Response
164	civic	Enzalutamide,Apalutamide	Prostate Cancer	AR	F877L	Resistance
165	civic	Bicalutamide	Prostate Carcinoma	AR	W742	Resistance
166	civic	Temozolomide	Glioblastoma	ATM	Mutation	Sensitivity/Response
167	civic	Temozolomide	Melanoma	ATM	Mutation	Sensitivity/Response
168	civic	NU7441,KU-0060648	Cancer	ATM	Underexpression	Sensitivity/Response
169	civic	Olaparib	Hematologic Cancer	ATM	Mutation	Sensitivity/Response
170	civic	Cisplatin,Alisertib	Esophagus Adenocarcinoma	AURKA	Amplification	Sensitivity/Response
171	civic	Paclitaxel	Cervical Adenocarcinoma	AURKA	Overexpression	Resistance
172	civic	Imatinib	Thymic Carcinoma	KIT	V560DEL	Sensitivity/Response
173	civic	Tamoxifen	Breast Cancer	PGR	Expression	Sensitivity/Response
174	civic	Exemestane,Tamoxifen	Breast Cancer	PGR	Expression	Sensitivity/Response
175	civic	Cetuximab	Colorectal Cancer	PTEN	Loss	Resistance
176	civic	Temsirolimus	Prostate Cancer	PTEN	Loss	Sensitivity/Response
177	civic	Trastuzumab	Her2-receptor Positive Breast Cancer	ERBB2	Amplification	Sensitivity/Response
178	civic	Trastuzumab	Her2-receptor Positive Breast Cancer	ERBB2	Amplification	Sensitivity/Response
179	civic	Gemcitabine,Trametinib	Pancreatic Adenocarcinoma	KRAS	G12/G13	Resistance
180	civic	Olaparib	Ovarian Serous Carcinoma	CDK12	Loss-of-function	Sensitivity/Response
181	civic	Mercaptopurine,Thioguanine	T-cell Acute Lymphoblastic Leukemia	NT5C2	R367Q	Resistance
182	civic	Thioguanine,Mercaptopurine	T-cell Acute Lymphoblastic Leukemia	NT5C2	K359Q	Resistance
183	civic	Mercaptopurine,Thioguanine	T-cell Acute Lymphoblastic Leukemia	NT5C2	D407A	Resistance
184	civic	Arabinosylguanine,Nelarabine	T-cell Acute Lymphoblastic Leukemia	NT5C2	R367Q	Resistance
185	civic	Nelarabine,Arabinosylguanine	T-cell Acute Lymphoblastic Leukemia	NT5C2	D407A	Resistance
186	civic	Arabinosylguanine,Nelarabine	T-cell Acute Lymphoblastic Leukemia	NT5C2	K359Q	Resistance
187	civic	Multikinase Inhibitor AEE788,Gefitinib	Lung Cancer	EGFR	T790M	Resistance
188	civic	Everolimus	Bladder Carcinoma	PTEN	Loss	Resistance
189	civic	Trastuzumab	Breast Cancer	PTEN	Loss	Resistance
190	civic	Rociletinib	Lung Non-small Cell Carcinoma	EGFR	T790M	Sensitivity/Response
191	civic	Olaparib	Prostate Cancer	ATM	S2289*	Sensitivity/Response
192	civic	Olaparib	Prostate Cancer	ATM	N2875H	Sensitivity/Response
193	civic	Cisplatin,Carboplatin	Peritoneal Mesothelioma	NF2	Y177fs	Resistance
194	civic	Olaparib	Prostate Cancer	BRCA2	Loss-of-function	Sensitivity/Response
195	civic	Imatinib	Gastrointestinal Stromal Tumor	PDGFRA	D842V	Resistance
196	civic	Imatinib	Gastrointestinal Stromal Tumor	PDGFRA	V561A	Sensitivity/Response
197	civic	Imatinib	Gastrointestinal Stromal Tumor	KIT	Exon 11 Mutation	Sensitivity/Response
198	civic	Docetaxel,Vinorelbine,Gemcitabine	Lung Non-small Cell Carcinoma	XRCC1	R194W	Sensitivity/Response
199	civic	Carboplatin,Paclitaxel,Cisplatin	Ovarian Carcinoma	GSTP1	Deletion	Sensitivity/Response
200	civic	Cisplatin	Colon Cancer	BIRC7	Amplification	Resistance
201	civic	Cisplatin	Epithelial Ovarian Cancer	EGFR	Exon 4 Deletion	Resistance
202	civic	Carboplatin,Paclitaxel	Epithelial Ovarian Cancer	KRAS	RS61764370	Resistance
203	civic	Fluorouracil	Stomach Cancer	MTHFR	A222V	Sensitivity/Response
204	civic	FOLFOX Regimen	Colorectal Cancer	GSTP1	I105V	Sensitivity/Response
205	civic	Carboplatin,Cisplatin	Cervical Cancer	XRCC1	Q399R	Sensitivity/Response
206	civic	Paclitaxel	Ovarian Cancer	ABCB1	S893T	Sensitivity/Response
207	civic	Cisplatin,Carboplatin	Lung Non-small Cell Carcinoma	ABCB1	I1145I	Sensitivity/Response
208	civic	Cisplatin	Osteosarcoma	ERCC2	K751Q	Resistance
209	civic	Carboplatin,Paclitaxel	Lung Non-small Cell Carcinoma	ERCC2	K751Q	Sensitivity/Response
210	civic	Irinotecan,Fluorouracil	Colorectal Cancer	TYMS	5' TANDEM REPEAT	Resistance
211	civic	Doxorubicin	Ovarian Cancer	LRP1B	EXON 12-22 DELETION	Resistance
212	civic	PD173074	Lung Squamous Cell Carcinoma	FGFR1	Amplification	Sensitivity/Response
213	civic	Ponatinib	Lung Cancer	FGFR1	Expression	Sensitivity/Response
214	civic	PD173074	Lung Non-small Cell Carcinoma	FGFR1	Amplification	Sensitivity/Response
215	civic	Crizotinib	Lung Non-small Cell Carcinoma	ROS1	Rearrangement	Sensitivity/Response
216	civic	Onartuzumab	Gastric Adenocarcinoma	MET	Amplification	Sensitivity/Response
217	civic	Platinum Compound,Cetuximab,Fluorouracil	Head And Neck Squamous Cell Carcinoma	EGFR	Amplification	Sensitivity/Response
218	civic	Cetuximab	Head And Neck Squamous Cell Carcinoma	EGFR	Overexpression	Sensitivity/Response
219	civic	Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor	Lung Non-small Cell Carcinoma	EGFR	Overexpression	Sensitivity/Response
220	civic	Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor	Head And Neck Squamous Cell Carcinoma	CDKN2A	p16 Expression	Resistance
221	civic	Panitumumab	Head And Neck Squamous Cell Carcinoma	CDKN2A	p16 Expression	Resistance
222	civic	Cetuximab	Head And Neck Squamous Cell Carcinoma	CDKN2A	p16 Expression	Resistance
223	civic	Vandetanib	Lung Adenocarcinoma	RET	KIF5B::RET	Sensitivity/Response
224	civic	Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor	Colorectal Cancer	HRAS	G13D	Resistance
225	civic	MTOR Kinase Inhibitor AZD8055,Mirdametinib,Everolimus,Binimetinib,Selumetinib	Cancer	HRAS	Mutation	Sensitivity/Response
226	civic	Nivolumab,Pembrolizumab	Melanoma	CD274	Expression	Sensitivity/Response
227	civic	Everolimus,Pazopanib	Bladder Carcinoma	MTOR	Mutation	Sensitivity/Response
228	civic	Trastuzumab	Breast Cancer	AKT2	EXPRESSION	Sensitivity/Response
229	civic	Uprosertib	Melanoma	AKT1	E17K	Sensitivity/Response
230	civic	Uprosertib	Melanoma	PTEN	Loss	Sensitivity/Response
231	civic	Capivasertib	Breast Cancer	AKT1	E17K	Sensitivity/Response
232	civic	Pictilisib,Akt Inhibitor MK2206	Breast Cancer	PIK3CA	E545K	Sensitivity/Response
233	civic	PI3Kbeta Inhibitor AZD8186	Breast Cancer	PTEN	Loss	Sensitivity/Response
234	civic	PI3K/BET Inhibitor LY294002,Capivasertib	Melanoma	MTOR	H1968Y	Sensitivity/Response
235	civic	Paclitaxel,Carboplatin,Buparlisib	Cancer	PTEN	Loss	Sensitivity/Response
236	civic	Temsirolimus	Breast Cancer	NF2	K159fs	Sensitivity/Response
237	civic	Alpelisib	Breast Cancer	PTEN	Loss	Resistance
238	civic	Cetuximab	Colorectal Cancer	EGFR	S492R	Resistance
239	civic	Panitumumab,Cetuximab	Colorectal Cancer	FBXW7	Mutation	Resistance
240	civic	Cetuximab,Panitumumab	Colorectal Cancer	SMAD4	Mutation	Resistance
241	civic	Cetuximab	Head And Neck Squamous Cell Carcinoma	SMAD4	Underexpression	Resistance
242	civic	PI3K/BET Inhibitor LY294002,Capivasertib	Melanoma	MTOR	P2213S	Sensitivity/Response
243	civic	Sorafenib	Melanoma	BRAF	AGK::BRAF	Sensitivity/Response
244	civic	Vemurafenib	Melanoma	BRAF	AGK::BRAF	Resistance
245	civic	Vemurafenib	Melanoma	BRAF	PAPSS1::BRAF	Resistance
246	civic	Trametinib	Melanoma	BRAF	PAPSS1::BRAF	Sensitivity/Response
247	civic	Trametinib	Melanoma	BRAF	TRIM24::BRAF	Sensitivity/Response
248	civic	Vemurafenib	Melanoma	BRAF	L597R	Sensitivity/Response
249	civic	Cetuximab	Colorectal Cancer	ERBB3	Overexpression	Resistance
250	civic	Cetuximab	Colorectal Cancer	NT5E	Overexpression	Sensitivity/Response
251	civic	GSK321	Acute Myeloid Leukemia	IDH1	R132C	Sensitivity/Response
252	civic	Gefitinib	Lung Non-small Cell Carcinoma	MET	Amplification	Resistance
253	civic	Paclitaxel	Breast Cancer	MYD88	Overexpression	Resistance
254	civic	Crizotinib	Lung Non-small Cell Carcinoma	MET	Amplification	Sensitivity/Response
255	civic	Crizotinib	Cancer	MET	Exon 14 Skipping Mutation	Sensitivity/Response
256	civic	Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor	Lung Non-small Cell Carcinoma	EGFR	Overexpression	Sensitivity/Response
257	civic	Imatinib	Gastrointestinal Stromal Tumor	PDGFRA	D842V	Resistance
258	civic	Idelalisib	Merkel Cell Carcinoma	PIK3CA	P471L	Sensitivity/Response
259	civic	Vandetanib	Breast Cancer	RET	Overexpression	Sensitivity/Response
260	civic	Pictilisib,Selumetinib	Lung Adenocarcinoma	RIT1	Mutation	Sensitivity/Response
261	civic	Pembrolizumab,Nivolumab	Lung Non-small Cell Carcinoma	CD274	Expression	Sensitivity/Response
262	civic	FACT Complex-targeting Curaxin CBL0137	Neuroblastoma	MYCN	Amplification	Sensitivity/Response
263	civic	Vismodegib	Medulloblastoma	SMO	D473H	Resistance
264	civic	Vismodegib	Basal Cell Carcinoma	SMO	Mutation	Resistance
265	civic	Arsenic Trioxide,PSI	Basal Cell Carcinoma	SMO	Mutation	Sensitivity/Response
266	civic	Sonidegib	Medulloblastoma	PTCH1	Mutation	Sensitivity/Response
267	civic	Vismodegib	Medulloblastoma	PTCH1	LOH	Sensitivity/Response
268	civic	SB202190	Prostate Cancer	STK11	Underexpression	Sensitivity/Response
269	civic	Paclitaxel	Ovarian Cancer	SYK	OVEREXPRESSION	Resistance
270	civic	Panitumumab	Head And Neck Squamous Cell Carcinoma	CDKN2A	p16 Expression	Sensitivity/Response
271	civic	Vismodegib	Basal Cell Carcinoma	SMO	D473H	Resistance
272	civic	Pictilisib	Epithelial Ovarian Cancer	PIK3CA	Amplification	Sensitivity/Response
273	civic	Pictilisib	Melanoma	BRAF	V600E	Sensitivity/Response
274	civic	Cetuximab	Oropharynx Cancer	CDKN2A	p16 Expression	Resistance
275	civic	AKTi-1/2	Breast Cancer	ERBB2	Amplification	Sensitivity/Response
276	civic	Neratinib	Her2-receptor Positive Breast Cancer	ERBB2	Amplification	Sensitivity/Response
277	civic	Rociletinib	Lung Non-small Cell Carcinoma	EGFR	T790M	Sensitivity/Response
278	civic	Lapatinib	Melanoma	ERBB4	Mutation	Sensitivity/Response
279	civic	Cabozantinib	Colorectal Cancer	PIK3CA	Mutation	Sensitivity/Response
280	civic	Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor	Glioblastoma	EGFR	VIII	Sensitivity/Response
281	civic	Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor	Glioblastoma	PTEN	Expression	Sensitivity/Response
282	civic	Dacomitinib	Glioblastoma	PTEN	Expression	Sensitivity/Response
283	civic	Lapatinib	Head And Neck Squamous Cell Carcinoma	NRG1	Expression	Sensitivity/Response
284	civic	Cetuximab	Colorectal Cancer	NRG1	Expression	Resistance
285	civic	Seribantumab	Ovarian Cancer	NRG1	Expression	Sensitivity/Response
286	civic	Gemcitabine,Paclitaxel,Cisplatin,Carboplatin	Lung Non-small Cell Carcinoma	NRG1	Expression	Sensitivity/Response
287	civic	Crizotinib	Lung Non-small Cell Carcinoma	AREG	Expression	Resistance
288	civic	Crizotinib	Lung Non-small Cell Carcinoma	AREG	Expression	Resistance
289	civic	Nimotuzumab	Esophagus Squamous Cell Carcinoma	EGFR	Overexpression	Sensitivity/Response
290	civic	Cetuximab	Colorectal Cancer	EGFR	G724S	Sensitivity/Response
291	civic	Cetuximab	Colorectal Cancer	EGFR	G719S	Sensitivity/Response
292	civic	Cetuximab	Colorectal Cancer	AREG	Expression	Sensitivity/Response
293	civic	Cetuximab	Colorectal Cancer	EREG	EXPRESSION	Sensitivity/Response
294	civic	Erlotinib	Head And Neck Squamous Cell Carcinoma	MAPK1	E322K	Sensitivity/Response
295	civic	WZ4002	Lung Non-small Cell Carcinoma	MAPK1	Amplification	Resistance
296	civic	Abemaciclib	Lung Non-small Cell Carcinoma	KRAS	A146V	Sensitivity/Response
297	civic	Palbociclib	Lung Non-small Cell Carcinoma	KRAS	G12V	Sensitivity/Response
298	civic	Foretinib	Papillary Renal Cell Carcinoma	MET	Mutation	Sensitivity/Response
299	civic	Crizotinib	Lung Adenocarcinoma	MET	Exon 14 Skipping Mutation	Sensitivity/Response
300	civic	Infigratinib	Head And Neck Squamous Cell Carcinoma	FGFR1	Expression	Sensitivity/Response
301	civic	Infigratinib	Gastric Adenocarcinoma	FGFR1	Expression	Sensitivity/Response
302	civic	PD173074,Dovitinib	Bladder Carcinoma	FGFR1	Expression	Sensitivity/Response
303	civic	Tyrosine Kinase Inhibitor SU5402,PD173074,Dovitinib	Bladder Carcinoma	FGFR3	Overexpression	Sensitivity/Response
304	civic	Olaparib	Cancer	CBLC	EXPRESSION	Resistance
305	civic	Cetuximab	Colorectal Cancer	KRAS	G13D	Resistance
306	civic	JSI-124	Head And Neck Carcinoma	PTPRD	Mutation	Sensitivity/Response
307	civic	Docetaxel	Prostate Cancer	DEFA1	EXPRESSION	Sensitivity/Response
308	civic	Cisplatin	Bladder Carcinoma	ERCC1	Expression	Sensitivity/Response
309	civic	NOTCH1 Antibody (PF-06293622)	Colorectal Cancer	NOTCH1	Amplification	Sensitivity/Response
310	civic	Patritumab	Lung Non-small Cell Carcinoma	NRG1	Expression	Sensitivity/Response
311	civic	Platinum Compound,Gemcitabine	Lung Non-small Cell Carcinoma	WEE1	RS3910384	Sensitivity/Response
312	civic	Lonafarnib	Ovarian Cancer	FNTB	RS11623866	Resistance
313	civic	Panitumumab,Cetuximab	Colorectal Cancer	BRAF	V600E	Resistance
314	civic	Stattic,JSI-124	Head And Neck Squamous Cell Carcinoma	PTPRT	Promoter Hypermethylation	Sensitivity/Response
315	civic	Irinotecan,Levoleucovorin,Fluorouracil,Bevacizumab	Colorectal Cancer	VEGFA	Decreased Peri-therapeutic Expression	Sensitivity/Response
316	civic	Decitabine	Ovarian Cancer	DNMT1	EXPRESSION	Sensitivity/Response
317	civic	Decitabine	Ovarian Cancer	KRAS	Mutation	Sensitivity/Response
318	civic	Paclitaxel	Lung Cancer	PDCD4	EXPRESSION	Sensitivity/Response
319	civic	Temozolomide	Glioblastoma	MGMT	RS16906252	Sensitivity/Response
320	civic	Tamoxifen,Aminoglutethimide	Breast Cancer	TFF3	EXPRESSION	Sensitivity/Response
321	civic	Irinotecan,Levoleucovorin,Oxaliplatin,Fluorouracil	Colorectal Cancer	DKK1	NUCLEAR EXPRESSION	Resistance
322	civic	RG7356	Cancer	CD44	CD44s Expression	Sensitivity/Response
323	civic	Cetuximab	Head And Neck Squamous Cell Carcinoma	EGF	EXPRESSION	Resistance
324	civic	Cisplatin,Pemetrexed	Malignant Pleural Mesothelioma	MDM2	EXPRESSION	Resistance
325	civic	Sunitinib,Sorafenib	Renal Cell Carcinoma	HMOX1	EXPRESSION	Resistance
326	civic	Conatumumab	Ewing Sarcoma Of Bone	CASP8	Overexpression	Sensitivity/Response
327	civic	Pemetrexed	Lung Non-small Cell Carcinoma	TYMS	Overexpression	Resistance
328	civic	Gefitinib	Lung Non-small Cell Carcinoma	PBK	OVEREXPRESSION	Resistance
329	civic	Crizotinib	Lung Adenocarcinoma	MET	Amplification	Sensitivity/Response
330	civic	Vinorelbine,Cisplatin	Lung Non-small Cell Carcinoma	SMARCA4	Underexpression	Sensitivity/Response
331	civic	Olaparib	Prostate Cancer	BRCA1	Loss-of-function	Sensitivity/Response
332	civic	Docetaxel,Cetuximab	Head And Neck Squamous Cell Carcinoma	AREG	Expression	Resistance
333	civic	Cetuximab,Docetaxel	Head And Neck Squamous Cell Carcinoma	EGFR	VIII	Resistance
334	civic	Cetuximab,Docetaxel	Head And Neck Squamous Cell Carcinoma	EGFR	Overexpression	Sensitivity/Response
335	civic	Chemotherapy	Gastric Adenocarcinoma	TP53	Mutation	Sensitivity/Response
336	civic	Doxorubicin	Breast Cancer	TP53	Mutation	Sensitivity/Response
337	civic	Fluorouracil	Colorectal Cancer	CDKN1A	EXPRESSION	Resistance
338	civic	Fluorouracil	Colorectal Cancer	ALCAM	EXPRESSION	Resistance
339	civic	Panitumumab,Cetuximab	Colorectal Cancer	EGFR	Amplification	Sensitivity/Response
340	civic	Paclitaxel	Endometrial Carcinoma	STMN1	EXPRESSION	Resistance
341	civic	Tamoxifen	Estrogen-receptor Positive Breast Cancer	CCND1	Overexpression	Resistance
342	civic	Tamoxifen	Breast Cancer	RSF1	Amplification	Resistance
343	civic	Tamoxifen	Breast Cancer	CCND1	Amplification	Resistance
344	civic	Dactolisib	Breast Cancer	AR	OVEREXPRESSION	Sensitivity/Response
345	civic	Lapatinib	Breast Cancer	CDKN1B	CYTOPLASMIC MISLOCALIZATION	Resistance
346	civic	Anti-ErbB3 Monoclonal Antibody AV-203	Cancer	NRG1	Expression	Sensitivity/Response
347	civic	Anti-ErbB3 Monoclonal Antibody AV-203	Cancer	ERBB3	EXPRESSION	Sensitivity/Response
348	civic	Abiraterone,Enzalutamide	Prostate Cancer	AR	V7 EXPRESSION	Resistance
349	civic	Lapatinib,Trastuzumab	Gastric Adenocarcinoma	PTEN	Loss	Resistance
350	civic	9F7-F11,Pertuzumab	Pancreatic Ductal Adenocarcinoma	ERBB3	EXPRESSION	Sensitivity/Response
351	civic	Ganetespib	Colorectal Cancer	UGT1A	EXPRESSION	Resistance
352	civic	Trastuzumab	Breast Cancer	ERBB4	NUCLEAR TRANSLOCATION	Resistance
353	civic	Trastuzumab	Breast Cancer	ERBB4	EXPRESSION	Resistance
354	civic	Lapatinib	Breast Cancer	ERBB4	EXPRESSION	Resistance
355	civic	7-Ethyl-10-Hydroxycamptothecin	Colorectal Cancer	SLFN11	EXPRESSION	Sensitivity/Response
356	civic	Cisplatin	Lung Non-small Cell Carcinoma	AURKA	Overexpression	Resistance
357	civic	Cisplatin	Head And Neck Squamous Cell Carcinoma	KRAS	RS61764370	Resistance
358	civic	Vemurafenib,Dabrafenib	Melanoma	RAC1	P29S	Resistance
359	civic	Platinum Compound,Taxane Compound	Lung Non-small Cell Carcinoma	BIRC5	NUCLEAR EXPRESSION	Sensitivity/Response
360	civic	Cetuximab,Oxaliplatin,Capecitabine	Colorectal Cancer	TP53	Wildtype	Sensitivity/Response
361	civic	Talazoparib	Endometrial Cancer	MRE11	Loss	Sensitivity/Response
362	civic	Olaparib	Gastric Adenocarcinoma	ATM	Underexpression	Sensitivity/Response
363	civic	Afatinib	Lung Adenocarcinoma	EGFR	L858R	Sensitivity/Response
364	civic	Afatinib	Lung Adenocarcinoma	EGFR	Exon 19 Deletion	Sensitivity/Response
365	civic	Afatinib	Lung Non-small Cell Carcinoma	EGFR	Exon 19 Deletion	Sensitivity/Response
366	civic	Afatinib	Lung Adenocarcinoma	EGFR	Exon 19 Deletion	Sensitivity/Response
367	civic	Afatinib	Lung Adenocarcinoma	EGFR	L858R	Sensitivity/Response
368	civic	Erlotinib	Lung Non-small Cell Carcinoma	EGFR	Exon 19 Deletion	Sensitivity/Response
369	civic	Erlotinib	Lung Non-small Cell Carcinoma	EGFR	L858R	Sensitivity/Response
370	civic	Afatinib	Uterine Corpus Endometrial Carcinoma	ERBB2	Amplification	Sensitivity/Response
371	civic	Trastuzumab,Lapatinib,Afatinib	Her2-receptor Positive Breast Cancer	ERBB2	Amplification	Sensitivity/Response
372	civic	Irinotecan	Colorectal Cancer	TOP1	Amplification	Sensitivity/Response
373	civic	Fluorouracil,Cisplatin	Head And Neck Squamous Cell Carcinoma	CDKN1B	EXPRESSION	Sensitivity/Response
374	civic	Crizotinib	Lung Squamous Cell Carcinoma	MET	Amplification	Sensitivity/Response
375	civic	Tamoxifen	Breast Cancer	AGR2	EXPRESSION	Resistance
376	civic	Temsirolimus,Ridaforolimus	Endometrial Cancer	PIK3CA	Mutation	Sensitivity/Response
377	civic	Temsirolimus,Ridaforolimus	Endometrial Cancer	PTEN	Loss	Resistance
378	civic	Temsirolimus,Ridaforolimus	Endometrial Cancer	KRAS	Mutation	Sensitivity/Response
379	civic	Cetuximab,Oxaliplatin,Capecitabine	Colorectal Cancer	ERBB2	Amplification	Resistance
380	civic	Infigratinib	Colorectal Cancer	FGFR1	Expression	Sensitivity/Response
381	civic	GNE-617	Cancer	NAPRT	Promoter Hypermethylation	Sensitivity/Response
382	civic	Bevacizumab,Erlotinib	Lung Non-small Cell Carcinoma	EGFR	Exon 18 Overexpression	Sensitivity/Response
383	civic	Gemcitabine,Cytarabine,Doxorubicin	Mantle Cell Lymphoma	ZEB1	Expression	Resistance
384	civic	Doxorubicin,Salinomycin	Mantle Cell Lymphoma	ZEB1	Expression	Sensitivity/Response
385	civic	Fulvestrant	Breast Cancer	TIMP1	Overexpression	Resistance
386	civic	Cetuximab	Colorectal Cancer	PTP4A3	OVEREXPRESSION	Sensitivity/Response
387	civic	Pemetrexed	Lung Adenocarcinoma	TYMS	Amplification	Resistance
388	civic	Gefitinib	Lung Non-small Cell Carcinoma	IGF1R	EXPRESSION	Resistance
389	civic	Bevacizumab	Colorectal Cancer	EPHB4	EXPRESSION	Resistance
390	civic	Chemotherapy	Esophageal Carcinoma	TP53	Wildtype	Sensitivity/Response
391	civic	Pemetrexed	Lung Non-small Cell Carcinoma	TYMS	Underexpression	Sensitivity/Response
392	civic	Pemetrexed	Prostate Cancer	TYMS	Underexpression	Sensitivity/Response
393	civic	Doxorubicin	Breast Cancer	TOP2A	EXPRESSION	Sensitivity/Response
394	civic	Topotecan,Carboplatin,Cyclophosphamide	Ovarian Cancer	TOP1	EXPRESSION	Sensitivity/Response
395	civic	Cetuximab	Colorectal Cancer	EGFR	Amplification	Sensitivity/Response
396	civic	Irinotecan	Colorectal Cancer	TOP1	EXPRESSION	Sensitivity/Response
397	civic	ACLY SiRNA	Cancer	PRKAA2	T172 PHOSPHORYLATION	Sensitivity/Response
398	civic	Fluorouracil	Colorectal Cancer	HSPA5	EXPRESSION	Sensitivity/Response
399	civic	Anti-EGFR Monoclonal Antibody	Colorectal Cancer	PIK3CA	Mutation	Resistance
400	civic	Erlotinib	Pancreatic Carcinoma	KRAS	Exon 2 Mutation	Resistance
401	civic	Everolimus	Gastric Adenocarcinoma	EIF4EBP1	PHOSPHORYLATION	Sensitivity/Response
402	civic	Imatinib,Pictilisib	Gastrointestinal Stromal Tumor	KIT	Mutation	Sensitivity/Response
403	civic	Paclitaxel	Cancer	TUBB3	EXPRESSION	Resistance
404	civic	Taxane Compound	Breast Cancer	TUBB3	EXPRESSION	Sensitivity/Response
405	civic	Pemetrexed	Lung Non-small Cell Carcinoma	TYMS	Overexpression	Resistance
406	civic	Gefitinib,Erlotinib	Lung Non-small Cell Carcinoma	EGFR	Y1092 PHOSPHORYLATION	Sensitivity/Response
407	civic	IGF1R Monoclonal Antibody	Sarcoma	IGF1R	NUCLEAR EXPRESSION	Sensitivity/Response
408	civic	Bicalutamide	Prostate Cancer	CFLAR	EXPRESSION	Resistance
409	civic	Sorafenib	Hepatocellular Carcinoma	PROM1	EXPRESSION	Resistance
410	civic	Paclitaxel	Breast Cancer	TIMP1	Overexpression	Resistance
411	civic	Epirubicin	Breast Cancer	FOXP3	EXPRESSION	Sensitivity/Response
412	civic	Raltitrexed	Gastric Adenocarcinoma	TYMS	Overexpression	Resistance
413	civic	Everolimus	Gastric Adenocarcinoma	RPS6	PHOSPHORYLATION	Sensitivity/Response
414	civic	Enzastaurin	Lung Non-small Cell Carcinoma	JAK1	OVEREXPRESSION	Sensitivity/Response
415	civic	WYE354,Dactolisib,MTOR Kinase Inhibitor PP242	Colorectal Cancer	EIF4EBP1	PHOSPHORYLATION	Resistance
416	civic	Vinorelbine	Malignant Mesothelioma	BRCA1	Expression	Sensitivity/Response
417	civic	Trametinib	Cancer	DUSP6	EXPRESSION	Sensitivity/Response
418	civic	Trametinib	Cancer	KRAS	Mutation	Sensitivity/Response
419	civic	Trametinib	Cancer	BRAF	Mutation	Sensitivity/Response
420	civic	Akt Inhibitor MK2206	Pancreatic Carcinoma	KRAS	G12D	Sensitivity/Response
421	civic	Akt Inhibitor MK2206	Pancreatic Carcinoma	PTEN	Loss	Sensitivity/Response
422	civic	Gemcitabine	Pancreatic Ductal Adenocarcinoma	HSPB1	EXPRESSION	Sensitivity/Response
423	civic	Amrubicin	Lung Cancer	NQO1	EXPRESSION	Resistance
424	civic	Amrubicin	Lung Cancer	NQO1	P187S	Sensitivity/Response
425	civic	Platinum Compound,Taxane Compound	Ovarian Cancer	BRCA1	Underexpression	Sensitivity/Response
426	civic	Immunomodulatory Oligonucleotide,Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor	Colorectal Cancer	KRAS	Mutation	Sensitivity/Response
427	civic	Paclitaxel	Lung Non-small Cell Carcinoma	ABCB1	Overexpression	Resistance
428	civic	Pemetrexed	Lung Non-small Cell Carcinoma	ALK	Fusion	Sensitivity/Response
429	civic	Cisplatin	Gastric Adenocarcinoma	DNMT1	EXPRESSION	Resistance
430	civic	Dasatinib,Cetuximab	Colorectal Cancer	KRAS	Mutation	Sensitivity/Response
431	civic	Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor	Lung Non-small Cell Carcinoma	EGFR	Amplification	Sensitivity/Response
432	civic	Docetaxel	Gastric Adenocarcinoma	CXCR4	EXPRESSION	Resistance
433	civic	Gemcitabine	Bile Duct Adenocarcinoma	MAGEH1	EXPRESSION	Resistance
434	civic	Paclitaxel,Monomethyl Auristatin E	Breast Cancer	ABCC3	Amplification	Resistance
435	civic	Paclitaxel	Lung Non-small Cell Carcinoma	ABCC10	Overexpression	Resistance
436	civic	Asparaginase	Ovarian Cancer	ASNS	Amplification	Resistance
437	civic	Gefitinib	Lung Non-small Cell Carcinoma	EGFR	Overexpression	Sensitivity/Response
438	civic	Trastuzumab	Breast Cancer	PTEN	Expression	Sensitivity/Response
439	civic	Oxaliplatin	Colon Cancer	POU5F1	EXPRESSION	Resistance
440	civic	Afatinib	Lung Adenocarcinoma	ERBB2	Kinase Domain Mutation	Sensitivity/Response
441	civic	Sirolimus,Afatinib	Lung Non-small Cell Carcinoma	ERBB2	Y772_A775DUP	Sensitivity/Response
442	civic	Afatinib	Her2-receptor Positive Breast Cancer	ERBB2	Amplification	Sensitivity/Response
443	civic	Afatinib	Pancreatic Adenocarcinoma	ERBB2	Amplification	Sensitivity/Response
444	civic	Osimertinib	Lung Non-small Cell Carcinoma	EGFR	T790M	Sensitivity/Response
445	civic	Osimertinib	Lung Non-small Cell Carcinoma	EGFR	C797S	Resistance
446	civic	Osimertinib	Lung Non-small Cell Carcinoma	EGFR	T790M	Sensitivity/Response
447	civic	Osimertinib	Lung Non-small Cell Carcinoma	EGFR	T790M	Sensitivity/Response
448	civic	Osimertinib,Rociletinib	Lung Non-small Cell Carcinoma	EGFR	T790M	Sensitivity/Response
449	civic	Afatinib	Lung Non-small Cell Carcinoma	EGFR	L858R	Sensitivity/Response
450	civic	Afatinib	Lung Non-small Cell Carcinoma	EGFR	Exon 19 Deletion	Sensitivity/Response
451	civic	Rindopepimut	Glioblastoma	EGFR	VIII	Sensitivity/Response
452	civic	Lapatinib	Breast Cancer	ERBB2	SERUM LEVELS	Sensitivity/Response
453	civic	Erlotinib,Gefitinib	Lung Non-small Cell Carcinoma	EGFR	Amplification	Sensitivity/Response
454	civic	Larotrectinib	Colorectal Cancer	NTRK1	Fusion	Sensitivity/Response
455	civic	AGI-5198	Oligodendroglioma	IDH1	R132H	Sensitivity/Response
456	civic	Afatinib	Lung Adenocarcinoma	EGFR	Exon 19 Deletion	Sensitivity/Response
457	civic	Afatinib	Lung Adenocarcinoma	EGFR	L858R	Sensitivity/Response
458	civic	Afatinib	Lung Adenocarcinoma	EGFR	Exon 19 Deletion	Sensitivity/Response
459	civic	Atezolizumab,Pembrolizumab,Nivolumab	Skin Melanoma	HLA-DRA	EXPRESSION	Sensitivity/Response
460	civic	Ibrutinib	Lymphoplasmacytic Lymphoma	MYD88	L265P	Sensitivity/Response
461	civic	B-Raf/VEGFR-2 Inhibitor RAF265,Selumetinib	Colorectal Cancer	KRAS	Mutation	Sensitivity/Response
462	civic	Selumetinib,B-Raf/VEGFR-2 Inhibitor RAF265	Lung Non-small Cell Carcinoma	KRAS	Mutation	Sensitivity/Response
463	civic	Trametinib	Pancreatic Adenocarcinoma	KRAS	G12/G13	Sensitivity/Response
464	civic	Afatinib,Trametinib	Colorectal Cancer	KRAS	Mutation	Sensitivity/Response
465	civic	Trametinib,Afatinib	Lung Non-small Cell Carcinoma	KRAS	Mutation	Sensitivity/Response
466	civic	Cetuximab	Colorectal Cancer	KRAS	Exon 2 Mutation	Resistance
467	civic	MEK Inhibitor RO4987655	Melanoma	BRAF	V600E	Resistance
468	civic	MEK Inhibitor RO4987655	Melanoma	BRAF	WILD TYPE	Resistance
469	civic	MEK Inhibitor RO4987655	Melanoma	NRAS	Mutation	Resistance
470	civic	MEK Inhibitor RO4987655	Lung Non-small Cell Carcinoma	KRAS	Mutation	Resistance
471	civic	MEK Inhibitor RO4987655	Colorectal Cancer	KRAS	Mutation	Sensitivity/Response
472	civic	Selumetinib,Docetaxel	Lung Non-small Cell Carcinoma	KRAS	Mutation	Sensitivity/Response
473	civic	Refametinib	Melanoma	BRAF	V600	Resistance
474	civic	Refametinib	Colorectal Cancer	KRAS	Mutation	Sensitivity/Response
475	civic	Binimetinib,Everolimus	Neuroblastoma	NRAS	Q61K	Sensitivity/Response
476	civic	PI3Kbeta Inhibitor AZD8186,SCH772984	Pancreatic Adenocarcinoma	KRAS	Mutation	Sensitivity/Response
477	civic	Teprotumumab,Selumetinib	Colorectal Cancer	KRAS	Mutation	Sensitivity/Response
478	civic	Dactolisib,Selumetinib	Melanoma	BRAF	V600E	Sensitivity/Response
479	civic	Trastuzumab,Lapatinib	Breast Cancer	ERBB2	Amplification	Sensitivity/Response
480	civic	Trastuzumab,Lapatinib	Her2-receptor Positive Breast Cancer	ERBB2	Amplification	Sensitivity/Response
481	civic	Trastuzumab,Lapatinib	Her2-receptor Positive Breast Cancer	ERBB2	Amplification	Sensitivity/Response
482	civic	Trastuzumab,Lapatinib	Her2-receptor Positive Breast Cancer	ERBB2	Amplification	Sensitivity/Response
483	civic	Afatinib	Her2-receptor Positive Breast Cancer	ERBB2	Amplification	Sensitivity/Response
484	civic	Afatinib	Her2-receptor Positive Breast Cancer	ERBB2	Amplification	Sensitivity/Response
485	civic	Afatinib,Trastuzumab	Her2-receptor Positive Breast Cancer	ERBB2	Amplification	Sensitivity/Response
486	civic	Olaparib	Prostate Cancer	MRE11	Frameshift	Sensitivity/Response
487	civic	Nimotuzumab	Brain Glioma	EGFR	VIII	Sensitivity/Response
488	civic	Crizotinib,Larotrectinib,Lestaurtinib	Lung Adenocarcinoma	NTRK1	Fusion	Sensitivity/Response
489	civic	Panitumumab	Colorectal Cancer	AREG	Expression	Sensitivity/Response
490	civic	Panitumumab	Colorectal Cancer	EREG	EXPRESSION	Sensitivity/Response
491	civic	Trastuzumab	Gastric Adenocarcinoma	ERBB2	Amplification	Sensitivity/Response
492	civic	Lapatinib	Gastric Adenocarcinoma	ERBB2	Amplification	Sensitivity/Response
493	civic	Imatinib	Endometrial Cancer	KIT	EXPRESSION	Sensitivity/Response
494	civic	Imatinib	Endometrial Cancer	KIT	EXPRESSION	Sensitivity/Response
495	civic	Crizotinib	Lung Non-small Cell Carcinoma	ROS1	Rearrangement	Sensitivity/Response
496	civic	Temsirolimus	Renal Carcinoma	VHL	Loss	Sensitivity/Response
497	civic	Quizartinib,Ponatinib	Acute Myeloid Leukemia	FLT3	D835	Resistance
498	civic	SU5614	Acute Myeloid Leukemia	FLT3	D835	Resistance
499	civic	Sorafenib,Quizartinib	Acute Myeloid Leukemia	FLT3	D835	Resistance
500	civic	Sorafenib	Acute Myeloid Leukemia	FLT3	D835	Resistance
501	civic	Sorafenib	Acute Myeloid Leukemia	FLT3	ITD	Sensitivity/Response
502	civic	Trastuzumab	Lung Non-small Cell Carcinoma	ERBB2	Amplification	Sensitivity/Response
503	civic	Trastuzumab	Lung Non-small Cell Carcinoma	ERBB2	Amplification	Sensitivity/Response
504	civic	Trastuzumab	Lung Adenocarcinoma	ERBB2	Kinase Domain Mutation	Sensitivity/Response
505	civic	Irinotecan,Trastuzumab	Lung Small Cell Carcinoma	ERBB2	Amplification	Sensitivity/Response
506	civic	Afatinib	Lung Adenocarcinoma	ERBB2	Y772_A775DUP	Sensitivity/Response
507	civic	Afatinib	Lung Carcinoma	ERBB2	Y772_A775DUP	Sensitivity/Response
508	civic	Dacomitinib	Lung Adenocarcinoma	ERBB2	P780INS	Sensitivity/Response
509	civic	Trastuzumab Emtansine	Lung Non-small Cell Carcinoma	ERBB2	Amplification	Sensitivity/Response
510	civic	Futuximab/Modotuximab Mixture	Colorectal Cancer	EGFR	G465R	Sensitivity/Response
511	civic	Panitumumab,Cetuximab	Colorectal Cancer	EGFR	G465R	Resistance
512	civic	Cisplatin,Paclitaxel	Lung Non-small Cell Carcinoma	ETS2	RS461155	Sensitivity/Response
513	civic	Pertuzumab,Trastuzumab,Docetaxel	Her2-receptor Positive Breast Cancer	ERBB2	Amplification	Sensitivity/Response
514	civic	Panitumumab	Colorectal Cancer	EGFR	S492R	Sensitivity/Response
515	civic	Panitumumab,Futuximab/Modotuximab Mixture	Colorectal Cancer	EGFR	S492R	Sensitivity/Response
516	civic	Cetuximab	Colorectal Cancer	EGFR	S492R	Resistance
517	civic	Cetuximab,Futuximab/Modotuximab Mixture,Panitumumab	Colorectal Cancer	EGFR	R451C	Sensitivity/Response
518	civic	Futuximab/Modotuximab Mixture,Panitumumab	Colorectal Cancer	EGFR	K467T	Sensitivity/Response
519	civic	Cetuximab	Colorectal Cancer	EGFR	K467T	Resistance
520	civic	Trastuzumab	Her2-receptor Positive Breast Cancer	FCGR3A	F212V	Sensitivity/Response
521	civic	Trastuzumab	Her2-receptor Positive Breast Cancer	FCGR2A	H167R	Sensitivity/Response
522	civic	Cetuximab,Sirolimus	Skin Squamous Cell Carcinoma	EGFR	P753S	Sensitivity/Response
523	civic	Arsenic Trioxide,Tretinoin	Acute Promyelocytic Leukemia	PML	PML::RARA	Sensitivity/Response
524	civic	Tretinoin	Acute Promyelocytic Leukemia	PML	B2 DOMAIN MUTATION	Resistance
525	civic	Tretinoin	Acute Promyelocytic Leukemia	PML	PML::RARA A216V	Resistance
526	civic	Tretinoin	Acute Promyelocytic Leukemia	PML	PML::RARA L218P	Resistance
527	civic	Trastuzumab	Endometrial Serous Adenocarcinoma	ERBB2	Amplification	Sensitivity/Response
528	civic	Trastuzumab	Endometrial Cancer	ERBB2	Amplification	Sensitivity/Response
529	civic	Patidegib	Medulloblastoma	SMO	D473H	Sensitivity/Response
530	civic	Crizotinib	Lung Adenocarcinoma	ROS1	CD74::ROS1 G2032R	Resistance
531	civic	Cabozantinib	Lung Non-small Cell Carcinoma	ROS1	CD74::ROS1 G2032R	Sensitivity/Response
532	civic	OICR-9429	Acute Myeloid Leukemia	CEBPA	N-TERMINAL FRAME SHIFT	Sensitivity/Response
533	civic	Midostaurin	Myeloproliferative Neoplasm	FGFR1	ZNF198::FGFR1	Sensitivity/Response
534	civic	Afimoxifene	Breast Cancer	FGFR1	Amplification	Resistance
535	civic	Sorafenib,Sunitinib	Angiosarcoma	KDR	A1065T	Sensitivity/Response
536	civic	Sunitinib,Sorafenib	Angiosarcoma	KDR	D717V	Sensitivity/Response
537	civic	Everolimus	Thyroid Gland Carcinoma	TSC2	Q1178*	Sensitivity/Response
538	civic	Everolimus	Thyroid Gland Carcinoma	MTOR	F2108L	Resistance
539	civic	Tretinoin,Anthracycline Antineoplastic Antibiotic	Acute Promyelocytic Leukemia	FLT3	ITD	Resistance
540	civic	Neratinib,Trastuzumab	Her2-receptor Positive Breast Cancer	ERBB2	Amplification	Sensitivity/Response
541	civic	Tretinoin	Head And Neck Squamous Cell Carcinoma	ALDH1A2	Underexpression	Sensitivity/Response
542	civic	Gemcitabine	Pancreatic Ductal Adenocarcinoma	CIP2A	Underexpression	Sensitivity/Response
543	civic	Erlotinib	Lung Acinar Adenocarcinoma	ALK	EML4::ALK	Resistance
544	civic	Trastuzumab	Her2-receptor Positive Breast Cancer	ERBB2	Amplification	Sensitivity/Response
545	civic	Trastuzumab Emtansine	Lung Adenocarcinoma	ERBB2	Y772_A775DUP	Sensitivity/Response
546	civic	Erlotinib,Gefitinib	Glioblastoma	EGFR	VIII	Sensitivity/Response
547	civic	Erlotinib,Gefitinib	Glioblastoma	PTEN	Expression	Sensitivity/Response
548	civic	Panitumumab	Colon Mucinous Adenocarcinoma	KRAS	Q22*	Resistance
549	civic	Capecitabine,Lapatinib	Her2-receptor Positive Breast Cancer	ERBB2	Amplification	Sensitivity/Response
550	civic	Trastuzumab,Capecitabine	Her2-receptor Positive Breast Cancer	ERBB2	Amplification	Sensitivity/Response
551	civic	Selumetinib,Trametinib,Mirdametinib	Uveal Melanoma	DDX43	Overexpression	Resistance
552	civic	Selumetinib	Acute Myeloid Leukemia	KIT	RS3733542	Sensitivity/Response
553	civic	Selumetinib	Acute Myeloid Leukemia	FLT3	ITD	Resistance
554	civic	Selumetinib,AZ909	Melanoma	TBK1	Overexpression	Sensitivity/Response
555	civic	Chemotherapy,Bevacizumab	Colorectal Cancer	KRAS	Mutation	Resistance
556	civic	MEK Inhibitor GDC-0623,G-573	Cancer	KRAS	Mutation	Sensitivity/Response
557	civic	Cobimetinib	Cancer	BRAF	V600E	Sensitivity/Response
558	civic	Docetaxel,Selumetinib	Lung Non-small Cell Carcinoma	KRAS	G12C	Sensitivity/Response
559	civic	Selumetinib,Docetaxel	Lung Non-small Cell Carcinoma	KRAS	G12V	Sensitivity/Response
560	civic	Docetaxel,Selumetinib	Lung Non-small Cell Carcinoma	STK11	Loss	Resistance
561	civic	Selumetinib,Docetaxel	Lung Non-small Cell Carcinoma	TP53	Mutation	Sensitivity/Response
562	civic	Docetaxel	Lung Non-small Cell Carcinoma	TP53	Loss	Resistance
563	civic	Adjuvant Chemotherapy	Lung Non-small Cell Carcinoma	TP53	Deleterious Mutation	Sensitivity/Response
564	civic	Adjuvant Chemotherapy	Lung Non-small Cell Carcinoma	TP53	Wildtype	Sensitivity/Response
565	civic	PD1 Inhibitor	Lung Non-small Cell Carcinoma	HAVCR2	Overexpression	Resistance
566	civic	PD1 Inhibitor,Anti-TIM-3 Monoclonal Antibody	Lung Non-small Cell Carcinoma	HAVCR2	Overexpression	Sensitivity/Response
567	civic	Afatinib,Selumetinib	Cancer	ERBB3	Overexpression	Sensitivity/Response
568	civic	Gefitinib,HER2 Inhibitor CP-724,714,Selumetinib	Cancer	ERBB3	Overexpression	Resistance
569	civic	Afatinib	Head And Neck Squamous Cell Carcinoma	CDKN2A	p16 Expression	Resistance
570	civic	Bevacizumab	Inflammatory Breast Carcinoma	MMP2	SERUM LEVELS	Sensitivity/Response
571	civic	Bevacizumab	Inflammatory Breast Carcinoma	MMP9	SERUM LEVELS	Resistance
572	civic	Bevacizumab	Brain Glioma	MMP2	SERUM LEVELS	Sensitivity/Response
573	civic	Trastuzumab Emtansine	Her2-receptor Positive Breast Cancer	ERBB2	Amplification	Sensitivity/Response
574	civic	Trastuzumab Emtansine	Her2-receptor Positive Breast Cancer	ERBB2	Amplification	Sensitivity/Response
575	civic	Cisplatin,Fluorouracil	Gastric Adenocarcinoma	HSPH1	NUCLEAR EXPRESSION	Sensitivity/Response
576	civic	Fluorouracil,Oxaliplatin	Colorectal Cancer	HSPH1	T17 DELETION	Sensitivity/Response
577	civic	Angiogenesis Inhibitor	Cancer	ECSCR	EXPRESSION	Sensitivity/Response
578	civic	Angiogenesis Inhibitor	Cancer	ROBO4	EXPRESSION	Sensitivity/Response
579	civic	Atezolizumab,Avelumab,Pembrolizumab,Nivolumab	Lung Non-small Cell Carcinoma	CD274	Expression	Sensitivity/Response
580	civic	Pazopanib	Sarcoma	TP53	Deleterious Mutation	Sensitivity/Response
581	civic	Gefitinib	Lung Adenocarcinoma	PIK3CA	E545K	Resistance
582	civic	Atezolizumab	Lung Non-small Cell Carcinoma	CD274	Expression	Sensitivity/Response
583	civic	Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor,ARS-853	Cancer	KRAS	G12C	Sensitivity/Response
584	civic	Trastuzumab,Neratinib,Lapatinib	Colon Cancer	ERBB2	V842I	Sensitivity/Response
585	civic	Ceritinib	Lung Non-small Cell Carcinoma	ALK	Fusion	Sensitivity/Response
586	civic	Neratinib,Lapatinib,Trastuzumab	Colon Cancer	ERBB2	L755S	Sensitivity/Response
587	civic	Trastuzumab,Neratinib,Lapatinib	Colon Cancer	ERBB2	V777L	Sensitivity/Response
588	civic	Lapatinib,Trastuzumab,Neratinib	Colon Cancer	ERBB2	L866M	Sensitivity/Response
589	civic	Lapatinib,Trastuzumab,Neratinib	Colon Cancer	ERBB2	S310F/Y	Sensitivity/Response
590	civic	Cetuximab	Colorectal Cancer	KRAS	G13D	Resistance
591	civic	Cetuximab	Colorectal Cancer	KRAS	G13D	Resistance
592	civic	Ixazomib	Colorectal Cancer	KRAS	Mutation	Resistance
593	civic	AZD5438	Cancer	KRAS	Mutation	Sensitivity/Response
594	civic	Crizotinib	Lung Adenocarcinoma	MET	Exon 14 Skipping Mutation	Sensitivity/Response
595	civic	Capmatinib	Lung Adenocarcinoma	MET	Exon 14 Skipping Mutation	Sensitivity/Response
596	civic	Crizotinib	Lung Non-small Cell Carcinoma	ALK	Fusion	Sensitivity/Response
597	civic	WHI-P154	Lung Non-small Cell Carcinoma	ALK	EML4::ALK	Sensitivity/Response
598	civic	Crizotinib	Lung Non-small Cell Carcinoma	ALK	EML4::ALK e20-e20	Sensitivity/Response
599	civic	Crizotinib	Lung Non-small Cell Carcinoma	ALK	EML4::ALK e2-e20	Sensitivity/Response
600	civic	Regorafenib	Colorectal Adenocarcinoma	KDR	R961W	Sensitivity/Response
601	civic	2,4-pyrimidinediamine	Lung Non-small Cell Carcinoma	ALK	EML4::ALK e6-e20	Sensitivity/Response
602	civic	Crizotinib	Lung Non-small Cell Carcinoma	ALK	EML4::ALK e6-e20	Sensitivity/Response
603	civic	TAE684	Lung Non-small Cell Carcinoma	ALK	EML4::ALK e6-e20	Sensitivity/Response
604	civic	TAE684	Lung Non-small Cell Carcinoma	ALK	EML4::ALK e6-e20	Sensitivity/Response
605	civic	Crizotinib	Lung Non-small Cell Carcinoma	ALK	EML4::ALK e20-e20	Sensitivity/Response
606	civic	Crizotinib	Lung Non-small Cell Carcinoma	ALK	EML4::ALK e6-e20	Sensitivity/Response
607	civic	Crizotinib	Lung Non-small Cell Carcinoma	ALK	Fusion	Sensitivity/Response
608	civic	Crizotinib	Lung Non-small Cell Carcinoma	ALK	Fusion	Sensitivity/Response
609	civic	Crizotinib	Lung Non-small Cell Carcinoma	ALK	Fusion	Sensitivity/Response
610	civic	Crizotinib	Lung Non-small Cell Carcinoma	ALK	Fusion	Sensitivity/Response
611	civic	Retaspimycin Hydrochloride	Lung Non-small Cell Carcinoma	ALK	Fusion	Sensitivity/Response
612	civic	Retaspimycin Hydrochloride,Crizotinib	Lung Non-small Cell Carcinoma	ALK	EML4::ALK	Sensitivity/Response
613	civic	Crizotinib,Alvespimycin	Lung Non-small Cell Carcinoma	ALK	EML4::ALK e20-e20	Sensitivity/Response
614	civic	Alvespimycin	Lung Non-small Cell Carcinoma	ALK	EML4::ALK e6-e20	Sensitivity/Response
615	civic	Crizotinib,Alvespimycin	Lung Non-small Cell Carcinoma	ALK	EML4::ALK	Sensitivity/Response
616	civic	Crizotinib	Lung Non-small Cell Carcinoma	ALK	EML4::ALK	Sensitivity/Response
617	civic	Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor	Colorectal Cancer	KRAS	Exon 2 Mutation	Resistance
618	civic	Cisplatin	Cancer	TP53	P47S	Resistance
619	civic	JQ1	Uveal Melanoma	GNAQ	Mutation	Sensitivity/Response
620	civic	JQ1	Uveal Melanoma	GNA11	Mutation	Sensitivity/Response
621	civic	Selumetinib	Uveal Melanoma	GNA11	Q209	Sensitivity/Response
622	civic	Selumetinib	Uveal Melanoma	GNAQ	Q209	Sensitivity/Response
623	civic	Nivolumab	Glioblastoma	PMS2	K706FS*19	Sensitivity/Response
624	civic	Gefitinib,Erlotinib	Colorectal Cancer	KRAS	G12C	Resistance
625	civic	Salirasib	Lung Adenocarcinoma	KRAS	Mutation	Sensitivity/Response
626	civic	Gemcitabine,Erlotinib	Pancreatic Cancer	KRAS	Exon 2 Mutation	Resistance
627	civic	Trametinib	Lung Non-small Cell Carcinoma	KRAS	Mutation	Sensitivity/Response
628	civic	Imatinib	Gastrointestinal Stromal Tumor	KIT	Exon 9 Mutation	Sensitivity/Response
629	civic	Imatinib	Melanoma	KIT	Mutation	Sensitivity/Response
630	civic	Sunitinib	Gastrointestinal Stromal Tumor	KIT	Exon 9 Mutation	Sensitivity/Response
631	civic	Sunitinib	Melanoma	KIT	Exon 11 Mutation	Sensitivity/Response
632	civic	Docetaxel,Trametinib	Skin Melanoma	NRAS	Mutation	Sensitivity/Response
633	civic	Binimetinib	Skin Melanoma	NRAS	Q61	Sensitivity/Response
634	civic	Trametinib	Melanoma	NRAS	Mutation	Sensitivity/Response
635	civic	Trametinib	Uveal Melanoma	GNA11	Mutation	Sensitivity/Response
636	civic	Trametinib	Uveal Melanoma	GNAQ	Mutation	Sensitivity/Response
637	civic	Trametinib,Metformin	Cancer	NRAS	Mutation	Sensitivity/Response
638	civic	Everolimus	Prostate Cancer	PTEN	Deletion	Sensitivity/Response
639	civic	Everolimus	Endometrial Carcinoma	PTEN	Mutation	Sensitivity/Response
640	civic	Refametinib	Uveal Melanoma	GNAQ	Q209	Sensitivity/Response
641	civic	Trichostatin A,Vorinostat,Panobinostat,Valproic Acid	Uveal Melanoma	BAP1	Mutation	Sensitivity/Response
642	civic	MC1568,Vorinostat,Mocetinostat	Malignant Mesothelioma	BAP1	Mutation	Sensitivity/Response
643	civic	Ponatinib	Endometrial Cancer	FGFR2	Mutation	Sensitivity/Response
644	civic	Ceritinib	Lung Non-small Cell Carcinoma	ALK	Mutation	Sensitivity/Response
645	civic	Crizotinib	Anaplastic Large Cell Lymphoma	ALK	NPM::ALK	Sensitivity/Response
646	civic	Crizotinib	Anaplastic Large Cell Lymphoma	ALK	Fusion	Sensitivity/Response
647	civic	Crizotinib	Anaplastic Large Cell Lymphoma	ALK	NPM::ALK	Sensitivity/Response
648	civic	Crizotinib	Inflammatory Myofibroblastic Tumor	ALK	Fusion	Sensitivity/Response
649	civic	Crizotinib	Inflammatory Myofibroblastic Tumor	ALK	RANBP2::ALK	Sensitivity/Response
650	civic	Crizotinib	Cancer	ALK	EML4::ALK e6-e20	Sensitivity/Response
651	civic	Ponatinib	Ewing Sarcoma Of Bone	FGFR1	N546K	Sensitivity/Response
652	civic	Ponatinib	Ewing Sarcoma Of Bone	FGFR1	Amplification	Sensitivity/Response
653	civic	Ceritinib	Lung Adenocarcinoma	ROS1	Rearrangement	Sensitivity/Response
654	civic	Cabozantinib,Foretinib	Lung Non-small Cell Carcinoma	ROS1	CD74::ROS1 G2032R	Sensitivity/Response
655	civic	Brigatinib,AZD3463,Ceritinib,Crizotinib	Lung Non-small Cell Carcinoma	ROS1	CD74::ROS1 G2032R	Resistance
656	civic	Lorlatinib	Lung Non-small Cell Carcinoma	ROS1	CD74::ROS1 G2032R	Sensitivity/Response
657	civic	Crizotinib	Lung Non-small Cell Carcinoma	ROS1	CD74::ROS1 L2026M	Resistance
658	civic	Lorlatinib	Lung Non-small Cell Carcinoma	ROS1	CD74::ROS1 L2026M	Sensitivity/Response
659	civic	Crizotinib	Lung Non-small Cell Carcinoma	ROS1	CD74::ROS1 G2032R	Resistance
660	civic	Foretinib	Lung Non-small Cell Carcinoma	ROS1	CD74::ROS1 G2032R	Sensitivity/Response
661	civic	Crizotinib,Foretinib,ALK Inhibitor TAE684	Lung Non-small Cell Carcinoma	ROS1	CD74::ROS1 L2155S	Resistance
662	civic	Crizotinib	Lung Non-small Cell Carcinoma	ROS1	CD74::ROS1 L2026M	Resistance
663	civic	Foretinib	Lung Non-small Cell Carcinoma	ROS1	CD74::ROS1 L2026M	Sensitivity/Response
664	civic	Crizotinib	Lung Non-small Cell Carcinoma	ROS1	CD74::ROS1 G2101A	Resistance
665	civic	Foretinib	Lung Non-small Cell Carcinoma	ROS1	CD74::ROS1 G2101A	Sensitivity/Response
666	civic	TAE684	Diffuse Large B-cell Lymphoma	ALK	CLTC::ALK	Sensitivity/Response
667	civic	Crizotinib	Diffuse Large B-cell Lymphoma	ALK	Fusion	Sensitivity/Response
668	civic	Crizotinib	Diffuse Large B-cell Lymphoma	ALK	CLTC::ALK	Sensitivity/Response
669	civic	Pan-RAF Inhibitor LY3009120	Cancer	BRAF	DEL 485-490	Sensitivity/Response
670	civic	Crizotinib	Neuroblastoma	ALK	R1275Q	Sensitivity/Response
671	civic	Crizotinib	Neuroblastoma	ALK	R1275Q	Sensitivity/Response
672	civic	Crizotinib	Neuroblastoma	ALK	F1174L	Sensitivity/Response
673	civic	Alectinib	Lung Non-small Cell Carcinoma	ALK	Fusion	Sensitivity/Response
674	civic	Alectinib	Lung Non-small Cell Carcinoma	ALK	Fusion	Sensitivity/Response
675	civic	Alectinib	Lung Non-small Cell Carcinoma	ALK	Fusion	Sensitivity/Response
676	civic	Imatinib	Chronic Myeloid Leukemia	BCL2L11	Deletion Polymorphism	Resistance
677	civic	Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor	Lung Non-small Cell Carcinoma	BCL2L11	Deletion Polymorphism	Resistance
678	civic	Alectinib	Lung Non-small Cell Carcinoma	ALK	Fusion	Sensitivity/Response
679	civic	Alectinib	Lung Non-small Cell Carcinoma	ALK	I1171	Resistance
680	civic	Ceritinib	Lung Non-small Cell Carcinoma	ALK	I1171	Sensitivity/Response
681	civic	TAE684	Lung Non-small Cell Carcinoma	ALK	I1171	Sensitivity/Response
682	civic	Crizotinib	Lung Non-small Cell Carcinoma	ALK	I1171	Resistance
683	civic	Niacinamide	Pancreatic Cancer	SIRT1	Overexpression	Resistance
684	civic	Midostaurin	Acute Myeloid Leukemia	FLT3	TKD MUTATION	Sensitivity/Response
685	civic	Everolimus	Her2-receptor Positive Breast Cancer	PIK3CA	Mutation	Sensitivity/Response
686	civic	Everolimus	Her2-receptor Positive Breast Cancer	PTEN	Loss	Sensitivity/Response
687	civic	Crizotinib	Colorectal Adenocarcinoma	ROS1	Rearrangement	Sensitivity/Response
688	civic	Mitomycin	Pancreatic Cancer	PALB2	Biallelic Inactivation	Sensitivity/Response
689	civic	Mitomycin,Melphalan,Chlorambucil,Cisplatin,Gemcitabine	Pancreatic Cancer	FANCC	Loss-of-function	Sensitivity/Response
690	civic	Mitomycin	Pancreatic Cancer	BRCA2	Loss-of-function	Sensitivity/Response
691	civic	Imatinib	Gastrointestinal Stromal Tumor	PDGFRA	I843DEL	Sensitivity/Response
692	civic	Imatinib	B-lymphoblastic Leukemia/lymphoma, BCR-ABL1–like	PDGFRB	EBF1::PDGFRB	Sensitivity/Response
693	civic	Oxaliplatin	Stomach Carcinoma	MLH1	METHYLATION	Resistance
694	civic	Sunitinib	Renal Cell Carcinoma	FLT3	T227M	Adverse Response
695	civic	Sirolimus	Endometrial Adenocarcinoma	MTOR	S2215Y	Sensitivity/Response
696	civic	Sirolimus	T-cell Acute Lymphoblastic Leukemia	MTOR	C1483Y	Sensitivity/Response
697	civic	Sirolimus	Clear Cell Renal Cell Carcinoma	MTOR	E1799K	Sensitivity/Response
698	civic	PD173074	Endometrial Cancer	FGFR2	N550K	Sensitivity/Response
699	civic	Gemcitabine,Mitomycin,Doxorubicin,Fluorouracil	Pancreatic Adenocarcinoma	RB1	Overexpression	Resistance
700	civic	Bevacizumab,FOLFIRI Regimen	Colorectal Cancer	PPP1R15A	RS557806	Sensitivity/Response
701	civic	Selumetinib,Irinotecan	Colorectal Cancer	KRAS	Exon 2 Mutation	Sensitivity/Response
702	civic	AZD3463	Neuroblastoma	ALK	F1174L	Sensitivity/Response
703	civic	Lorlatinib	Neuroblastoma	ALK	F1174L	Sensitivity/Response
704	civic	Lorlatinib	Neuroblastoma	ALK	F1245C	Sensitivity/Response
705	civic	Lorlatinib	Neuroblastoma	ALK	R1275Q	Sensitivity/Response
706	civic	Lorlatinib	Lung Non-small Cell Carcinoma	ALK	EML4::ALK	Sensitivity/Response
707	civic	Crizotinib	Neuroblastoma	ALK	F1245C	Resistance
708	civic	Crizotinib	Colorectal Adenocarcinoma	ALK	Fusion	Sensitivity/Response
709	civic	Crizotinib	Breast Cancer	ALK	Fusion	Sensitivity/Response
710	civic	Brigatinib	Neuroblastoma	ALK	Exon 4-11 Deletion	Sensitivity/Response
711	civic	Ceritinib	Lung Non-small Cell Carcinoma	ALK	EML4::ALK e6-e20	Sensitivity/Response
712	civic	Ceritinib	Lung Non-small Cell Carcinoma	ALK	I1171	Sensitivity/Response
713	civic	Crizotinib	Cancer	ALK	NPM::ALK	Sensitivity/Response
714	civic	Pictilisib,Tanespimycin	Cancer	PIK3CA	Mutation	Sensitivity/Response
715	civic	Pictilisib,Tanespimycin	Head And Neck Cancer	PTEN	Mutation	Sensitivity/Response
716	civic	Dactolisib	Head And Neck Cancer	PIK3CA	Mutation	Sensitivity/Response
717	civic	Dactolisib	Head And Neck Cancer	PIK3CA	H1047R	Sensitivity/Response
718	civic	Dactolisib	Head And Neck Cancer	PIK3CA	H1047R	Sensitivity/Response
719	civic	Dactolisib,Cetuximab	Head And Neck Cancer	PIK3CA	H1047R	Sensitivity/Response
720	civic	Tanespimycin,Pictilisib,Trametinib	Head And Neck Cancer	PIK3CA	Mutation	Sensitivity/Response
721	civic	Sorafenib	Thyroid Gland Medullary Carcinoma	RET	M918T	Sensitivity/Response
722	civic	Palbociclib	Liposarcoma	CDK4	Amplification	Sensitivity/Response
723	civic	Alectinib	Lung Non-small Cell Carcinoma	ALK	I1171	Resistance
724	civic	Ceritinib	Lung Non-small Cell Carcinoma	ALK	I1171	Sensitivity/Response
725	civic	Olaparib	Cancer	BRCA1	Mutation	Sensitivity/Response
726	civic	Olaparib	Cancer	BRCA2	Mutation	Sensitivity/Response
727	civic	Alvocidib	Skin Melanoma	CDKN2A	Loss	Sensitivity/Response
728	civic	Palbociclib	Renal Cell Carcinoma	CDKN2A	Loss	Sensitivity/Response
729	civic	Palbociclib	Renal Cell Carcinoma	CDKN2B	Loss	Sensitivity/Response
730	civic	Palbociclib	Skin Melanoma	CDKN2A	Loss	Sensitivity/Response
731	civic	Palbociclib	Skin Melanoma	CDK4	R24C	Sensitivity/Response
732	civic	Palbociclib	Ovarian Cancer	CDKN2A	Loss	Sensitivity/Response
733	civic	Pictilisib	Her2-receptor Positive Breast Cancer	ERBB2	Amplification	Sensitivity/Response
734	civic	A66	Her2-receptor Positive Breast Cancer	ERBB2	Amplification	Sensitivity/Response
735	civic	Tgx 221	Her2-receptor Positive Breast Cancer	ERBB2	Amplification	Sensitivity/Response
736	civic	Trastuzumab	Her2-receptor Positive Breast Cancer	PTEN	Loss	Resistance
737	civic	Trastuzumab	Her2-receptor Positive Breast Cancer	PIK3CA	Mutation	Resistance
738	civic	Trastuzumab	Her2-receptor Positive Breast Cancer	PTEN	Loss	Resistance
739	civic	Trastuzumab	Her2-receptor Positive Breast Cancer	PTEN	Loss	Resistance
740	civic	Gefitinib,Erlotinib	Lung Adenocarcinoma	EGFR	T790M	Resistance
741	civic	Gefitinib,Erlotinib	Lung Adenocarcinoma	MET	Amplification	Resistance
742	civic	Erlotinib,Gefitinib	Lung Adenocarcinoma	ERBB2	Amplification	Resistance
743	civic	Erlotinib	Lung Adenocarcinoma	EGFR	S768I	Sensitivity/Response
744	civic	Gefitinib	Lung Adenocarcinoma	EGFR	S768I	Sensitivity/Response
745	civic	Osimertinib	Lung Adenocarcinoma	EGFR	C797S	Resistance
746	civic	Osimertinib	Lung Adenocarcinoma	EGFR	T790M	Sensitivity/Response
747	civic	Vemurafenib	Melanoma	BRAF	V600E	Sensitivity/Response
748	civic	Vemurafenib	Melanoma	BRAF	V600K	Sensitivity/Response
749	civic	Vemurafenib	Melanoma	BRAF	V600K	Sensitivity/Response
750	civic	Alpelisib	Head And Neck Cancer	PIK3CA	H1047R	Sensitivity/Response
751	civic	Alpelisib	Cancer	PIK3CA	Mutation	Sensitivity/Response
752	civic	Alpelisib	Stomach Carcinoma	PIK3CA	Amplification	Sensitivity/Response
753	civic	Cetuximab,Panitumumab	Colorectal Cancer	BRAF	Mutation	Sensitivity/Response
754	civic	Vemurafenib	Colorectal Cancer	BRAF	V600E	Sensitivity/Response
755	civic	Dabrafenib	Colorectal Cancer	BRAF	V600E	Sensitivity/Response
756	civic	Dabrafenib	Melanoma	BRAF	V600	Sensitivity/Response
757	civic	Gefitinib,Cetuximab,Vemurafenib	Colorectal Cancer	BRAF	V600E	Sensitivity/Response
758	civic	Vemurafenib	Skin Melanoma	BRAF	V600E	Sensitivity/Response
759	civic	Vemurafenib	Skin Melanoma	BRAF	V600E	Sensitivity/Response
760	civic	Dabrafenib,Trametinib	Skin Melanoma	BRAF	V600	Sensitivity/Response
761	civic	Vemurafenib,Panitumumab	Colorectal Cancer	BRAF	V600E	Sensitivity/Response
762	civic	Vemurafenib	Thyroid Gland Papillary Carcinoma	BRAF	V600E	Sensitivity/Response
763	civic	Trametinib,Dabrafenib	Colorectal Cancer	BRAF	V600	Sensitivity/Response
764	civic	Vemurafenib	Skin Melanoma	BRAF	TRIM24::BRAF	Resistance
765	civic	Spliceostatin A	Breast Cancer	SF3B1	K700E	Sensitivity/Response
766	civic	Spliceostatin A	Breast Cancer	SF3B1	K666N	Sensitivity/Response
767	civic	Crizotinib	Lung Non-small Cell Carcinoma	ALK	Fusion	Sensitivity/Response
768	civic	Cobimetinib,Vemurafenib	Melanoma	BRAF	V600E	Sensitivity/Response
769	civic	Cobimetinib,Vemurafenib	Melanoma	BRAF	V600	Sensitivity/Response
770	civic	Imatinib	Chronic Leukemia	KIT	M541L	Sensitivity/Response
771	civic	Sunitinib	Gastrointestinal Stromal Tumor	KIT	Exon 9 Mutation	Sensitivity/Response
772	civic	Dactolisib,GDC-0879	Colorectal Cancer	BRAF	V600E	Sensitivity/Response
773	civic	Trametinib,Omipalisib	Melanoma	NRAS	Mutation	Sensitivity/Response
774	civic	Dabrafenib,Trametinib,Vemurafenib	Gastrointestinal Neuroendocrine Tumor	BRAF	V600E	Sensitivity/Response
775	civic	Trastuzumab Emtansine	Her2-receptor Positive Breast Cancer	ERBB2	Amplification	Sensitivity/Response
776	civic	Docetaxel,Trastuzumab,Pertuzumab	Her2-receptor Positive Breast Cancer	ERBB2	Amplification	Sensitivity/Response
777	civic	Trastuzumab,Lapatinib	Her2-receptor Positive Breast Cancer	ERBB2	Amplification	Sensitivity/Response
778	civic	Onatasertib,Sapanisertib	Lung Adenocarcinoma	RICTOR	Amplification	Sensitivity/Response
779	civic	Imatinib	Myeloid And Lymphoid Neoplasms With Eosinophilia And Abnormalities Of PDGFRA, PDGFRB, And FGFR1	PDGFRA	FIP1L1::PDGFRA	Sensitivity/Response
780	civic	Crizotinib	Bronchiolo-alveolar Adenocarcinoma	ROS1	Rearrangement	Sensitivity/Response
781	civic	Crizotinib	Inflammatory Myofibroblastic Tumor	ROS1	TFG::ROS1	Sensitivity/Response
782	civic	Imatinib	Myeloid And Lymphoid Neoplasms With Eosinophilia And Abnormalities Of PDGFRA, PDGFRB, And FGFR1	PDGFRA	FIP1L1::PDGFRA	Sensitivity/Response
783	civic	Imatinib	Myeloid And Lymphoid Neoplasms With Eosinophilia And Abnormalities Of PDGFRA, PDGFRB, And FGFR1	PDGFRA	FIP1L1::PDGFRA T674I	Resistance
784	civic	Dactolisib	Lung Adenocarcinoma	PIK3CA	H1047R	Sensitivity/Response
785	civic	Trastuzumab,Pilaralisib	Her2-receptor Positive Breast Cancer	ERBB2	Amplification	Sensitivity/Response
786	civic	Trastuzumab	Her2-receptor Positive Breast Cancer	BIRC5	Overexpression	Resistance
787	civic	Trastuzumab	Her2-receptor Positive Breast Cancer	PIK3CA	E545K	Resistance
788	civic	Sorafenib,Mitogen-Activated Protein Kinase Kinase Inhibitor	Skin Melanoma	BRAF	D594A	Sensitivity/Response
789	civic	PI3K/BET Inhibitor LY294002,Trastuzumab	Her2-receptor Positive Breast Cancer	PTEN	Loss	Sensitivity/Response
790	civic	Trametinib,Sorafenib	Skin Melanoma	BRAF	D594V	Sensitivity/Response
791	civic	Sorafenib,Mitogen-Activated Protein Kinase Kinase Inhibitor	Skin Melanoma	BRAF	K483M	Sensitivity/Response
792	civic	Trametinib,Vemurafenib	Skin Melanoma	BRAF	L597R	Sensitivity/Response
793	civic	Vemurafenib,Trametinib	Skin Melanoma	BRAF	L597S	Sensitivity/Response
794	civic	MEK Inhibitor TAK-733	Skin Melanoma	BRAF	L597S	Sensitivity/Response
795	civic	Trametinib,Vemurafenib	Skin Melanoma	BRAF	L597Q	Sensitivity/Response
796	civic	Trametinib,Vemurafenib	Skin Melanoma	BRAF	K601E	Sensitivity/Response
797	civic	Trametinib	Skin Melanoma	BRAF	L597V	Sensitivity/Response
798	civic	Taselisib	Head And Neck Squamous Cell Carcinoma	PIK3CA	Amplification	Sensitivity/Response
799	civic	Taselisib	Head And Neck Squamous Cell Carcinoma	PIK3CA	H1047R	Sensitivity/Response
800	civic	Imatinib	Mucosal Melanoma	KIT	Amplification	Resistance
801	civic	Taselisib	Head And Neck Squamous Cell Carcinoma	PTEN	Mutation	Resistance
802	civic	Vemurafenib	Skin Melanoma	NF1	Mutation	Resistance
803	civic	Mirdametinib,Sirolimus	Skin Melanoma	NF1	Mutation	Sensitivity/Response
804	civic	Vemurafenib	Skin Melanoma	NF1	Mutation	Resistance
805	civic	VTX-11e,AZ628	Skin Melanoma	NF1	Mutation	Sensitivity/Response
806	civic	Binimetinib	Skin Melanoma	NRAS	Mutation	Sensitivity/Response
807	civic	Selumetinib	Skin Melanoma	NRAS	Q61	Sensitivity/Response
808	civic	Vemurafenib	Skin Melanoma	NRAS	Q61K	Resistance
809	civic	Selumetinib	Skin Melanoma	NRAS	Q61K	Sensitivity/Response
810	civic	Amuvatinib	Skin Melanoma	NRAS	Mutation	Sensitivity/Response
811	civic	Vismodegib,Sonidegib	Basal Cell Carcinoma	SMO	Mutation	Resistance
812	civic	Alemtuzumab	Chronic Lymphocytic Leukemia	TP53	Mutation	Sensitivity/Response
813	civic	Peginterferon Alfa-2a	Essential Thrombocythemia	CALR	EXON 9 FRAMESHIFT	Sensitivity/Response
814	civic	Radiation Therapy,Taselisib	Head And Neck Squamous Cell Carcinoma	PIK3CA	Mutation	Sensitivity/Response
815	civic	Ipatasertib	Cancer	PTEN	Mutation	Sensitivity/Response
816	civic	Cisplatin	Ovarian Cancer	PTEN	Loss	Resistance
817	civic	Chemotherapy	Stomach Carcinoma	PTEN	Loss	Resistance
818	civic	GSK126	Skin Melanoma	EZH2	Y646	Sensitivity/Response
819	civic	Carboplatin,Paclitaxel,Sorafenib	Skin Melanoma	CCND1	Amplification	Sensitivity/Response
820	civic	Carboplatin,Sorafenib,Paclitaxel	Skin Melanoma	RAF1	Amplification	Sensitivity/Response
821	civic	Carboplatin,Docetaxel,Sorafenib	Skin Melanoma	KRAS	Amplification	Sensitivity/Response
822	civic	Imatinib	Myeloproliferative Neoplasm	PDGFRB	Fusion	Sensitivity/Response
823	civic	Trastuzumab	Gastric Adenocarcinoma	ERBB2	Amplification	Sensitivity/Response
824	civic	Docetaxel,Capivasertib	Stomach Cancer	PTEN	Loss	Sensitivity/Response
825	civic	Capivasertib	Stomach Cancer	PIK3CA	Mutation	Sensitivity/Response
826	civic	Capivasertib	Cancer	PTEN	Loss	Sensitivity/Response
827	civic	Capivasertib	Cancer	PIK3CA	Mutation	Sensitivity/Response
828	civic	Capivasertib	Her2-receptor Positive Breast Cancer	PIK3CA	Mutation	Sensitivity/Response
829	civic	Trastuzumab,Capivasertib	Her2-receptor Positive Breast Cancer	PIK3CA	H1047R	Sensitivity/Response
830	civic	Capivasertib,Lapatinib	Her2-receptor Positive Breast Cancer	PIK3CA	H1047R	Sensitivity/Response
831	civic	Binimetinib	Melanoma	NRAS	Mutation	Sensitivity/Response
832	civic	Nivolumab	Cancer	CD274	Expression	Sensitivity/Response
833	civic	Sunitinib	Papillary Adenocarcinoma	RET	Overexpression	Sensitivity/Response
834	civic	Tretinoin	Acute Promyelocytic Leukemia	PML	PML::RARA	Sensitivity/Response
835	civic	Ipilimumab	Sezary's Disease	CTLA4	CTLA4::CD28	Sensitivity/Response
836	civic	Cyproterone Acetate,Flutamide,Bicalutamide,Nilutamide	Prostate Cancer	AR	Mutation	Resistance
837	civic	Alpelisib,Enzalutamide,PI3Kbeta Inhibitor AZD8186	Prostate Cancer	PTEN	Mutation	Sensitivity/Response
838	civic	Porcupine Inhibitor WNT974	Head And Neck Squamous Cell Carcinoma	NOTCH1	Loss-of-function	Sensitivity/Response
839	civic	Fulvestrant	Estrogen-receptor Positive Breast Cancer	CDK6	Overexpression	Resistance
840	civic	Fulvestrant,Palbociclib	Estrogen-receptor Positive Breast Cancer	CDK6	Overexpression	Sensitivity/Response
841	civic	Sunitinib	B-cell Adult Acute Lymphocytic Leukemia	FLT3	Overexpression	Sensitivity/Response
842	civic	Platinum Compound	Ovarian Carcinoma	BRCA1	Mutation	Sensitivity/Response
843	civic	Platinum Compound	Ovarian Carcinoma	BRCA2	Mutation	Sensitivity/Response
844	civic	Platinum Compound	Ovarian Carcinoma	BRCA1	Mutation	Sensitivity/Response
845	civic	Platinum Compound	Ovarian Carcinoma	BRCA2	Mutation	Sensitivity/Response
846	civic	Vemurafenib	Skin Melanoma	GNAQ	Q209P	Resistance
847	civic	MEK Inhibitor CI-1040,Akt Inhibitor MK2206	Skin Melanoma	PTEN	V317FS	Sensitivity/Response
848	civic	Palbociclib	Breast Cancer	RB1	Loss-of-function	Resistance
849	civic	Palbociclib	Mantle Cell Lymphoma	CCND1	Overexpression	Sensitivity/Response
850	civic	PLX4720	Skin Melanoma	GNAQ	Q209P	Resistance
851	civic	Palbociclib,Letrozole	Breast Cancer	ESR1	Overexpression	Sensitivity/Response
852	civic	Sirolimus	Breast Cancer	MTOR	F2108L	Resistance
853	civic	MTOR Kinase Inhibitor AZD8055	Breast Cancer	MTOR	M2327I	Resistance
854	civic	RapaLink-1,Sirolimus	Breast Cancer	MTOR	M2327I	Resistance
855	civic	Sirolimus	Breast Cancer	MTOR	A2034V	Resistance
856	civic	RapaLink-1,MTOR Kinase Inhibitor AZD8055	Breast Cancer	MTOR	A2034V	Resistance
857	civic	Apitolisib	Head And Neck Squamous Cell Carcinoma	PIK3CA	E542K	Sensitivity/Response
858	civic	Apitolisib	Cancer	PIK3CA	E545K	Sensitivity/Response
859	civic	Cetuximab,Panitumumab	Colorectal Cancer	BRAF	D594G	Resistance
860	civic	Sorafenib	Acute Myeloid Leukemia	FLT3	ITD	Sensitivity/Response
861	civic	Sorafenib	Acute Myeloid Leukemia	FLT3	D835H	Resistance
862	civic	Sorafenib	Acute Myeloid Leukemia	FLT3	D835H/Y	Resistance
863	civic	Palbociclib	Renal Cell Carcinoma	CCND1	Amplification	Sensitivity/Response
864	civic	Palbociclib,Trastuzumab	Her2-receptor Positive Breast Cancer	ERBB2	Amplification	Sensitivity/Response
865	civic	Palbociclib	Breast Cancer	CCND1	Amplification	Sensitivity/Response
866	civic	Palbociclib	Mantle Cell Lymphoma	CCND1	Overexpression	Sensitivity/Response
867	civic	Crizotinib	Glioblastoma	MET	Amplification	Sensitivity/Response
868	civic	Crizotinib	Lung Non-small Cell Carcinoma	MET	Amplification	Sensitivity/Response
869	civic	Pembrolizumab	Skin Melanoma	JAK1	Q503*	Resistance
870	civic	Pembrolizumab	Skin Melanoma	JAK2	c.1641+1dup	Resistance
871	civic	Pembrolizumab	Skin Melanoma	B2M	S14FS	Resistance
872	civic	Trametinib	Skin Melanoma	BRAF	PPFIBP2::BRAF	Sensitivity/Response
873	civic	Trametinib	Skin Melanoma	BRAF	KIAA1549::BRAF	Sensitivity/Response
874	civic	Cetuximab	Colorectal Cancer	EGFR	Expression	Sensitivity/Response
875	civic	Vemurafenib	Lung Non-small Cell Carcinoma	BRAF	V600	Sensitivity/Response
876	civic	Vemurafenib	Langerhans-cell Histiocytosis	BRAF	V600	Sensitivity/Response
877	civic	Vemurafenib	Colorectal Cancer	BRAF	V600	Resistance
878	civic	Crizotinib	Lung Non-small Cell Carcinoma	ALK	Fusion	Sensitivity/Response
879	civic	Pembrolizumab	Merkel Cell Carcinoma	CD274	Expression	Sensitivity/Response
880	civic	Vemurafenib	Hairy Cell Leukemia	BRAF	V600E	Sensitivity/Response
881	civic	Vemurafenib	Hairy Cell Leukemia	KRAS	G12D	Resistance
882	civic	Vemurafenib	Skin Melanoma	MET	Overexpression	Resistance
883	civic	Crizotinib	Uveal Melanoma	MET	Overexpression	Sensitivity/Response
884	civic	Vemurafenib	Skin Melanoma	MET	Overexpression	Resistance
885	civic	Decitabine	Acute Myeloid Leukemia	DNMT3A	Mutation	Sensitivity/Response
886	civic	Crizotinib,Vemurafenib	Colorectal Cancer	MET	Amplification	Sensitivity/Response
887	civic	Panitumumab,Vemurafenib	Colorectal Cancer	BRAF	V600E	Sensitivity/Response
888	civic	Vemurafenib	Thyroid Gland Papillary Carcinoma	BRAF	V600E	Sensitivity/Response
889	civic	Osimertinib	Lung Non-small Cell Carcinoma	EGFR	T790M	Sensitivity/Response
890	civic	Palbociclib	Glioblastoma	RB1	Loss-of-function	Resistance
891	civic	Vorinostat	Sarcoma	RAD23B	EXPRESSION	Sensitivity/Response
892	civic	Vemurafenib,Cetuximab	Colorectal Cancer	BRAF	V600	Sensitivity/Response
893	civic	Palbociclib	Ovarian Cancer	CCND1	Amplification	Sensitivity/Response
894	civic	Phosphatidylinositide 3-Kinase Inhibitor,Ribociclib	Breast Cancer	PIK3CA	Mutation	Sensitivity/Response
895	civic	Nintedanib	Lung Non-small Cell Carcinoma	RET	CCDC6::RET	Sensitivity/Response
896	civic	Vemurafenib	Melanoma	MAP2K1	C121S	Resistance
897	civic	Pazopanib	Transitional Cell Carcinoma	FGFR3	S249C	Sensitivity/Response
898	civic	Dovitinib	Breast Cancer	FGFR1	Amplification	Sensitivity/Response
899	civic	Dovitinib	Breast Cancer	FGFR2	Amplification	Sensitivity/Response
900	civic	Dovitinib	Breast Cancer	FGF3	Amplification	Sensitivity/Response
901	civic	Palbociclib,Phosphatidylinositide 3-Kinase Inhibitor	Breast Cancer	PIK3CA	Mutation	Sensitivity/Response
902	civic	Ruxolitinib	Chuvash Polycythemia	VHL	R200W (c.598C>T)	Sensitivity/Response
903	civic	Alpelisib	Breast Cancer	RB1	PHOSPHORYLATION	Resistance
904	civic	MTOR Kinase Inhibitor PP242,Everolimus	Breast Cancer	PIK3CA	Mutation	Sensitivity/Response
905	civic	MTOR Kinase Inhibitor PP242,Everolimus	Breast Cancer	PTEN	Loss	Sensitivity/Response
906	civic	MTOR Kinase Inhibitor PP242	Breast Cancer	PIK3R1	Mutation	Sensitivity/Response
907	civic	MTOR Kinase Inhibitor PP242	Breast Cancer	ERBB2	Amplification	Sensitivity/Response
908	civic	Temsirolimus	Endometrial Cancer	PTEN	Loss	Sensitivity/Response
909	civic	Ipilimumab,Nivolumab	Melanoma	CD274	Expression	Sensitivity/Response
910	civic	Pictilisib	Endometrial Cancer	PIK3CA	Mutation	Sensitivity/Response
911	civic	Everolimus	Pancreatic Cancer	STK11	D194E	Sensitivity/Response
912	civic	Sirolimus	Peutz-Jeghers Syndrome	STK11	Loss	Sensitivity/Response
913	civic	Sirolimus	Peutz-Jeghers Syndrome	STK11	Loss	Sensitivity/Response
914	civic	Everolimus,Sirolimus	Lung Non-small Cell Carcinoma	STK11	Loss	Sensitivity/Response
915	civic	Vandetanib,Everolimus	Lung Adenocarcinoma	AKT2	Amplification	Sensitivity/Response
916	civic	Vandetanib,Everolimus	Lung Adenocarcinoma	RET	KIF5B::RET	Sensitivity/Response
917	civic	Fulvestrant,Everolimus	Her2-receptor Positive Breast Cancer	PIK3CA	H1047R	Sensitivity/Response
918	civic	Fulvestrant,Everolimus	Her2-receptor Positive Breast Cancer	PTEN	Expression	Resistance
919	civic	Temsirolimus,Perifosine	Thyroid Gland Cancer	PIK3CA	H1047R	Sensitivity/Response
920	civic	Temsirolimus,Perifosine	Thyroid Gland Cancer	PIK3CA	E542K	Sensitivity/Response
921	civic	Perifosine,Temsirolimus	Thyroid Gland Cancer	PTEN	R130*	Sensitivity/Response
922	civic	Everolimus	Renal Cell Carcinoma	FBXW7	Loss-of-function	Sensitivity/Response
923	civic	Palbociclib	Estrogen-receptor Positive Breast Cancer	CCNE1	Amplification	Resistance
924	civic	Palbociclib	Estrogen-receptor Positive Breast Cancer	RB1	M695FS*26	Resistance
925	civic	MTOR Inhibitor	Cancer	FBXW7	Mutation	Sensitivity/Response
926	civic	Sirolimus	Cancer	FBXW7	Loss-of-function	Sensitivity/Response
927	civic	Irbesartan	Colorectal Adenocarcinoma	JUN	Overexpression	Sensitivity/Response
928	civic	Irbesartan	Colon Adenocarcinoma	FOS	Overexpression	Sensitivity/Response
929	civic	IRAK-1/4 Inhibitor,IMG-2005-5	Lymphoplasmacytic Lymphoma	MYD88	L265P	Sensitivity/Response
930	civic	Refametinib,Sorafenib	Hepatocellular Carcinoma	KRAS	Mutation	Sensitivity/Response
931	civic	Fluorouracil	Colorectal Cancer	SMAD4	Deletion	Resistance
932	civic	PCV Regimen,Temozolomide	Malignant Astrocytoma	ATRX	Underexpression	Sensitivity/Response
933	civic	Platinum Compound	Ovarian Serous Carcinoma	AURKA	Overexpression	Resistance
934	civic	Crizotinib	Lung Adenocarcinoma	MET	Exon 14 Skipping Mutation	Sensitivity/Response
935	civic	Crizotinib	Lung Non-small Cell Carcinoma	MET	D1228N	Resistance
936	civic	Radiation Therapy,Cisplatin,Fluorouracil	Esophagus Squamous Cell Carcinoma	AURKA	EXPRESSION	Sensitivity/Response
937	civic	Docetaxel	Prostate Cancer	GAS6	EXPRESSION	Resistance
938	civic	Vemurafenib	Melanoma	STAG2	Underexpression	Resistance
939	civic	Vemurafenib	Melanoma	STAG3	Underexpression	Resistance
940	civic	Selumetinib	Ovarian Serous Carcinoma	MAP2K1	Q56_V60del	Sensitivity/Response
941	civic	Mitogen-Activated Protein Kinase Kinase Inhibitor	Ovarian Serous Carcinoma	BRAF	BRAF::CUL1	Sensitivity/Response
942	civic	Trametinib	Melanoma	BRAF	ZKSCAN1::BRAF	Sensitivity/Response
943	civic	Sorafenib,Bevacizumab,Temsirolimus	Spindle Cell Sarcoma	BRAF	KIAA1549::BRAF	Sensitivity/Response
944	civic	Gefitinib	Lung Non-small Cell Carcinoma	EGFR	L858R	Sensitivity/Response
945	civic	Gefitinib	Lung Non-small Cell Carcinoma	EGFR	Exon 19 Deletion	Sensitivity/Response
946	civic	Erlotinib,Gefitinib	Lung Non-small Cell Carcinoma	EGFR	T790M	Resistance
947	civic	Vemurafenib	Melanoma	BRAF	L505H	Resistance
948	civic	Vemurafenib	Melanoma	BRAF	L505H	Resistance
949	civic	Erlotinib,Gefitinib	Lung Adenocarcinoma	PIK3CA	E545K	Resistance
950	civic	Pazopanib	Renal Cell Carcinoma	VHL	Mutation	Sensitivity/Response
951	civic	Pazopanib	Renal Cell Carcinoma	EPAS1	Overexpression	Sensitivity/Response
952	civic	Pazopanib	Renal Cell Carcinoma	HIF1A	EXPRESSION	Sensitivity/Response
953	civic	Cediranib,Olaparib	Ovarian Cancer	BRCA1	Mutation	Sensitivity/Response
954	civic	Olaparib,Cediranib	Ovarian Cancer	BRCA2	Mutation	Sensitivity/Response
955	civic	Carboplatin,Cisplatin	Triple-receptor Negative Breast Cancer	BRCA1	Mutation	Sensitivity/Response
956	civic	Cisplatin,Carboplatin	Triple-receptor Negative Breast Cancer	BRCA2	Mutation	Sensitivity/Response
957	civic	Cetuximab	Colorectal Cancer	ERBB2	Amplification	Resistance
958	civic	Cetuximab	Colorectal Cancer	ERBB2	Amplification	Resistance
959	civic	Cetuximab,Panitumumab	Colorectal Cancer	ERBB2	Amplification	Resistance
960	civic	Lapatinib,Trastuzumab	Colorectal Cancer	ERBB2	Amplification	Sensitivity/Response
961	civic	Crizotinib	Lung Adenocarcinoma	ROS1	Rearrangement	Sensitivity/Response
962	civic	Crizotinib	Lung Adenocarcinoma	ALK	Fusion	Sensitivity/Response
963	civic	Crizotinib	Lung Adenocarcinoma	MET	Amplification	Sensitivity/Response
964	civic	Trastuzumab	Scrotum Paget's Disease	ERBB2	Amplification	Sensitivity/Response
965	civic	Platinum Compound	Bladder Carcinoma	ERBB2	Mutation	Sensitivity/Response
966	civic	Vemurafenib	Multiple Myeloma	BRAF	V600E	Sensitivity/Response
967	civic	Vemurafenib	Multiple Myeloma	BRAF	V600E	Sensitivity/Response
968	civic	Cetuximab	Colorectal Cancer	KRAS	Mutation	Resistance
969	civic	Cetuximab	Colorectal Cancer	NRAS	Mutation	Resistance
970	civic	Cetuximab	Colorectal Cancer	BRAF	Mutation	Resistance
971	civic	Cetuximab	Colorectal Cancer	PIK3CA	Mutation	Resistance
972	civic	JQ1,I-BET151	Multiple Myeloma	MYCL	EXPRESSION	Sensitivity/Response
973	civic	MET Tyrosine Kinase Inhibitor SGX523	Glioblastoma	HGF	EXPRESSION	Sensitivity/Response
974	civic	Panitumumab	Colorectal Cancer	EGFR	Expression	Sensitivity/Response
975	civic	Cetuximab	Colorectal Cancer	EGFR	Expression	Sensitivity/Response
976	civic	Vemurafenib	Melanoma	SOX10	Loss	Resistance
977	civic	Quizartinib	Acute Myeloid Leukemia	FGF2	EXPRESSION	Resistance
978	civic	Crizotinib	Lung Non-small Cell Carcinoma	MET	Amplification	Sensitivity/Response
979	civic	Crizotinib	Cancer	MET	Amplification	Sensitivity/Response
980	civic	Crizotinib	Cancer	KRAS	G12V	Resistance
981	civic	Erlotinib	Cholangiocarcinoma	ERRFI1	E384*	Sensitivity/Response
982	civic	Midostaurin	Systemic Mastocytosis	KIT	D816V	Sensitivity/Response
983	civic	Aromatase Inhibitor	Estrogen-receptor Positive Breast Cancer	ESR1	S463P	Resistance
984	civic	Afatinib	Lung Non-small Cell Carcinoma	EGFR	Mutation	Sensitivity/Response
985	civic	Alpelisib	Breast Cancer	SGK1	Overexpression	Resistance
986	civic	Alpelisib	Breast Cancer	SGK1	Overexpression	Resistance
987	civic	SGK1-Inh,Alpelisib	Breast Cancer	SGK1	Overexpression	Sensitivity/Response
988	civic	Pembrolizumab	Lung Non-small Cell Carcinoma	CD274	Expression	Sensitivity/Response
989	civic	CDK Inhibitor SNS-032	Ovarian Cancer	CCNE1	Overexpression	Sensitivity/Response
990	civic	Dinaciclib,Akt Inhibitor MK2206	Ovarian Serous Cystadenocarcinoma	CCNE1	Amplification	Sensitivity/Response
991	civic	Gefitinib,Erlotinib	Lung Non-small Cell Carcinoma	EGFR	G719S	Sensitivity/Response
992	civic	Trametinib,Dabrafenib	Lung Non-small Cell Carcinoma	BRAF	G596C	Sensitivity/Response
993	civic	Tazemetostat	Synovial Sarcoma	SMARCB1	Underexpression	Sensitivity/Response
994	civic	Tazemetostat	Rhabdoid Cancer	SMARCB1	Deletion	Sensitivity/Response
995	civic	Selumetinib	Thyroid Gland Carcinoma	NF2	Loss	Sensitivity/Response
996	civic	JQ1 Compound	Malignant Peripheral Nerve Sheath Tumor	NF1	Loss	Sensitivity/Response
997	civic	Afatinib	Transitional Cell Carcinoma	ERBB3	V104M	Sensitivity/Response
998	civic	Afatinib	Transitional Cell Carcinoma	ERBB3	R103G	Sensitivity/Response
999	civic	Afatinib	Transitional Cell Carcinoma	ERBB3	G284R	Sensitivity/Response
1000	civic	Vemurafenib	Melanoma	BRAF	V600E	Sensitivity/Response
1001	civic	Trametinib	Melanoma	BRAF	V600	Sensitivity/Response
1002	civic	Fluorouracil	Rectum Cancer	MTHFR	A222V	Sensitivity/Response
1003	civic	Erlotinib,Gefitinib	Lung Non-small Cell Carcinoma	EGFR	D761Y	Resistance
1004	civic	Trastuzumab Emtansine	Her2-receptor Positive Breast Cancer	ERBB2	Amplification	Sensitivity/Response
1005	civic	Letrozole,Palbociclib	Her2-receptor Negative Breast Cancer	CDKN2A	Loss	Sensitivity/Response
1006	civic	Lenalidomide,Pomalidomide	Multiple Myeloma	CRBN	Mutation	Resistance
1007	civic	Ponatinib	Estrogen-receptor Positive Breast Cancer	FGFR1	Amplification	Sensitivity/Response
1008	civic	Ibrutinib	Chronic Lymphocytic Leukemia	BTK	C481S	Resistance
1009	civic	Sunitinib	Lung Non-small Cell Carcinoma	PDGFRA	Amplification	Sensitivity/Response
1010	civic	Olaparib	Ovarian Cancer	BRCA1	Mutation	Sensitivity/Response
1011	civic	Olaparib	Ovarian Cancer	BRCA2	Mutation	Sensitivity/Response
1012	civic	Imatinib	Myeloid And Lymphoid Neoplasms With Eosinophilia And Abnormalities Of PDGFRA, PDGFRB, And FGFR1	PDGFRA	FIP1L1::PDGFRA	Sensitivity/Response
1013	civic	Olaparib	Triple-receptor Negative Breast Cancer	BRCA1	Mutation	Resistance
1014	civic	Olaparib	Triple-receptor Negative Breast Cancer	BRCA2	Mutation	Sensitivity/Response
1015	civic	Ponatinib	Myeloid And Lymphoid Neoplasms With Eosinophilia And Abnormalities Of PDGFRA, PDGFRB, And FGFR1	PDGFRA	FIP1L1::PDGFRA	Sensitivity/Response
1016	civic	Ponatinib	Myeloid And Lymphoid Neoplasms With Eosinophilia And Abnormalities Of PDGFRA, PDGFRB, And FGFR1	PDGFRA	FIP1L1::PDGFRA T674I	Sensitivity/Response
1017	civic	Erlotinib	Lung Adenocarcinoma	EGFR	G719	Sensitivity/Response
1018	civic	JQ1	NUT Midline Carcinoma	BRD4	BRD4::NUTM1	Sensitivity/Response
1019	civic	Erlotinib	Lung Adenocarcinoma	EGFR	S720	Resistance
1020	civic	Erlotinib	Lung Adenocarcinoma	EGFR	K757R	Sensitivity/Response
1021	civic	Erlotinib	Lung Adenocarcinoma	EGFR	E746G	Sensitivity/Response
1022	civic	Belinostat	Cancer	UGT1A1	UGT1A1*28	Adverse Response
1023	civic	Belinostat	Cancer	UGT1A1	UGT1A1*60	Adverse Response
1024	civic	Erlotinib	Lung Adenocarcinoma	EGFR	V769_D770insASV	Sensitivity/Response
1025	civic	Fluorouracil,Capecitabine,Tegafur	Cancer	DPYD	DPYD*2A HOMOZYGOSITY	Adverse Response
1026	civic	Tegafur,Fluorouracil,Capecitabine	Cancer	DPYD	DPYD*13 HOMOZYGOSITY	Adverse Response
1027	civic	Capecitabine,Tegafur,Fluorouracil	Cancer	DPYD	RS67376798 HOMOZYGOSITY	Adverse Response
1028	civic	Afatinib	Lung Adenocarcinoma	EGFR	Exon 20 Insertion	Resistance
1029	civic	Imatinib	Myeloid And Lymphoid Neoplasms With Eosinophilia And Abnormalities Of PDGFRA, PDGFRB, And FGFR1	PDGFRA	TNKS2::PDGFRA	Sensitivity/Response
1030	civic	Methotrexate	Cancer	SLCO1B1	RS4149056	Adverse Response
1031	civic	Methotrexate	Cancer	SLCO1B1	N130D	Adverse Response
1032	civic	Methotrexate	Cancer	TYMS	RS34743033	Adverse Response
1033	civic	Afatinib,Pertuzumab	Lung Non-small Cell Carcinoma	ERBB3	V855A	Sensitivity/Response
1034	civic	Infigratinib,PD173074	Cholangiocarcinoma	FGFR2	FGFR2::BICC1	Sensitivity/Response
1035	civic	PD173074,Infigratinib	Cholangiocarcinoma	FGFR2	FGFR2::AHCYL1	Sensitivity/Response
1036	civic	Teprotumumab,Cixutumumab	Ewing Sarcoma Of Bone	PTPRD	V253I	Sensitivity/Response
1037	civic	Gemcitabine	Pancreatic Cancer	RRM1	Overexpression	Resistance
1038	civic	Gemcitabine	Pancreatic Cancer	RRM2	OVEREXPRESSION	Resistance
1039	civic	Pembrolizumab	Glioblastoma	POLE	Mutation	Sensitivity/Response
1040	civic	Pembrolizumab	Endometrial Cancer	POLE	Mutation	Sensitivity/Response
1041	civic	Afatinib	Lung Non-small Cell Carcinoma	EGFR	T790M	Resistance
1042	civic	Cabozantinib	Lung Non-small Cell Carcinoma	MET	D1228V	Sensitivity/Response
1043	civic	Savolitinib	Lung Non-small Cell Carcinoma	MET	D1228V	Resistance
1044	civic	Chemotherapy	Lung Small Cell Carcinoma	RB1	Mutation	Sensitivity/Response
1045	civic	Osimertinib	Lung Non-small Cell Carcinoma	EGFR	T790M	Sensitivity/Response
1046	civic	Entrectinib	Lung Non-small Cell Carcinoma	NTRK1	SQSTM1::NTRK1	Sensitivity/Response
1047	civic	Entrectinib	Mammary Analogue Secretory Carcinoma	NTRK3	ETV6::NTRK3	Sensitivity/Response
1048	civic	Crizotinib	Mammary Analogue Secretory Carcinoma	NTRK3	ETV6::NTRK3	Sensitivity/Response
1049	civic	Entrectinib	Mammary Analogue Secretory Carcinoma	NTRK3	ETV6::NTRK3 G623R	Resistance
1050	civic	Anti-PD-1 Monoclonal Antibody MEDI0680,Durvalumab	Transitional Cell Carcinoma	MSH2	Loss	Sensitivity/Response
1051	civic	Anti-PD-1 Monoclonal Antibody MEDI0680,Durvalumab	Transitional Cell Carcinoma	MSH6	LOSS	Sensitivity/Response
1052	civic	Palbociclib,Linsitinib	Ewing Sarcoma	CDKN2A	Loss	Sensitivity/Response
1053	civic	Palbociclib,Linsitinib	Ewing Sarcoma	CDKN2B	Loss	Sensitivity/Response
1054	civic	Palbociclib	Dermatofibrosarcoma Protuberans	CDKN2A	Loss	Sensitivity/Response
1055	civic	Afatinib	Lung Adenocarcinoma	ERBB2	Y772_A775DUP	Sensitivity/Response
1056	civic	Afatinib	Lung Adenocarcinoma	ERBB2	G776L	Sensitivity/Response
1057	civic	Afatinib	Lung Adenocarcinoma	ERBB2	G778_P780DUP	Sensitivity/Response
1058	civic	Dacomitinib	Lung Non-small Cell Carcinoma	ERBB2	Amplification	Sensitivity/Response
1059	civic	Dacomitinib	Lung Non-small Cell Carcinoma	ERBB2	G778_P780DUP	Sensitivity/Response
1060	civic	Dacomitinib	Lung Non-small Cell Carcinoma	ERBB2	Y772_A775DUP	Sensitivity/Response
1061	civic	Dacomitinib	Lung Non-small Cell Carcinoma	ERBB2	M774DELINSWLV	Sensitivity/Response
1062	civic	Vatalanib,Sunitinib	Angiosarcoma	PTPRB	Loss-of-function	Sensitivity/Response
1063	civic	Rucaparib	Ovarian Cancer	BRCA1	Mutation	Sensitivity/Response
1064	civic	Therapeutic Tumor Infiltrating Lymphocytes	Colorectal Cancer	KRAS	G12D	Sensitivity/Response
1065	civic	Therapeutic Tumor Infiltrating Lymphocytes	Colorectal Cancer	HLA-C	COPY-NEUTRAL LOSS OF HETEROZYGOSITY	Resistance
1066	civic	Ruxolitinib	Hepatocellular Carcinoma	JAK1	S703I	Sensitivity/Response
1067	civic	Vemurafenib,Irinotecan,Cetuximab	Colorectal Cancer	BRAF	V600E	Sensitivity/Response
1068	civic	Irinotecan,Vemurafenib,Cetuximab	Colorectal Cancer	ARAF	S490T	Resistance
1069	civic	Vemurafenib,Irinotecan,Cetuximab	Colorectal Cancer	GNAS	R201C	Resistance
1070	civic	Olaparib	Mantle Cell Lymphoma	ATM	Mutation	Sensitivity/Response
1071	civic	Infigratinib	Lung Squamous Cell Carcinoma	FGFR1	Amplification	Sensitivity/Response
1072	civic	Infigratinib	Breast Cancer	FGFR1	Amplification	Resistance
1073	civic	Infigratinib	Bladder Carcinoma	FGFR3	Mutation	Sensitivity/Response
1074	civic	Infigratinib	Bladder Carcinoma	FGFR1	Amplification	Sensitivity/Response
1075	civic	Infigratinib	Cholangiocarcinoma	FGFR2	Mutation	Sensitivity/Response
1076	civic	Infigratinib	Cholangiocarcinoma	FGFR2	Fusion	Sensitivity/Response
1077	civic	Erdafitinib	Transitional Cell Carcinoma	FGFR2	FGFR2::BICC1	Sensitivity/Response
1078	civic	Erdafitinib	Cancer	FGFR2	Fusion	Sensitivity/Response
1079	civic	Erdafitinib	Cancer	FGFR3	FGFR3::TACC3	Sensitivity/Response
1080	civic	Erdafitinib	Endometrial Cancer	FGFR2	FGFR2::BICC1	Sensitivity/Response
1081	civic	Akt Inhibitor MK2206	Breast Cancer	AKT3	Overexpression	Resistance
1082	civic	Pan-AKT Kinase Inhibitor GSK690693	Triple-receptor Negative Breast Cancer	AKT3	Overexpression	Sensitivity/Response
1083	civic	Quarfloxin,Pidnarulex	Breast Cancer	BRCA1	Loss-of-function	Sensitivity/Response
1084	civic	Pidnarulex,Quarfloxin	Breast Cancer	BRCA2	Loss-of-function	Sensitivity/Response
1085	civic	Crizotinib	Skin Melanoma	ALK	Alternative Transcript (ATI)	Sensitivity/Response
1086	civic	Gefitinib	Lung Non-small Cell Carcinoma	EGFR	Mutation	Sensitivity/Response
1087	civic	Mirdametinib,Sotrastaurin Acetate	Uveal Melanoma	GNA11	Mutation	Sensitivity/Response
1088	civic	Sotrastaurin Acetate,Mirdametinib	Uveal Melanoma	GNAQ	Mutation	Sensitivity/Response
1089	civic	Selumetinib	Plexiform Neurofibroma	NF1	Mutation	Sensitivity/Response
1090	civic	Olaparib	Prostate Cancer	ATM	Mutation	Sensitivity/Response
1091	civic	Olaparib	Prostate Cancer	PALB2	Biallelic Inactivation	Sensitivity/Response
1092	civic	Anti-EGFR Monoclonal Antibody	Colorectal Cancer	MET	Amplification	Resistance
1093	civic	Crenolanib,Imatinib	Melanoma	PDGFRA	P577S	Sensitivity/Response
1094	civic	Imatinib,Crenolanib	Melanoma	PDGFRA	R841K	Sensitivity/Response
1095	civic	Imatinib,Crenolanib	Melanoma	PDGFRA	H845Y	Sensitivity/Response
1096	civic	Imatinib,Crenolanib	Melanoma	PDGFRA	G853D	Sensitivity/Response
1097	civic	Cetuximab,Crizotinib	Colorectal Cancer	MET	Amplification	Sensitivity/Response
1098	civic	Pyrimidine Antagonist	Breast Cancer	MTAP	Underexpression	Sensitivity/Response
1099	civic	Cetuximab	Ovarian Cancer	VPS37A	Underexpression	Resistance
1100	civic	Lapatinib	Chordoma	EGFR	Expression	Sensitivity/Response
1101	civic	Ibrutinib	Chronic Lymphocytic Leukemia	BTK	T316A	Resistance
1102	civic	Lapatinib	Cancer	ERBB2	T862A	Sensitivity/Response
1103	civic	Lapatinib	Cancer	ERBB2	V773A	Sensitivity/Response
1104	civic	Lapatinib	Cancer	ERBB2	N857S	Sensitivity/Response
1105	civic	Lapatinib	Cancer	ERBB2	H878Y	Sensitivity/Response
1106	civic	FGFR Inhibitor AZD4547	Stomach Carcinoma	FGFR2	Amplification	Sensitivity/Response
1107	civic	FGFR Inhibitor AZD4547	Breast Cancer	FGFR1	Amplification	Sensitivity/Response
1108	civic	Lapatinib	Head And Neck Squamous Cell Carcinoma	ERBB2	Overexpression	Sensitivity/Response
1109	civic	Cetuximab	Colorectal Cancer	ERBB2	Amplification	Resistance
1110	civic	Erlotinib,Gefitinib	Lung Non-small Cell Carcinoma	GNAS	c.393T>C	Resistance
1111	civic	Cetuximab	Colorectal Cancer	PIK3CA	C420R	Resistance
1112	civic	Selumetinib,Dactolisib	Colorectal Cancer	KRAS	G12V	Sensitivity/Response
1113	civic	Irinotecan,Cetuximab	Colorectal Cancer	NRAS	G12D	Resistance
1114	civic	Panitumumab	Colorectal Cancer	KRAS	G12/G13	Resistance
1115	civic	Gefitinib	Lung Cancer	KRAS	G12A	Resistance
1116	civic	Melphalan	Multiple Myeloma	KRAS	G12A	Resistance
1117	civic	Melphalan	Multiple Myeloma	KRAS	G12A	Resistance
1118	civic	Melphalan	Multiple Myeloma	KRAS	G12A	Resistance
1119	civic	Melphalan	Multiple Myeloma	KRAS	G12A	Resistance
1120	civic	Bevacizumab,Sunitinib	High Grade Glioma	IDH1	R132	Sensitivity/Response
1121	civic	Pictilisib	Her2-receptor Positive Breast Cancer	PIK3CA	E542K	Sensitivity/Response
1122	civic	Pictilisib	Breast Cancer	PIK3CA	E542K	Sensitivity/Response
1123	civic	Pictilisib	Breast Cancer	PIK3CA	E545K	Sensitivity/Response
1124	civic	Trastuzumab	Her2-receptor Positive Breast Cancer	PTEN	Loss	Resistance
1125	civic	Trastuzumab Emtansine	Her2-receptor Positive Breast Cancer	PIK3CA	E545K	Resistance
1126	civic	Cetuximab,Panitumumab	Colorectal Cancer	PIK3CA	E545K	Resistance
1127	civic	Aspirin	Colorectal Cancer	PIK3CA	Wildtype	Sensitivity/Response
1128	civic	PI103	Lung Non-small Cell Carcinoma	PIK3CA	E545K	Sensitivity/Response
1129	civic	Pictilisib	Breast Cancer	KRAS	G13D	Resistance
1130	civic	Trastuzumab	Breast Cancer	PTEN	Loss	Resistance
1131	civic	Pictilisib	Her2-receptor Positive Breast Cancer	PTEN	Loss	Sensitivity/Response
1132	civic	Erlotinib,Gefitinib	Lung Non-small Cell Carcinoma	EGFR	Mutation	Sensitivity/Response
1133	civic	PI-103	Her2-receptor Positive Breast Cancer	PIK3CA	E542K	Sensitivity/Response
1134	civic	Pictilisib	Her2-receptor Positive Breast Cancer	PIK3CA	E545K	Sensitivity/Response
1135	civic	Pictilisib	Breast Cancer	ERBB2	Amplification	Sensitivity/Response
1136	civic	Pictilisib	Breast Cancer	PTEN	Loss	Sensitivity/Response
1137	civic	Pictilisib	Her2-receptor Positive Breast Cancer	PIK3CA	C420R	Sensitivity/Response
1138	civic	Pictilisib	Her2-receptor Positive Breast Cancer	PIK3CA	K111N	Sensitivity/Response
1139	civic	Trastuzumab	Breast Cancer	PIK3CA	Mutation	Resistance
1140	civic	Pictilisib	Breast Cancer	PIK3CA	H1047L	Sensitivity/Response
1141	civic	Pictilisib	Her2-receptor Positive Breast Cancer	PIK3CA	H1047R	Sensitivity/Response
1142	civic	Trastuzumab	Her2-receptor Positive Breast Cancer	PIK3CA	Mutation	Resistance
1143	civic	Pictilisib	Breast Cancer	PIK3CA	H1047R	Sensitivity/Response
1144	civic	Trastuzumab Emtansine	Her2-receptor Positive Breast Cancer	PIK3CA	H1047R	Resistance
1145	civic	Cetuximab,Panitumumab	Colorectal Cancer	BRAF	V600E	Resistance
1146	civic	Oxaliplatin	Colorectal Cancer	BRAF	V600E	Resistance
1147	civic	Irinotecan	Colorectal Cancer	BRAF	V600E	Resistance
1148	civic	Capecitabine,Bevacizumab,Oxaliplatin	Colorectal Cancer	BRAF	V600E	Resistance
1149	civic	Trametinib	Melanoma	BRAF	V600E	Sensitivity/Response
1150	civic	Gefitinib	Lung Non-small Cell Carcinoma	EGFR	Mutation	Sensitivity/Response
1151	civic	Afatinib	Lung Non-small Cell Carcinoma	EGFR	Mutation	Sensitivity/Response
1152	civic	Gefitinib	Lung Non-small Cell Carcinoma	EGFR	Ex19 del L858R	Sensitivity/Response
1153	civic	Osimertinib	Lung Adenocarcinoma	EGFR	T790M	Sensitivity/Response
1154	civic	Gefitinib,Erlotinib	Lung Non-small Cell Carcinoma	EGFR	T790M	Resistance
1155	civic	Gefitinib	Lung Non-small Cell Carcinoma	EGFR	T790M	Resistance
1156	civic	Lapatinib	Lung Non-small Cell Carcinoma	EGFR	T790M	Resistance
1157	civic	Dacomitinib	Lung Non-small Cell Carcinoma	EGFR	T790M	Sensitivity/Response
1158	civic	Neratinib	Lung Non-small Cell Carcinoma	EGFR	T790M	Sensitivity/Response
1159	civic	Afatinib	Lung Non-small Cell Carcinoma	EGFR	T790M	Sensitivity/Response
1160	civic	Afatinib	Lung Non-small Cell Carcinoma	EGFR	T790M	Sensitivity/Response
1161	civic	Canertinib	Lung Non-small Cell Carcinoma	EGFR	T790M	Sensitivity/Response
1162	civic	Imatinib	Chronic Myeloid Leukemia	ABL1	BCR::ABL F359V	Resistance
1163	civic	Imatinib	Chronic Myeloid Leukemia	ABL1	BCR::ABL F359V	Resistance
1164	civic	Imatinib	Chronic Myeloid Leukemia	ABL1	BCR::ABL F359V	Resistance
1165	civic	Nilotinib	Chronic Myeloid Leukemia	ABL1	BCR::ABL F359V	Resistance
1166	civic	Panitumumab	Colorectal Cancer	KRAS	G13D	Resistance
1167	civic	Irinotecan,Cetuximab	Colorectal Cancer	NRAS	Q61L	Resistance
1168	civic	Selumetinib,Dactolisib	Colorectal Cancer	KRAS	G13D	Sensitivity/Response
1169	civic	Cetuximab	Colorectal Cancer	NRAS	Q61R	Resistance
1170	civic	Chemotherapy,Cetuximab	Colorectal Cancer	BRAF	Mutation	Resistance
1171	civic	Chemotherapy,Cetuximab	Colorectal Cancer	NRAS	Q61K	Resistance
1172	civic	Dactolisib,Selumetinib	Colorectal Cancer	NRAS	Q61K	Sensitivity/Response
1173	civic	Panitumumab	Colorectal Cancer	KRAS	G12D	Resistance
1174	civic	Cetuximab,Irinotecan	Colorectal Cancer	PIK3CA	Q546K	Resistance
1175	civic	Cetuximab,Irinotecan	Colorectal Cancer	BRAF	D594G	Resistance
1176	civic	Irinotecan,Cetuximab	Colorectal Cancer	NRAS	G13R	Resistance
1177	civic	Selumetinib,Dactolisib	Colorectal Cancer	KRAS	A146T	Sensitivity/Response
1178	civic	Cetuximab	Colorectal Cancer	KRAS	G12D	Resistance
1179	civic	Selumetinib,Dactolisib	Colorectal Cancer	KRAS	A146V	Sensitivity/Response
1180	civic	Cetuximab,Chemotherapy	Colorectal Cancer	NRAS	Mutation	Resistance
1181	civic	Selumetinib,Dactolisib	Colorectal Cancer	KRAS	G12C	Sensitivity/Response
1182	civic	Cetuximab,Irinotecan	Colorectal Cancer	PIK3CA	E545Q	Resistance
1183	civic	Cetuximab	Colorectal Cancer	PIK3CA	E545K	Resistance
1184	civic	Dactolisib,Selumetinib	Colorectal Cancer	KRAS	G12D	Sensitivity/Response
1185	civic	Cetuximab	Colorectal Cancer	KRAS	G12V	Resistance
1186	civic	Doxorubicin	Chronic Lymphocytic Leukemia	ATM	T2666A	Resistance
1187	civic	Doxorubicin	Chronic Lymphocytic Leukemia	ATM	Mutation	Resistance
1188	civic	Doxorubicin	Chronic Lymphocytic Leukemia	ATM	R3008C	Resistance
1189	civic	Doxorubicin	Chronic Lymphocytic Leukemia	ATM	c.902-1G>T	Resistance
1190	civic	Irinotecan,Cetuximab	Colorectal Cancer	KRAS	A146P	Resistance
1191	civic	Panitumumab	Colorectal Cancer	KRAS	G12V	Resistance
1192	civic	Panitumumab	Colorectal Cancer	KRAS	G12D	Resistance
1193	civic	Gefitinib	Lung Cancer	KRAS	G12D	Resistance
1194	civic	Erlotinib	Lung Non-small Cell Carcinoma	KRAS	Mutation	Resistance
1195	civic	Melphalan	Multiple Myeloma	KRAS	G12D	Resistance
1196	civic	Melphalan	Multiple Myeloma	KRAS	G12D	Resistance
1197	civic	Melphalan	Multiple Myeloma	KRAS	G12D	Resistance
1198	civic	Melphalan	Multiple Myeloma	KRAS	G12D	Resistance
1199	civic	Panitumumab	Colorectal Cancer	KRAS	G12C	Resistance
1200	civic	Gefitinib	Lung Cancer	KRAS	G12C	Resistance
1201	civic	Melphalan	Multiple Myeloma	KRAS	G12C	Resistance
1202	civic	Melphalan	Multiple Myeloma	KRAS	G12C	Resistance
1203	civic	Melphalan	Multiple Myeloma	KRAS	G12C	Resistance
1204	civic	Melphalan	Multiple Myeloma	KRAS	G12C	Resistance
1205	civic	Panitumumab	Colorectal Cancer	KRAS	G12R	Resistance
1206	civic	Gefitinib	Lung Cancer	KRAS	G12V	Resistance
1207	civic	Panitumumab	Colorectal Cancer	KRAS	G12S	Resistance
1208	civic	Gefitinib	Lung Cancer	KRAS	G12S	Resistance
1209	civic	Melphalan	Multiple Myeloma	KRAS	G12S	Resistance
1210	civic	Melphalan	Multiple Myeloma	KRAS	G12S	Resistance
1211	civic	Melphalan	Multiple Myeloma	KRAS	G12S	Resistance
1212	civic	Melphalan	Multiple Myeloma	KRAS	G12S	Resistance
1213	civic	Cisplatin,Carboplatin	Ovarian Cancer	TP53	R273L	Resistance
1214	civic	Mitomycin,Cisplatin,Etoposide	Stomach Carcinoma	TP53	R273C	Sensitivity/Response
1215	civic	Mitomycin,Cisplatin,Etoposide	Stomach Carcinoma	TP53	Y220C	Sensitivity/Response
1216	civic	EAP Protocol	Stomach Carcinoma	TP53	R175H	Sensitivity/Response
1217	civic	Temozolomide	Brain Glioma	IDH1	R132C	Sensitivity/Response
1218	civic	AGI-5198	High Grade Glioma	IDH1	R132C	Sensitivity/Response
1219	civic	Ivosidenib	Acute Myeloid Leukemia	IDH1	R132C	Sensitivity/Response
1220	civic	BPTES	Acute Myeloid Leukemia	IDH1	R132C	Sensitivity/Response
1221	civic	Trastuzumab Emtansine	Her2-receptor Positive Breast Cancer	PIK3CA	C420R	Resistance
1222	civic	Gefitinib,Erlotinib	Lung Non-small Cell Carcinoma	PIK3CA	Mutation	Resistance
1223	civic	Erlotinib,Gefitinib	Lung Non-small Cell Carcinoma	KRAS	Mutation	Resistance
1224	civic	Imatinib	Gastrointestinal Stromal Tumor	KIT	T417_D419delinsY	Sensitivity/Response
1225	civic	Imatinib	Gastrointestinal Stromal Tumor	KIT	F506_F508DUP	Sensitivity/Response
1226	civic	Imatinib	Cancer	KIT	N822H	Resistance
1227	civic	Imatinib	Cancer	KIT	N822K	Sensitivity/Response
1228	civic	Imatinib	Cancer	KIT	D816V	Resistance
1229	civic	Imatinib	Cancer	PDGFRA	V561D	Resistance
1230	civic	Imatinib	Cancer	PDGFRA	D842_H845DELDIMH	Resistance
1231	civic	Imatinib	Cancer	PDGFRA	D842V	Resistance
1232	civic	Imatinib	Gastrointestinal Stromal Tumor	KIT	K484_G487DEL	Sensitivity/Response
1233	civic	Imatinib	Gastrointestinal Stromal Tumor	KIT	Exon 9 Mutation	Sensitivity/Response
1234	civic	Imatinib	Cancer	KIT	V560G	Resistance
1235	civic	Imatinib	Gastrointestinal Stromal Tumor	KIT	Exon 11 Mutation	Sensitivity/Response
1236	civic	Imatinib	Cancer	KIT	K642E	Resistance
1237	civic	Imatinib	Gastrointestinal Stromal Tumor	PDGFRA	V561D	Sensitivity/Response
1238	civic	Imatinib	Gastrointestinal Stromal Tumor	KIT	Exon 13 Mutation	Sensitivity/Response
1239	civic	Imatinib	Gastrointestinal Stromal Tumor	KIT	Exon 9 Mutation	Reduced Sensitivity
1240	civic	Imatinib	Gastrointestinal Stromal Tumor	PDGFRA	D842V	Resistance
1241	civic	Imatinib	Gastrointestinal Stromal Tumor	KIT	EXPRESSION	Sensitivity/Response
1242	civic	Imatinib	Cancer	KIT	W557_K558del	Resistance
1243	civic	Imatinib	Cancer	KIT	Y503_F504insAY	Resistance
1244	civic	Imatinib	Gastrointestinal Stromal Tumor	PDGFRA	Exon 18 Mutation	Sensitivity/Response
1245	civic	Imatinib	Gastrointestinal Stromal Tumor	PDGFRA	Mutation	Sensitivity/Response
1246	civic	Dabrafenib	Melanoma	BRAF	V600K	Sensitivity/Response
1247	civic	Trametinib	Melanoma	BRAF	V600K	Sensitivity/Response
1248	civic	Gefitinib	Lung Non-small Cell Carcinoma	EGFR	G719A	Sensitivity/Response
1249	civic	Gefitinib	Lung Non-small Cell Carcinoma	EGFR	Wildtype	Resistance
1250	civic	Erlotinib	Bronchiolo-alveolar Adenocarcinoma	EGFR	E746_A750del	Sensitivity/Response
1251	civic	Gefitinib	Lung Adenocarcinoma	EGFR	Exon 19 Deletion	Sensitivity/Response
1252	civic	Gefitinib	Lung Non-small Cell Carcinoma	EGFR	Mutation	Sensitivity/Response
1253	civic	Gefitinib	Lung Non-small Cell Carcinoma	EGFR	L858R	Sensitivity/Response
1254	civic	Gefitinib	Lung Adenocarcinoma	EGFR	L858R	Sensitivity/Response
1255	civic	Gefitinib	Lung Non-small Cell Carcinoma	EGFR	E746_A750del	Sensitivity/Response
1256	civic	Lapatinib	Lung Non-small Cell Carcinoma	EGFR	L858R	Sensitivity/Response
1257	civic	Dacomitinib	Lung Non-small Cell Carcinoma	EGFR	L858R	Sensitivity/Response
1258	civic	Neratinib	Lung Non-small Cell Carcinoma	EGFR	L858R	Sensitivity/Response
1259	civic	Afatinib	Lung Non-small Cell Carcinoma	EGFR	L858R	Sensitivity/Response
1260	civic	Canertinib	Lung Non-small Cell Carcinoma	EGFR	L858R	Sensitivity/Response
1261	civic	Erlotinib	Lung Non-small Cell Carcinoma	EGFR	L858R	Sensitivity/Response
1262	civic	Gefitinib	Lung Adenocarcinoma	EGFR	L858R	Sensitivity/Response
1263	civic	Imatinib	Chronic Myeloid Leukemia	ABL1	BCR::ABL M244V	Resistance
1264	civic	Imatinib	Cancer	ABL1	BCR::ABL M244V	Sensitivity/Response
1265	civic	Nilotinib,Dasatinib	Cancer	ABL1	BCR::ABL M244V	Resistance
1266	civic	Imatinib	Chronic Myeloid Leukemia	ABL1	BCR::ABL L248V	Resistance
1267	civic	Imatinib	Chronic Myeloid Leukemia	ABL1	BCR::ABL L248V	Resistance
1268	civic	Imatinib Mesylate,Nilotinib,Dasatinib	Chronic Myeloid Leukemia	ABL1	BCR::ABL L248V	Resistance
1269	civic	Imatinib	Chronic Myeloid Leukemia	ABL1	BCR::ABL Q252H	Sensitivity/Response
1270	civic	Imatinib	Chronic Myeloid Leukemia	ABL1	BCR::ABL Q252H	Resistance
1271	civic	Nilotinib,Dasatinib	Cancer	ABL1	BCR::ABL Q252H	Resistance
1272	civic	Imatinib	Chronic Myeloid Leukemia	ABL1	BCR::ABL Y253F	Resistance
1273	civic	Imatinib	Chronic Myeloid Leukemia	ABL1	BCR::ABL E255V	Resistance
1274	civic	Imatinib	Chronic Myeloid Leukemia	ABL1	BCR::ABL Y253F	Resistance
1275	civic	Bafetinib,Dasatinib,Nilotinib	Cancer	ABL1	BCR::ABL Y253F	Resistance
1276	civic	Imatinib	Chronic Myeloid Leukemia	ABL1	BCR::ABL E355G	Resistance
1277	civic	Imatinib	Chronic Myeloid Leukemia	ABL1	BCR::ABL S417Y	Resistance
1278	civic	Bafetinib,Dasatinib	Chronic Myeloid Leukemia	ABCB1	Overexpression	Resistance
1279	civic	Imatinib	Chronic Myeloid Leukemia	ABL1	BCR::ABL H396R	Resistance
1280	civic	Imatinib	Chronic Myeloid Leukemia	ABL1	BCR::ABL H396R	Resistance
1281	civic	Imatinib	Chronic Myeloid Leukemia	ABL1	BCR::ABL H396R	Resistance
1282	civic	Cisplatin,Carboplatin	Ovarian Cancer	TP53	Y234C	Resistance
1283	civic	Cisplatin,Carboplatin	Ovarian Cancer	TP53	ALTERATION	Resistance
1284	civic	Tamoxifen	Breast Cancer	TP53	DNA Binding Domain Mutation	Resistance
1285	civic	Tamoxifen	Breast Cancer	TP53	Mutation	Resistance
1286	civic	Etoposide,Mitomycin,Cisplatin	Stomach Cancer	TP53	Overexpression	Sensitivity/Response
1287	civic	EAP Protocol	Stomach Carcinoma	TP53	R282L	Sensitivity/Response
1288	civic	EAP Protocol	Stomach Carcinoma	TP53	R213P	Sensitivity/Response
1289	civic	Etoposide,Doxorubicin,Cisplatin	Stomach Carcinoma	TP53	Mutation	Sensitivity/Response
1290	civic	Nilotinib	Chronic Myeloid Leukemia	ABL1	BCR::ABL F486S	Sensitivity/Response
1291	civic	Doxorubicin	Chronic Lymphocytic Leukemia	ATM	c.7089+1del	Resistance
1292	civic	Doxorubicin	Chronic Lymphocytic Leukemia	ATM	c.7515+1_2del	Resistance
1293	civic	Doxorubicin	Chronic Lymphocytic Leukemia	ATM	K293*	Resistance
1294	civic	Doxorubicin	Chronic Lymphocytic Leukemia	ATM	F1025L	Resistance
1295	civic	Doxorubicin	Chronic Lymphocytic Leukemia	ATM	D1930V	Resistance
1296	civic	Doxorubicin	Chronic Lymphocytic Leukemia	ATM	E2187*	Resistance
1297	civic	Doxorubicin	Chronic Lymphocytic Leukemia	ATM	L2427P	Resistance
1298	civic	Doxorubicin	Chronic Lymphocytic Leukemia	ATM	F2732V	Resistance
1299	civic	Doxorubicin	Chronic Lymphocytic Leukemia	ATM	K468FS	Resistance
1300	civic	Doxorubicin	Chronic Lymphocytic Leukemia	ATM	D1682H	Resistance
1301	civic	Doxorubicin	Chronic Lymphocytic Leukemia	ATM	A2062V	Resistance
1302	civic	Doxorubicin	Chronic Lymphocytic Leukemia	ATM	C2488Y	Resistance
1303	civic	Nilotinib	Chronic Myeloid Leukemia	ABL1	BCR::ABL E255V	Resistance
1304	civic	Nilotinib,Imatinib Mesylate	Chronic Myeloid Leukemia	ABL1	BCR::ABL E255V	Resistance
1305	civic	Nilotinib	Chronic Myeloid Leukemia	ABL1	BCR::ABL E292V	Resistance
1306	civic	Nilotinib,Imatinib Mesylate	Chronic Myeloid Leukemia	ABL1	BCR::ABL F359C	Resistance
1307	civic	Imatinib Mesylate,Nilotinib	Chronic Myeloid Leukemia	ABL1	BCR::ABL L384M	Resistance
1308	civic	Nilotinib	Chronic Myeloid Leukemia	ABL1	BCR::ABL V299L	Sensitivity/Response
1309	civic	Nilotinib	Chronic Myeloid Leukemia	ABL1	BCR::ABL L387F	Resistance
1310	civic	Nilotinib	Chronic Myeloid Leukemia	ABL1	BCR::ABL G398R	Sensitivity/Response
1311	civic	Trastuzumab Emtansine	Her2-receptor Positive Breast Cancer	PIK3CA	K111N	Resistance
1312	civic	Trastuzumab Emtansine	Her2-receptor Positive Breast Cancer	PIK3CA	I391M	Resistance
1313	civic	Rucaparib	Ovarian Cancer	BRCA2	Mutation	Sensitivity/Response
1314	civic	Rucaparib	Ovarian Cancer	BRCA1	Q1467*	Sensitivity/Response
1315	civic	Rucaparib	Ovarian Cancer	BRCA2	M1R	Sensitivity/Response
1316	civic	Rucaparib	Ovarian Cancer	BRCA2	M1I	Sensitivity/Response
1317	civic	Rucaparib	Ovarian Cancer	BRCA2	V159M	Sensitivity/Response
1318	civic	Rucaparib	Ovarian Cancer	BRCA2	V211L	Sensitivity/Response
1319	civic	Rucaparib	Ovarian Cancer	BRCA2	V211I	Sensitivity/Response
1320	civic	Rucaparib	Ovarian Cancer	BRCA2	R2336P	Sensitivity/Response
1321	civic	Imatinib	Melanoma	KIT	D820Y	Resistance
1322	civic	Sunitinib	Melanoma	KIT	D820Y	Sensitivity/Response
1323	civic	Imatinib	Mucosal Melanoma	KIT	K642E	Sensitivity/Response
1324	civic	Fluorouracil,Cisplatin	Esophageal Cancer	GNAS	c.393T>C	Resistance
1325	civic	Temozolomide	Glioblastoma	MGMT	Underexpression	Sensitivity/Response
1326	civic	Temozolomide	High Grade Glioma	MGMT	Underexpression	Sensitivity/Response
1327	civic	Temozolomide	Oligodendroglioma	MGMT	Underexpression	Sensitivity/Response
1328	civic	Temozolomide	Glioblastoma	MGMT	Underexpression	Sensitivity/Response
1329	civic	Temozolomide	Neuroendocrine Tumor	MGMT	Underexpression	Sensitivity/Response
1330	civic	Gemcitabine,Cisplatin	Lung Non-small Cell Carcinoma	RRM1	Underexpression	Sensitivity/Response
1331	civic	Erlotinib	Lung Non-small Cell Carcinoma	EGFR	S768I	Sensitivity/Response
1332	civic	Trametinib,Selumetinib	Lung Non-small Cell Carcinoma	NRAS	Q61K	Sensitivity/Response
1333	civic	FGF/VEGF Receptor Tyrosine Kinase Inhibitor, PD173074,Infigratinib,FGFR Inhibitor AZD4547	Sarcoma	FGFR1	Expression	Sensitivity/Response
1334	civic	Imatinib	Gastrointestinal Stromal Tumor	KIT	N822K	Resistance
1335	civic	Imatinib	Gastrointestinal Stromal Tumor	KIT	Y823D	Resistance
1336	civic	Imatinib	Gastrointestinal Stromal Tumor	KIT	C809G	Resistance
1337	civic	Imatinib	Gastrointestinal Stromal Tumor	KIT	D820A	Resistance
1338	civic	Imatinib	Gastrointestinal Stromal Tumor	KIT	D820G	Resistance
1339	civic	Imatinib	Gastrointestinal Stromal Tumor	KIT	D816H	Resistance
1340	civic	Imatinib	Gastrointestinal Stromal Tumor	KIT	T670I	Resistance
1341	civic	Pembrolizumab,Nivolumab,Atezolizumab	Cancer	DNMT3A	Mutation	Resistance
1342	civic	Dabrafenib,Panitumumab	Colorectal Cancer	BRAF	Amplification	Resistance
1343	civic	Binimetinib,Ribociclib	Skin Melanoma	NRAS	Mutation	Sensitivity/Response
1344	civic	Olaparib	Brain Glioma	IDH1	Mutation	Sensitivity/Response
1345	civic	Crizotinib	Lung Adenocarcinoma	ROS1	G2032R	Resistance
1346	civic	Selumetinib	Lung Adenocarcinoma	MAP2K1	K57N	Sensitivity/Response
1347	civic	Binimetinib	Skin Melanoma	NRAS	Mutation	Sensitivity/Response
1348	civic	Gefitinib	Lung Cancer	EGFR	Mutation	Sensitivity/Response
1349	civic	Letetresgene Autoleucel	Multiple Myeloma	CTAG1B	Overexpression	Sensitivity/Response
1350	civic	Letetresgene Autoleucel	Multiple Myeloma	CTAG2	Overexpression	Sensitivity/Response
1351	civic	Cetuximab	Colorectal Cancer	KRAS	A146T	Resistance
1352	civic	Entrectinib	Cancer	NTRK1	Fusion	Sensitivity/Response
1353	civic	Entrectinib	Cancer	NTRK3	Fusion	Sensitivity/Response
1354	civic	Entrectinib	Lung Non-small Cell Carcinoma	NTRK1	SQSTM1::NTRK1	Sensitivity/Response
1355	civic	Entrectinib	Cancer	ROS1	Rearrangement	Sensitivity/Response
1356	civic	Entrectinib	Cancer	ALK	Fusion	Sensitivity/Response
1357	civic	Larotrectinib	Cancer	NTRK1	Fusion	Sensitivity/Response
1358	civic	Larotrectinib	Sarcoma	NTRK1	LMNA::NTRK1	Sensitivity/Response
1359	civic	Entrectinib	Cancer	NTRK1	Amplification	Sensitivity/Response
1360	civic	Entrectinib	Cancer	NTRK3	Amplification	Sensitivity/Response
1361	civic	Entrectinib	Colorectal Adenocarcinoma	NTRK1	LMNA::NTRK1	Sensitivity/Response
1362	civic	Entrectinib	Colorectal Adenocarcinoma	NTRK1	LMNA::NTRK1 G595R and G667C	Resistance
1363	civic	Rebemadlin	Cancer	TP53	Wildtype	Sensitivity/Response
1364	civic	MDM2 Inhibitor AMGMDS3	Cancer	TP53	Wildtype	Sensitivity/Response
1365	civic	RG7112	Leukemia	TP53	Wildtype	Sensitivity/Response
1366	civic	RG7112	Leukemia	TP53	Deleterious Mutation	Resistance
1367	civic	MDM2 Inhibitor AMGMDS3	Cancer	TP53	Deleterious Mutation	Resistance
1368	civic	Rebemadlin	Cancer	TP53	Deleterious Mutation	Resistance
1369	civic	Dasatinib	Ovarian Clear Cell Carcinoma	ARID1A	Loss	Sensitivity/Response
1370	civic	GSK126	Ovarian Clear Cell Carcinoma	ARID1A	Loss	Sensitivity/Response
1371	civic	Cisplatin,Pictilisib	Cervix Carcinoma	PIK3CA	E545K	Sensitivity/Response
1372	civic	Cisplatin	Cervical Cancer	PIK3CA	E545K	Resistance
1373	civic	Entrectinib	Neuroblastoma	ALK	F1245V	Sensitivity/Response
1374	civic	Anti-CTLA-4 Monoclonal Antibody,Anti-PD-L1 Monoclonal Antibody	Melanoma	CTNNB1	Activating Mutation	Resistance
1375	civic	UNC1062	Melanoma	MERTK	OVEREXPRESSION	Sensitivity/Response
1376	civic	Erlotinib	Lung Non-small Cell Carcinoma	EGFR	L858R	Sensitivity/Response
1377	civic	Erlotinib	Lung Non-small Cell Carcinoma	EGFR	Exon 19 Deletion	Sensitivity/Response
1378	civic	Afatinib	Lung Non-small Cell Carcinoma	EGFR	Exon 19 Deletion	Sensitivity/Response
1379	civic	Afatinib	Lung Non-small Cell Carcinoma	EGFR	L858R	Sensitivity/Response
1380	civic	Docetaxel,Selumetinib	Lung Non-small Cell Carcinoma	KRAS	Mutation	Resistance
1381	civic	Radiation Therapy	Head And Neck Squamous Cell Carcinoma	CD274	Expression	Resistance
1382	civic	Cisplatin,Olaparib,Prexasertib	Lung Small Cell Carcinoma	MYC	Overexpression	Sensitivity/Response
1383	civic	Lapatinib	Cancer	ERBB2	L755S	Resistance
1384	civic	Lapatinib	Cancer	ERBB2	L755P	Resistance
1385	civic	Lapatinib	Cancer	ERBB2	T798M	Resistance
1386	civic	Tandutinib	Acute Myeloid Leukemia	FLT3	D835V	Resistance
1387	civic	Sunitinib	Acute Myeloid Leukemia	FLT3	D835V	Sensitivity/Response
1388	civic	Sunitinib,Cytarabine	Acute Myeloid Leukemia	FLT3	D835V	Sensitivity/Response
1389	civic	Daunorubicin,Sunitinib	Acute Myeloid Leukemia	FLT3	D835V	Sensitivity/Response
1390	civic	Quizartinib	Acute Myeloid Leukemia	FLT3	D835V	Sensitivity/Response
1391	civic	Carboplatin,Cisplatin	Ovarian Cancer	TP53	Overexpression	Resistance
1392	civic	Osimertinib,Rociletinib	Lung Non-small Cell Carcinoma	EGFR	Amplification	Resistance
1393	civic	Gefitinib	Lung Non-small Cell Carcinoma	EGFR	Mutation	Sensitivity/Response
1394	civic	Dabrafenib,Trametinib	Lung Non-small Cell Carcinoma	BRAF	V600E	Sensitivity/Response
1395	civic	Dovitinib	Lung Non-small Cell Carcinoma	FGFR1	Amplification	Sensitivity/Response
1396	civic	Imatinib	Gastrointestinal Stromal Tumor	KIT	V559D	Sensitivity/Response
1397	civic	Sunitinib,Dasatinib,Tandutinib,PD-180970,Imatinib	Cancer	KIT	V559D	Sensitivity/Response
1398	civic	Tyrphostin AG 1296,AS602868	Acute Myeloid Leukemia	FLT3	D835V	Sensitivity/Response
1399	civic	Trametinib,Selumetinib	Uveal Melanoma	MET	Overexpression	Resistance
1400	civic	Capivasertib	Cancer	AKT1	E17K	Sensitivity/Response
1401	civic	Capivasertib	Cancer	PIK3CA	Mutation	Sensitivity/Response
1402	civic	MDM2 Inhibitor AMGMDS3	Cancer	TP53	R248Q	Resistance
1403	civic	Radioactive Iodine	Thyroid Gland Follicular Carcinoma	GNAS	R201H	Sensitivity/Response
1404	civic	Cabozantinib	Uveal Melanoma	GNA11	Mutation	Sensitivity/Response
1405	civic	Irinotecan,Cetuximab	Colorectal Cancer	NRAS	Q61H	Resistance
1406	civic	Cetuximab	Colorectal Cancer	NRAS	G12D	Resistance
1407	civic	Cetuximab,Chemotherapy	Colorectal Cancer	KRAS	Mutation	Resistance
1408	civic	Regorafenib	Colorectal Cancer	KRAS	G12A	Resistance
1409	civic	Erlotinib,Teprotumumab	Lung Non-small Cell Carcinoma	KRAS	Mutation	Sensitivity/Response
1410	civic	Vemurafenib	Melanoma	PIK3CA	E545K	Resistance
1411	civic	Vemurafenib	Melanoma	PIK3CA	E545G	Resistance
1412	civic	Chemotherapy,Cetuximab	Colorectal Cancer	PIK3CA	Mutation	Resistance
1413	civic	Vemurafenib	Colorectal Cancer	PIK3CA	H1047R	Resistance
1414	civic	FOLFOX-4 Regimen,Cetuximab	Colorectal Cancer	BRAF	V600E	Resistance
1415	civic	Vemurafenib	Melanoma	BRAF	V600E	Sensitivity/Response
1416	civic	Vemurafenib	Melanoma	BRAF	V600E	Sensitivity/Response
1417	civic	Vemurafenib	Melanoma	BRAF	V600E	Sensitivity/Response
1418	civic	Trametinib,Dabrafenib	Skin Melanoma	BRAF	V600E	Sensitivity/Response
1419	civic	Vemurafenib	Childhood Pilocytic Astrocytoma	BRAF	V600E	Sensitivity/Response
1420	civic	Vemurafenib	Ovarian Serous Carcinoma	BRAF	V600E	Sensitivity/Response
1421	civic	Erlotinib	Lung Adenocarcinoma	EGFR	Ex19 del L858R	Sensitivity/Response
1422	civic	Erlotinib	Lung Non-small Cell Carcinoma	EGFR	Mutation	Sensitivity/Response
1423	civic	Gefitinib	Lung Non-small Cell Carcinoma	EGFR	L861Q	Sensitivity/Response
1424	civic	Multikinase Inhibitor AEE788,Erlotinib,Gefitinib	Cancer	EGFR	T790M	Resistance
1425	civic	Multikinase Inhibitor AEE788,Erlotinib,Gefitinib	Cancer	EGFR	L858R	Sensitivity/Response
1426	civic	Bosutinib	Chronic Myeloid Leukemia	ABL1	BCR::ABL F359V	Resistance
1427	civic	Bosutinib	Chronic Myeloid Leukemia	ABL1	BCR::ABL F359V	Resistance
1428	civic	Dasatinib	Chronic Myeloid Leukemia	ABL1	BCR::ABL F359V	Reduced Sensitivity
1429	civic	Dasatinib	Chronic Myeloid Leukemia	ABL1	BCR::ABL F359V	Resistance
1430	civic	Dasatinib	Chronic Myeloid Leukemia	ABL1	BCR::ABL F359V	Resistance
1431	civic	Axitinib	Chronic Myeloid Leukemia	ABL1	BCR::ABL F359V	Resistance
1432	civic	Panitumumab	Colorectal Cancer	KRAS	G12V	Resistance
1433	civic	Panitumumab	Colorectal Cancer	BRAF	V600E	Resistance
1434	civic	Irinotecan,Cetuximab	Colorectal Cancer	PIK3CA	R88Q	Resistance
1435	civic	Irinotecan,Cetuximab	Colorectal Cancer	PIK3CA	H1047R	Resistance
1436	civic	Panitumumab	Colorectal Cancer	NRAS	G13R	Resistance
1437	civic	Chemotherapy,Cetuximab	Colorectal Cancer	NRAS	G12C	Resistance
1438	civic	Cetuximab	Colorectal Cancer	PIK3CA	G1049R	Resistance
1439	civic	Vemurafenib	Skin Squamous Cell Carcinoma	HRAS	G13D	Resistance
1440	civic	Cetuximab	Colorectal Cancer	HRAS	G13D	Resistance
1441	civic	Cetuximab,FOLFOX-4 Regimen	Colorectal Cancer	KRAS	A146T	Resistance
1442	civic	Chemotherapy,Cetuximab	Colorectal Cancer	KRAS	Q61H	Resistance
1443	civic	Cetuximab	Colorectal Cancer	KRAS	Q61H	Resistance
1444	civic	Erlotinib	Lung Cancer	EGFR	Mutation	Sensitivity/Response
1445	civic	Cetuximab,Chemotherapy	Colorectal Cancer	KRAS	Q61L	Resistance
1446	civic	Cetuximab,Irinotecan	Colorectal Cancer	KRAS	Q61R	Resistance
1447	civic	Cetuximab,Chemotherapy	Colorectal Cancer	KRAS	Q61K	Resistance
1448	civic	Cetuximab	Colorectal Cancer	KRAS	G13D	Resistance
1449	civic	Cetuximab	Colorectal Cancer	KRAS	G13D	Resistance
1450	civic	Cetuximab	Colorectal Cancer	KRAS	G13D	Resistance
1451	civic	Regorafenib	Colorectal Cancer	KRAS	G13D	Resistance
1452	civic	Erlotinib	Lung Non-small Cell Carcinoma	KRAS	Mutation	Resistance
1453	civic	Chemotherapy,Cetuximab	Colorectal Cancer	KRAS	Q61	Resistance
1454	civic	Regorafenib	Colorectal Cancer	KRAS	G12V	Resistance
1455	civic	Chemotherapy,Cetuximab	Colorectal Cancer	KRAS	A146	Resistance
1456	civic	Regorafenib	Colorectal Cancer	KRAS	G12D	Resistance
1457	civic	Vemurafenib	Melanoma	KRAS	G12D	Resistance
1458	civic	Cetuximab	Ovarian Cancer	KRAS	G12D	Resistance
1459	civic	Cetuximab,Chemotherapy	Colorectal Cancer	KRAS	G12C	Resistance
1460	civic	Regorafenib	Colorectal Cancer	KRAS	G12C	Resistance
1461	civic	Chemotherapy,Cetuximab	Colorectal Cancer	KRAS	G12R	Resistance
1462	civic	Cetuximab	Colorectal Cancer	KRAS	G12R	Resistance
1463	civic	Regorafenib	Colorectal Cancer	KRAS	G12R	Resistance
1464	civic	Cetuximab	Colorectal Cancer	KRAS	G12S	Resistance
1465	civic	Regorafenib	Colorectal Cancer	KRAS	G12S	Resistance
1466	civic	Sunitinib	Acute Myeloid Leukemia	FLT3	D835V	Sensitivity/Response
1467	civic	Vemurafenib	Melanoma	AKT1	E17K	Resistance
1468	civic	Cetuximab	Colorectal Cancer	PIK3CA	N345K	Resistance
1469	civic	Sunitinib	Cancer	PDGFRA	V561D	Resistance
1470	civic	Sunitinib	Cancer	PDGFRA	D842V	Resistance
1471	civic	Regorafenib	Gastrointestinal Stromal Tumor	KIT	V560_L576DEL	Sensitivity/Response
1472	civic	Sunitinib	Gastrointestinal Stromal Tumor	KIT	K550_K558del	Resistance
1473	civic	Sunitinib	Gastrointestinal Stromal Tumor	KIT	Exon 11 Mutation	Resistance
1474	civic	Sunitinib	Cancer	KIT	V560D	Resistance
1475	civic	Sunitinib	Gastrointestinal Stromal Tumor	KIT	W557_K558del	Resistance
1476	civic	Ponatinib,Imatinib	Gastrointestinal Stromal Tumor	KIT	W557_K558del	Sensitivity/Response
1477	civic	Sunitinib,Regorafenib	Gastrointestinal Stromal Tumor	KIT	W557_K558del	Sensitivity/Response
1478	civic	Sunitinib	Gastrointestinal Stromal Tumor	KIT	K558_V559del	Resistance
1479	civic	Sunitinib	Cancer	KIT	A502_Y503insAY	Resistance
1480	civic	Regorafenib	Gastrointestinal Stromal Tumor	KIT	Exon 9 Mutation	Reduced Sensitivity
1481	civic	Regorafenib	Gastrointestinal Stromal Tumor	BRAF	Exon 15 Mutation	Sensitivity/Response
1482	civic	Sunitinib	Gastrointestinal Stromal Tumor	KIT	V560D	Resistance
1483	civic	Ponatinib	Gastrointestinal Stromal Tumor	KIT	P551_E554delPMYE	Sensitivity/Response
1484	civic	Imatinib,Sunitinib,Regorafenib,Ponatinib	Gastrointestinal Stromal Tumor	KIT	V560D	Sensitivity/Response
1485	civic	Sunitinib	Gastrointestinal Stromal Tumor	KIT	L576P	Resistance
1486	civic	Regorafenib	Gastrointestinal Stromal Tumor	KIT	Exon 9 Mutation	Reduced Sensitivity
1487	civic	Imatinib,Dasatinib	Cancer	KIT	L576P	Sensitivity/Response
1488	civic	Sunitinib	Gastrointestinal Stromal Tumor	KIT	D579del	Resistance
1489	civic	Regorafenib	Gastrointestinal Stromal Tumor	KIT	WILDTYPE	Sensitivity/Response
1490	civic	Dasatinib	Melanoma	KIT	K642E	Sensitivity/Response
1491	civic	Ponatinib	Gastrointestinal Stromal Tumor	KIT	N822K	Resistance
1492	civic	Regorafenib	Gastrointestinal Stromal Tumor	KIT	N822K	Resistance
1493	civic	Vemurafenib	Melanoma	BRAF	V600K	Sensitivity/Response
1494	civic	Dabrafenib,Trametinib	Skin Melanoma	BRAF	V600K	Sensitivity/Response
1495	civic	Erlotinib	High Grade Glioma	EGFR	R108K	Sensitivity/Response
1496	civic	Erlotinib	High Grade Glioma	EGFR	T263P	Sensitivity/Response
1497	civic	Erlotinib	High Grade Glioma	EGFR	A289V	Sensitivity/Response
1498	civic	Gefitinib,Erlotinib	Lung Non-small Cell Carcinoma	EGFR	G719	Sensitivity/Response
1499	civic	Erlotinib	Lung Non-small Cell Carcinoma	EGFR	G719S	Sensitivity/Response
1500	civic	Erlotinib	Lung Non-small Cell Carcinoma	EGFR	V742A	Sensitivity/Response
1501	civic	Gefitinib	Lung Non-small Cell Carcinoma	EGFR	E746_A750del	Sensitivity/Response
1502	civic	Erlotinib	Lung Non-small Cell Carcinoma	EGFR	Mutation	Sensitivity/Response
1503	civic	Gefitinib	Lung Adenocarcinoma	EGFR	E746_T751>I	Sensitivity/Response
1504	civic	Gefitinib,Erlotinib	Lung Non-small Cell Carcinoma	EGFR	G719D	Sensitivity/Response
1505	civic	Gefitinib,Erlotinib	Lung Non-small Cell Carcinoma	EGFR	L747P	Sensitivity/Response
1506	civic	Gefitinib	Lung Non-small Cell Carcinoma	EGFR	V774A	Sensitivity/Response
1507	civic	Erlotinib	Lung Non-small Cell Carcinoma	EGFR	V774M	Sensitivity/Response
1508	civic	Gefitinib	Lung Non-small Cell Carcinoma	EGFR	K806E	Sensitivity/Response
1509	civic	Gefitinib	Lung Non-small Cell Carcinoma	EGFR	N826Y	Sensitivity/Response
1510	civic	Gefitinib	Lung Non-small Cell Carcinoma	EGFR	V834I	Sensitivity/Response
1511	civic	Gefitinib	Lung Non-small Cell Carcinoma	EGFR	L838P	Sensitivity/Response
1512	civic	Gefitinib	Lung Non-small Cell Carcinoma	EGFR	N842S	Sensitivity/Response
1513	civic	Gefitinib	Lung Non-small Cell Carcinoma	EGFR	T847I	Sensitivity/Response
1514	civic	Gefitinib	Lung Non-small Cell Carcinoma	EGFR	V851I	Sensitivity/Response
1515	civic	Erlotinib	Cancer	EGFR	L858R	Sensitivity/Response
1516	civic	Erlotinib	Lung Non-small Cell Carcinoma	EGFR	L747_P753delinsS	Sensitivity/Response
1517	civic	Erlotinib	Lung Adenocarcinoma	EGFR	S768I	Resistance
1518	civic	Erlotinib,Gefitinib	Cancer	EGFR	S768I	Sensitivity/Response
1519	civic	Erlotinib	Lung Non-small Cell Carcinoma	EGFR	D770_N771insSVD	Resistance
1520	civic	Erlotinib	Lung Non-small Cell Carcinoma	EGFR	H773_V774insH	Resistance
1521	civic	Erlotinib	Cancer	EGFR	R831H	Sensitivity/Response
1522	civic	Erlotinib,Gefitinib	Cancer	EGFR	L838V	Resistance
1523	civic	Erlotinib	Lung Non-small Cell Carcinoma	EGFR	L858R	Sensitivity/Response
1524	civic	Erlotinib	Cancer	EGFR	L858R	Sensitivity/Response
1525	civic	Erlotinib	Lung Non-small Cell Carcinoma	EGFR	L858R	Sensitivity/Response
1526	civic	Erlotinib	Lung Non-small Cell Carcinoma	EGFR	L858R	Sensitivity/Response
1527	civic	Crizotinib	Lung Non-small Cell Carcinoma	EGFR	L858R	Resistance
1528	civic	Erlotinib	Lung Adenocarcinoma	EGFR	L858R	Sensitivity/Response
1529	civic	Erlotinib	Lung Adenocarcinoma	EGFR	L858R	Sensitivity/Response
1530	civic	Cetuximab	Lung Adenocarcinoma	EGFR	L858R	Sensitivity/Response
1531	civic	Erlotinib	Lung Small Cell Carcinoma	EGFR	L858R	Sensitivity/Response
1532	civic	Osimertinib	Lung Non-small Cell Carcinoma	EGFR	L858R	Sensitivity/Response
1533	civic	Erlotinib	High Grade Glioma	EGFR	L858R	Sensitivity/Response
1534	civic	Erlotinib,Gefitinib	Lung Non-small Cell Carcinoma	EGFR	L861	Sensitivity/Response
1535	civic	Erlotinib	High Grade Glioma	EGFR	L861Q	Sensitivity/Response
1536	civic	Erlotinib	Cancer	EGFR	E868G	Sensitivity/Response
1537	civic	Dasatinib	Chronic Myeloid Leukemia	ABL1	BCR::ABL M244V	Resistance
1538	civic	Dasatinib	Chronic Myeloid Leukemia	ABL1	BCR::ABL M244V	Resistance
1539	civic	Dasatinib	Chronic Myeloid Leukemia	ABL1	BCR::ABL M244V	Resistance
1540	civic	Bosutinib	Chronic Myeloid Leukemia	ABL1	BCR::ABL M244V	Resistance
1541	civic	Bosutinib	Chronic Myeloid Leukemia	ABL1	BCR::ABL M244V	Resistance
1542	civic	Bosutinib	Chronic Myeloid Leukemia	ABL1	BCR::ABL L248V	Resistance
1543	civic	Axitinib	Chronic Myeloid Leukemia	ABL1	BCR::ABL L248V	Resistance
1544	civic	Axitinib	Chronic Myeloid Leukemia	ABL1	BCR::ABL Q252H	Resistance
1545	civic	Dasatinib	Chronic Myeloid Leukemia	ABL1	BCR::ABL Q252H	Resistance
1546	civic	Bosutinib	Chronic Myeloid Leukemia	ABL1	BCR::ABL Y253F	Resistance
1547	civic	Axitinib	Chronic Myeloid Leukemia	ABL1	BCR::ABL Y253F	Resistance
1548	civic	Bosutinib	Chronic Myeloid Leukemia	ABL1	BCR::ABL E355G	Resistance
1549	civic	Dasatinib	Chronic Myeloid Leukemia	ABL1	BCR::ABL E355G	Resistance
1550	civic	Dasatinib	Chronic Myeloid Leukemia	ABL1	BCR::ABL E355G	Resistance
1551	civic	Dasatinib	Chronic Myeloid Leukemia	ABL1	BCR::ABL E355G	Resistance
1552	civic	Dasatinib	Chronic Myeloid Leukemia	ABL1	BCR::ABL L387M	Resistance
1553	civic	Dasatinib	Chronic Myeloid Leukemia	ABL1	BCR::ABL L387M	Resistance
1554	civic	Bosutinib	Chronic Myeloid Leukemia	ABL1	BCR::ABL H396R	Resistance
1555	civic	Bosutinib	Chronic Myeloid Leukemia	ABL1	BCR::ABL H396R	Resistance
1556	civic	Dasatinib	Chronic Myeloid Leukemia	ABL1	BCR::ABL H396R	Resistance
1557	civic	Axitinib	Chronic Myeloid Leukemia	ABL1	BCR::ABL H396R	Resistance
1558	civic	Cetuximab	Colorectal Cancer	PIK3CA	E542K	Resistance
1559	civic	Cetuximab	Colorectal Cancer	KRAS	G12A	Resistance
1560	civic	Cetuximab,Irinotecan	Colorectal Cancer	PIK3CA	H1047L	Resistance
1561	civic	Dasatinib	Chronic Myeloid Leukemia	ABL1	BCR::ABL L364I	Resistance
1562	civic	Dasatinib	Acute Lymphoblastic Leukemia	ABL1	BCR::ABL	Sensitivity/Response
1563	civic	Axitinib	Chronic Myeloid Leukemia	ABL1	BCR::ABL F486S	Resistance
1564	civic	Bosutinib	Chronic Myeloid Leukemia	ABL1	BCR::ABL F486S	Resistance
1565	civic	Axitinib	Chronic Myeloid Leukemia	ABL1	BCR::ABL E255V	Resistance
1566	civic	Bosutinib	Chronic Myeloid Leukemia	ABL1	BCR::ABL E255V	Resistance
1567	civic	Bosutinib	Chronic Myeloid Leukemia	ABL1	BCR::ABL E255V	Reduced Sensitivity
1568	civic	Dasatinib	Chronic Myeloid Leukemia	ABL1	BCR::ABL E255V	Resistance
1569	civic	Dasatinib	Chronic Myeloid Leukemia	ABL1	BCR::ABL E255V	Resistance
1570	civic	Imatinib,Sunitinib,Regorafenib	Gastrointestinal Stromal Tumor	KIT	P551_E554delPMYE	Sensitivity/Response
1571	civic	Imatinib,Ponatinib,Regorafenib	Gastrointestinal Stromal Tumor	KIT	V559D	Sensitivity/Response
1572	civic	Cetuximab,Irinotecan	Colorectal Cancer	PIK3CA	S158L	Resistance
1573	civic	Fluorouracil,Cetuximab,Oxaliplatin	Colorectal Cancer	PIK3CA	E81K	Resistance
1574	civic	Fluorouracil,Oxaliplatin,Cetuximab	Colorectal Cancer	PIK3CA	R93W	Resistance
1575	civic	Erlotinib	Lung Non-small Cell Carcinoma	EGFR	R776C	Sensitivity/Response
1576	civic	Cetuximab,Irinotecan	Colorectal Cancer	BRAF	D594G	Resistance
1577	civic	Bosutinib	Chronic Myeloid Leukemia	ABL1	L298V	Resistance
1578	civic	Bosutinib	Chronic Myeloid Leukemia	ABL1	BCR::ABL F359C	Resistance
1579	civic	Dasatinib	Chronic Myeloid Leukemia	ABL1	BCR::ABL F359C	Resistance
1580	civic	Dasatinib	Chronic Myeloid Leukemia	ABL1	BCR::ABL F359C	Resistance
1581	civic	Dasatinib	Chronic Myeloid Leukemia	ABL1	BCR::ABL F359C	Resistance
1582	civic	Bosutinib	Chronic Myeloid Leukemia	ABL1	BCR::ABL E453Q	Resistance
1583	civic	Dasatinib	Ovarian Clear Cell Carcinoma	ARID1A	Q456*	Sensitivity/Response
1584	civic	Vemurafenib	Melanoma	BRAF	V600D	Sensitivity/Response
1585	civic	Vemurafenib	Melanoma	BRAF	V600D	Sensitivity/Response
1586	civic	Erlotinib	Lung Adenocarcinoma	EGFR	H773_V774insNPH	Resistance
1587	civic	Erlotinib	Lung Adenocarcinoma	EGFR	D770_N771insGL	Resistance
1588	civic	Erlotinib	Lung Non-small Cell Carcinoma	EGFR	A864T	Sensitivity/Response
1589	civic	Erlotinib	Lung Non-small Cell Carcinoma	EGFR	N826S	Resistance
1590	civic	Erlotinib	Lung Non-small Cell Carcinoma	EGFR	A763_Y764insFQEA	Sensitivity/Response
1591	civic	Vemurafenib	Melanoma	AKT1	Q79K	Resistance
1592	civic	Erlotinib	High Grade Glioma	EGFR	VIII	Sensitivity/Response
1593	civic	Regorafenib	Gastrointestinal Stromal Tumor	KIT	T670I	Resistance
1594	civic	Vemurafenib	Melanoma	AKT3	E17K	Resistance
1595	civic	Axitinib	Chronic Myeloid Leukemia	ABL1	BCR::ABL L384M	Resistance
1596	civic	Dasatinib	Chronic Myeloid Leukemia	ABL1	BCR::ABL L384M	Resistance
1597	civic	Axitinib	Chronic Myeloid Leukemia	ABL1	BCR::ABL F359I	Resistance
1598	civic	Bosutinib	Chronic Myeloid Leukemia	ABL1	BCR::ABL F359I	Resistance
1599	civic	Bosutinib	Chronic Myeloid Leukemia	ABL1	BCR::ABL F359I	Resistance
1600	civic	Dasatinib	Chronic Myeloid Leukemia	ABL1	BCR::ABL F359I	Resistance
1601	civic	Dasatinib	Chronic Myeloid Leukemia	ABL1	BCR::ABL F359I	Resistance
1602	civic	Axitinib	Chronic Myeloid Leukemia	ABL1	BCR::ABL M343T	Resistance
1603	civic	Bosutinib	Chronic Myeloid Leukemia	ABL1	BCR::ABL V299L	Reduced Sensitivity
1604	civic	Dasatinib	Chronic Myeloid Leukemia	ABL1	BCR::ABL V299L	Resistance
1605	civic	Dasatinib	Chronic Myeloid Leukemia	ABL1	BCR::ABL E279K	Resistance
1606	civic	Bosutinib	Chronic Myeloid Leukemia	ABL1	BCR::ABL Q300R	Resistance
1607	civic	Bosutinib	Chronic Myeloid Leukemia	ABL1	BCR::ABL F311L	Resistance
1608	civic	Bosutinib	Chronic Myeloid Leukemia	ABL1	BCR::ABL N331S	Resistance
1609	civic	Bosutinib	Chronic Myeloid Leukemia	ABL1	BCR::ABL L364P	Resistance
1610	civic	Bosutinib	Chronic Myeloid Leukemia	ABL1	BCR::ABL L387F	Resistance
1611	civic	Bosutinib	Chronic Myeloid Leukemia	ABL1	BCR::ABL H396P	Resistance
1612	civic	Bosutinib	Chronic Myeloid Leukemia	ABL1	BCR::ABL D421G	Resistance
1613	civic	Dasatinib	Chronic Myeloid Leukemia	ABL1	BCR::ABL G398R	Sensitivity/Response
1614	civic	Bosutinib	Chronic Myeloid Leukemia	ABL1	BCR::ABL E450V	Resistance
1615	civic	Bosutinib	Chronic Myeloid Leukemia	ABL1	BCR::ABL E453K	Resistance
1616	civic	Bosutinib	Chronic Myeloid Leukemia	ABL1	BCR::ABL E453A	Resistance
1617	civic	Bosutinib	Chronic Myeloid Leukemia	ABL1	BCR::ABL P480A	Resistance
1618	civic	Dasatinib	Chronic Myeloid Leukemia	ABL1	BCR::ABL F486S	Resistance
1619	civic	Sunitinib,Imatinib,Ponatinib,Regorafenib	Gastrointestinal Stromal Tumor	KIT	K550_W557del	Sensitivity/Response
1620	civic	Regorafenib	Gastrointestinal Stromal Tumor	KIT	D820Y	Sensitivity/Response
1621	civic	Ponatinib,Sunitinib,Imatinib,Regorafenib	Gastrointestinal Stromal Tumor	KIT	K558delinsNP	Sensitivity/Response
1622	civic	Regorafenib	Gastrointestinal Stromal Tumor	KIT	N822K	Sensitivity/Response
1623	civic	Sunitinib	Gastrointestinal Stromal Tumor	PDGFRA	D842V	Resistance
1624	civic	Regorafenib	Gastrointestinal Stromal Tumor	KIT	Exon 11 Mutation	Sensitivity/Response
1625	civic	Regorafenib	Gastrointestinal Stromal Tumor	BRAF	Exon 15 Mutation	Resistance
1626	civic	Olaparib	Endometrioid Ovary Carcinoma	BRCA1	W1815X	Sensitivity/Response
1627	civic	Regorafenib	Gastrointestinal Stromal Tumor	KIT	Exon 9 Mutation	Sensitivity/Response
1628	civic	Regorafenib	Gastrointestinal Stromal Tumor	KIT	Exon 11 Mutation	Sensitivity/Response
1629	civic	Regorafenib,Imatinib,Ponatinib	Gastrointestinal Stromal Tumor	KIT	A502_Y503insAY	Sensitivity/Response
1630	civic	Sunitinib,Imatinib	Gastrointestinal Stromal Tumor	KIT	D816E	Resistance
1631	civic	Erlotinib	Lung Adenocarcinoma	EGFR	D770_N771insGT	Resistance
1632	civic	Erlotinib	Lung Adenocarcinoma	EGFR	Exon 20 Insertion	Resistance
1633	civic	Vismodegib	Basal Cell Carcinoma	SMO	L412F	Resistance
1634	civic	Vismodegib	Basal Cell Carcinoma	SMO	L412F	Resistance
1635	civic	Erlotinib	Cancer	EGFR	W731L	Sensitivity/Response
1636	civic	Erlotinib	Cancer	EGFR	E734Q	Sensitivity/Response
1637	civic	Erlotinib	Cancer	EGFR	T785A	Sensitivity/Response
1638	civic	Erlotinib	Cancer	EGFR	C797Y	Sensitivity/Response
1639	civic	Erlotinib	Cancer	EGFR	Y801H	Sensitivity/Response
1640	civic	Erlotinib	Lung Adenocarcinoma	EGFR	A767_V769dupASV	Resistance
1641	civic	Erlotinib	Lung Adenocarcinoma	EGFR	L747_S752delinsQ	Sensitivity/Response
1642	civic	Gefitinib	Lung Non-small Cell Carcinoma	EGFR	L861R	Sensitivity/Response
1643	civic	Dasatinib	Chronic Myeloid Leukemia	ABL1	BCR::ABL D363G	Resistance
1644	civic	Dasatinib	Chronic Myeloid Leukemia	ABL1	BCR::ABL V379I	Resistance
1645	civic	Dasatinib	Chronic Myeloid Leukemia	ABL1	BCR::ABL V379I	Resistance
1646	civic	Dasatinib	Chronic Myeloid Leukemia	ABL1	BCR::ABL	Sensitivity/Response
1647	civic	Dasatinib	Chronic Myeloid Leukemia	ABL1	BCR::ABL A397P	Resistance
1648	civic	Dasatinib	Chronic Myeloid Leukemia	ABL1	BCR::ABL E98G	Resistance
1649	civic	Vemurafenib	Colorectal Cancer	BRAF	G596R	Sensitivity/Response
1650	civic	Erlotinib,Gefitinib	Lung Non-small Cell Carcinoma	EGFR	Rare Exon 18-21 Mutation	Sensitivity/Response
1651	civic	Gefitinib,Erlotinib	Lung Non-small Cell Carcinoma	EGFR	Ex19 del L858R	Sensitivity/Response
1652	civic	Gefitinib,Erlotinib	Lung Non-small Cell Carcinoma	EGFR	Rare Exon 18-21 Mutation	Sensitivity/Response
1653	civic	Erlotinib	Lung Adenocarcinoma	EGFR	Exon 19 Deletion	Sensitivity/Response
1654	civic	Bosutinib	Chronic Myeloid Leukemia	ABL1	C475V	Resistance
1655	civic	Bosutinib	Chronic Myeloid Leukemia	ABL1	BCR::ABL N336S	Resistance
1656	civic	Pembrolizumab	Lung Adenocarcinoma	POLD1	C284Y	Sensitivity/Response
1657	civic	Pembrolizumab	Lung Non-small Cell Carcinoma	POLD1	E374K	Sensitivity/Response
1658	civic	Vemurafenib	Melanoma	PIK3R2	N561D	Resistance
1659	civic	Vemurafenib	Melanoma	PIK3CA	D350G	Resistance
1660	civic	Cetuximab	Colorectal Cancer	NRAS	Q179X	Resistance
1661	civic	Crizotinib	Lung Adenocarcinoma	MET	Exon 14 Skipping Mutation	Sensitivity/Response
1662	civic	Dasatinib	Lung Non-small Cell Carcinoma	ABL1	R351W	Sensitivity/Response
1663	civic	Dasatinib,Imatinib Mesylate	Lung Non-small Cell Carcinoma	ABL1	G340L	Sensitivity/Response
1664	civic	Dasatinib,Imatinib	Cancer	KIT	S628N	Sensitivity/Response
1665	civic	Erlotinib	Lung Non-small Cell Carcinoma	EGFR	M766_A767insAI	Resistance
1666	civic	Erlotinib	Lung Non-small Cell Carcinoma	EGFR	Y764_V765insHH	Resistance
1667	civic	Erlotinib	Lung Adenocarcinoma	EGFR	D770delinsGY	Resistance
1668	civic	Erlotinib	Lung Non-small Cell Carcinoma	EGFR	P772_H773insYNP	Resistance
1669	civic	Erlotinib	Lung Adenocarcinoma	EGFR	P772_V774insPHV	Sensitivity/Response
1670	civic	Palbociclib,Letrozole	Breast Cancer	ESR1	D538G	Sensitivity/Response
1671	civic	Pembrolizumab	Melanoma	JAK2	Splice Site (c.1641+2T>G)	Resistance
1672	civic	Dasatinib	Ovarian Clear Cell Carcinoma	ARID1A	P1175FS*5	Sensitivity/Response
1673	civic	Anti-VEGF Monoclonal Antibody	Renal Cell Carcinoma	VHL	Mutation	Sensitivity/Response
1674	civic	Enasidenib	Acute Myeloid Leukemia	IDH2	Mutation	Sensitivity/Response
1675	civic	Brigatinib	Lung Non-small Cell Carcinoma	ALK	Fusion	Sensitivity/Response
1676	civic	Talazoparib	Breast Cancer	BRCA1	Loss-of-function	Sensitivity/Response
1677	civic	Talazoparib	Breast Cancer	BRCA2	Loss-of-function	Sensitivity/Response
1678	civic	Trastuzumab Emtansine	Her2-receptor Positive Breast Cancer	ERBB2	Overexpression	Sensitivity/Response
1679	civic	Palbociclib	Liposarcoma	CDK4	Amplification	Sensitivity/Response
1680	civic	Abemaciclib	Lung Non-small Cell Carcinoma	KRAS	Mutation	Sensitivity/Response
1681	civic	Cabozantinib	Lung Adenocarcinoma	RET	Fusion	Sensitivity/Response
1682	civic	Vandetanib	Lung Non-small Cell Carcinoma	RET	Fusion	Sensitivity/Response
1683	civic	Vandetanib	Lung Non-small Cell Carcinoma	RET	Fusion	Sensitivity/Response
1684	civic	Alectinib	Lung Non-small Cell Carcinoma	RET	Fusion	Sensitivity/Response
1685	civic	Pembrolizumab,Durvalumab,Nivolumab,Avelumab,Atezolizumab	Lung Non-small Cell Carcinoma	CD274	Expression	Sensitivity/Response
1686	civic	Crizotinib,Alectinib	Lung Non-small Cell Carcinoma	ALK	Fusion	Sensitivity/Response
1687	civic	Dacomitinib,Erlotinib	Lung Non-small Cell Carcinoma	EGFR	Exon 19 Deletion	Sensitivity/Response
1688	civic	Dacomitinib	Lung Non-small Cell Carcinoma	EGFR	L858R	Sensitivity/Response
1689	civic	Erdafitinib	Adrenal Carcinoma	FGFR3	Fusion	Sensitivity/Response
1690	civic	Pemetrexed,Docetaxel,Trametinib	Lung Non-small Cell Carcinoma	KRAS	Mutation	Sensitivity/Response
1691	civic	Atezolizumab,Nivolumab	Lung Non-small Cell Carcinoma	KRAS	Mutation	Sensitivity/Response
1692	civic	Immune Checkpoint Inhibitor	Lung Non-small Cell Carcinoma	KRAS	Mutation	Sensitivity/Response
1693	civic	Selumetinib,Cetuximab	Colorectal Cancer	KRAS	Mutation	Sensitivity/Response
1694	civic	Trametinib	Lung Non-small Cell Carcinoma	KRAS	Mutation	Sensitivity/Response
1695	civic	Selumetinib,Erlotinib	Lung Non-small Cell Carcinoma	KRAS	Mutation	Sensitivity/Response
1696	civic	Palbociclib,Binimetinib	Colorectal Cancer	KRAS	Mutation	Sensitivity/Response
1697	civic	Palbociclib	Sarcoma	CDK4	EXPRESSION	Sensitivity/Response
1698	civic	Prexasertib,Cisplatin,Olaparib	Lung Small Cell Carcinoma	CHEK1	Overexpression	Sensitivity/Response
1699	civic	Talazoparib	Ovarian Cancer	BRCA2	Loss-of-function	Sensitivity/Response
1700	civic	Talazoparib	Ovarian Cancer	BRCA1	Loss-of-function	Sensitivity/Response
1701	civic	Gefitinib	Lung Non-small Cell Carcinoma	EGFR	Expression	Sensitivity/Response
1702	civic	MDM2 Inhibitor AMGMDS3	Cancer	TP53	R248W	Resistance
1703	civic	MDM2 Inhibitor AMGMDS3	Cancer	TP53	R175H	Resistance
1704	civic	MDM2 Inhibitor AMGMDS3	Cancer	TP53	R273C	Resistance
1705	civic	MDM2 Inhibitor AMGMDS3	Cancer	TP53	R273H	Resistance
1706	civic	MDM2 Inhibitor AMGMDS3	Cancer	TP53	G245S	Resistance
1707	civic	MDM2 Inhibitor AMGMDS3	Cancer	TP53	Y220C	Resistance
1708	civic	MDM2 Inhibitor AMGMDS3	Glioblastoma	TP53	M237I	Resistance
1709	civic	MDM2 Inhibitor AMGMDS3	Vulva Squamous Cell Carcinoma	TP53	R158H	Resistance
1710	civic	MDM2 Inhibitor AMGMDS3	Cancer	TP53	V157F	Resistance
1711	civic	MDM2 Inhibitor AMGMDS3	Cancer	TP53	R249S	Resistance
1712	civic	MDM2 Inhibitor AMGMDS3	Cancer	TP53	R280K	Resistance
1713	civic	MDM2 Inhibitor AMGMDS3	Cancer	TP53	R280T	Resistance
1714	civic	MDM2 Inhibitor AMGMDS3	Cancer	TP53	R158L	Resistance
1715	civic	Trametinib	Skin Melanoma	BRAF	L597Q	Sensitivity/Response
1716	civic	Gefitinib	Lung Non-small Cell Carcinoma	EGFR	Gain-of-function	Sensitivity/Response
1717	civic	Trastuzumab,Fluorouracil,Leucovorin	Colorectal Adenocarcinoma	ERBB2	L755S	Sensitivity/Response
1718	civic	Docetaxel,Erlotinib	Lung Non-small Cell Carcinoma	KRAS	Mutation	Sensitivity/Response
1719	civic	Docetaxel	Lung Non-small Cell Carcinoma	KRAS	Mutation	Sensitivity/Response
1720	civic	Cabozantinib	Uveal Melanoma	GNAQ	Mutation	Sensitivity/Response
1721	civic	Enasidenib	Acute Myeloid Leukemia	IDH2	Mutation	Sensitivity/Response
1722	civic	Olaparib,Paclitaxel	Stomach Cancer	ATM	Underexpression	Sensitivity/Response
1723	civic	Midostaurin	Acute Myeloid Leukemia	FLT3	Mutation	Sensitivity/Response
1724	civic	Everolimus	Renal Cell Carcinoma	VHL	Mutation	Sensitivity/Response
1725	civic	Neratinib	Breast Cancer	ERBB2	Mutation	Sensitivity/Response
1726	civic	Sunitinib,Everolimus	Renal Cell Carcinoma	BAP1	Mutation	Resistance
1727	civic	Cetuximab,Panitumumab	Colorectal Cancer	NRAS	Mutation	Resistance
1728	civic	Panitumumab,Cetuximab	Colorectal Cancer	KRAS	Mutation	Resistance
1729	civic	Imatinib Mesylate	Cancer	PDGFRA	D842V	Resistance
1730	civic	Imatinib Mesylate	Cancer	PDGFRA	V561D	Resistance
1731	civic	Imatinib Mesylate	Cancer	KIT	V560D	Sensitivity/Response
1732	civic	JQ-1	Multiple Myeloma	MYC	Overexpression	Sensitivity/Response
1733	civic	Gemcitabine	Pancreatic Cancer	RRM1	Underexpression	Sensitivity/Response
1734	civic	Gemcitabine	Pancreatic Cancer	RRM1	Underexpression	Sensitivity/Response
1735	civic	Gemcitabine	Lung Non-small Cell Carcinoma	RRM1	Underexpression	Sensitivity/Response
1736	civic	Vinorelbine,Gemcitabine,Paclitaxel	Lung Non-small Cell Carcinoma	RRM1	Underexpression	Sensitivity/Response
1737	civic	Pembrolizumab	Lung Non-small Cell Carcinoma	CD274	Expression	Sensitivity/Response
1738	civic	Olaparib	Her2-receptor Negative Breast Cancer	BRCA1	Loss-of-function	Sensitivity/Response
1739	civic	Olaparib	Her2-receptor Negative Breast Cancer	BRCA2	Loss-of-function	Sensitivity/Response
1740	civic	Checkpoint Kinase Inhibitor AZD7762,Irinotecan	Ureter Small Cell Carcinoma	RAD50	L1237F	Sensitivity/Response
1741	civic	Olaparib	Her2-receptor Negative Breast Cancer	BRCA1	Mutation	Sensitivity/Response
1742	civic	Olaparib	Breast Cancer	BRCA2	Mutation	Sensitivity/Response
1743	civic	Rilotumumab	Stomach Carcinoma	MET	Overexpression	Sensitivity/Response
1744	civic	Everolimus	Cancer	PTEN	Loss	Sensitivity/Response
1745	civic	Afatinib	Cholangiocarcinoma	NRG1	ATP1B1::NRG1	Sensitivity/Response
1746	civic	Afatinib	Lung Adenocarcinoma	NRG1	SDC4::NRG1	Sensitivity/Response
1747	civic	Trametinib,Dabrafenib	Cholangiocarcinoma	BRAF	V600E	Sensitivity/Response
1748	civic	Dabrafenib,Trametinib	Intrahepatic Cholangiocarcinoma	BRAF	V600E	Sensitivity/Response
1749	civic	Trametinib,Dabrafenib	Intrahepatic Cholangiocarcinoma	BRAF	V600E	Sensitivity/Response
1750	civic	Vemurafenib	Cholangiocarcinoma	BRAF	V600	Sensitivity/Response
1751	civic	Irinotecan,Panitumumab,Vemurafenib	Cholangiocarcinoma	BRAF	V600E	Sensitivity/Response
1752	civic	Infigratinib	Cholangiocarcinoma	FGFR2	Fusion	Sensitivity/Response
1753	civic	Erlotinib	Lung Adenocarcinoma	EGFR	EGFR::RAD51	Sensitivity/Response
1754	civic	Infigratinib	Cholangiocarcinoma	FGFR2	Mutation	Sensitivity/Response
1755	civic	Olaparib	Pancreatic Cancer	BRCA2	Mutation	Sensitivity/Response
1756	civic	Olaparib	Pancreatic Cancer	BRCA1	Mutation	Sensitivity/Response
1757	civic	Oxaliplatin,Cisplatin	Pancreatic Cancer	BRCA1	Mutation	Sensitivity/Response
1758	civic	Platinum Compound	Pancreatic Cancer	BRCA2	Mutation	Sensitivity/Response
1759	civic	Erlotinib	Cancer	EGFR	L858R	Sensitivity/Response
1760	civic	Cytoreductive Surgery,Hyperthermic Intraperitoneal Chemotherapy	Peritoneal Mesothelioma	EGFR	Mutation	Sensitivity/Response
1761	civic	Gefitinib,Erlotinib	Lung Non-small Cell Carcinoma	EGFR	Amplification	Sensitivity/Response
1762	civic	Erlotinib,Gefitinib	Lung Non-small Cell Carcinoma	EGFR	Amplification	Sensitivity/Response
1763	civic	Olaparib,Apitolisib	Malignant Mesothelioma	BAP1	ALTERNATIVE TRANSCRIPT (ATI)	Sensitivity/Response
1764	civic	Veliparib,Cisplatin,Gemcitabine	Pancreatic Cancer	BRCA1	Mutation	Sensitivity/Response
1765	civic	Cisplatin,Veliparib,Gemcitabine	Pancreatic Cancer	BRCA2	Mutation	Sensitivity/Response
1766	civic	Veliparib	Pancreatic Cancer	BRCA1	Mutation	Sensitivity/Response
1767	civic	Veliparib	Pancreatic Cancer	BRCA2	Mutation	Sensitivity/Response
1768	civic	Iniparib	Pancreatic Cancer	BRCA2	Mutation	Sensitivity/Response
1769	civic	Erlotinib	Lung Non-small Cell Carcinoma	EGFR	M766_A767insASV	Sensitivity/Response
1770	civic	Afatinib,Gefitinib	Lung Non-small Cell Carcinoma	EGFR	D770_N771insNPG	Sensitivity/Response
1771	civic	Ceritinib	Colon Adenocarcinoma	ALK	STRN::ALK	Sensitivity/Response
1772	civic	Olaparib	Colorectal Cancer	BARD1	Loss-of-function	Sensitivity/Response
1773	civic	Crizotinib	Thyroid Gland Anaplastic Carcinoma	ALK	Fusion	Sensitivity/Response
1774	civic	Trastuzumab,Capecitabine	Pancreatic Cancer	ERBB2	Overexpression	Sensitivity/Response
1775	civic	Trastuzumab,Gemcitabine	Pancreatic Cancer	ERBB2	Overexpression	Sensitivity/Response
1776	civic	Carboplatin,Buparlisib,Paclitaxel	Solid Tumor	PTEN	Loss	Sensitivity/Response
1777	civic	Vemurafenib	Lung Non-small Cell Carcinoma	BRAF	V600E	Sensitivity/Response
1778	civic	Vemurafenib	Ovarian Cancer	BRAF	V600E	Sensitivity/Response
1779	civic	Vemurafenib	Colorectal Cancer	BRAF	V600E	Sensitivity/Response
1780	civic	Vemurafenib,Pertuzumab	Thyroid Gland Anaplastic Carcinoma	BRAF	V600E	Sensitivity/Response
1781	civic	Vemurafenib	Laryngeal Squamous Cell Carcinoma	BRAF	V600E	Sensitivity/Response
1782	civic	Vemurafenib	Cancer	BRAF	G464V	Sensitivity/Response
1783	civic	Vemurafenib	Cancer	BRAF	G469A	Sensitivity/Response
1784	civic	Vemurafenib	Cancer	BRAF	G496A	Sensitivity/Response
1785	civic	Vemurafenib	Cancer	BRAF	N581S	Sensitivity/Response
1786	civic	Vemurafenib	Cancer	BRAF	G466V	Sensitivity/Response
1787	civic	Vemurafenib	Cancer	BRAF	G596R	Sensitivity/Response
1788	civic	Vemurafenib	Cancer	BRAF	G606E	Sensitivity/Response
1789	civic	Vemurafenib	Cancer	BRAF	L597Q	Sensitivity/Response
1790	civic	Vemurafenib	Cancer	BRAF	P731T	Sensitivity/Response
1791	civic	Vemurafenib	Cancer	BRAF	intron 9 rearrangement	Sensitivity/Response
1792	civic	Vemurafenib	Cancer	BRAF	intron 10 rearrangement	Sensitivity/Response
1793	civic	Vemurafenib	Cancer	BRAF	MACF1::BRAF	Sensitivity/Response
1794	civic	Vemurafenib	Cancer	BRAF	WASFL::BRAF	Sensitivity/Response
1795	civic	Vemurafenib	Pancreatic Cancer	BRAF	CUX1::BRAF	Sensitivity/Response
1796	civic	Vismodegib	Cancer	PTCH1	Mutation	Sensitivity/Response
1797	civic	Vismodegib	Cancer	SMO	Mutation	Sensitivity/Response
1798	civic	Trastuzumab,Pertuzumab	Lung Non-small Cell Carcinoma	ERBB2	Mutation	Sensitivity/Response
1799	civic	Pertuzumab,Trastuzumab	Colorectal Cancer	ERBB2	Amplification	Sensitivity/Response
1800	civic	Pertuzumab,Trastuzumab	Bladder Carcinoma	ERBB2	Amplification	Sensitivity/Response
1801	civic	Trastuzumab,Pertuzumab	Biliary Tract Cancer	ERBB2	Amplification	Sensitivity/Response
1802	civic	Trastuzumab,Pertuzumab	Salivary Gland Carcinoma	ERBB2	Amplification	Sensitivity/Response
1803	civic	Trastuzumab,Pertuzumab	Pancreatic Cancer	ERBB2	Amplification	Sensitivity/Response
1804	civic	Pertuzumab,Trastuzumab	Uterine Cancer	ERBB2	Amplification	Sensitivity/Response
1805	civic	Ivosidenib	Pancreatic Ductal Adenocarcinoma	IDH1	R132H	Sensitivity/Response
1806	civic	Pegargiminase,Chloroquine	Sarcoma	ASS1	Loss	Sensitivity/Response
1807	civic	Taxol,Cisplatin,Carboplatin	Ovarian Cancer	ASS1	Loss	Resistance
1808	civic	Trametinib	Lung Non-small Cell Carcinoma	RASA1	Loss-of-function	Sensitivity/Response
1809	civic	GF109203X,Go6983	Breast Cancer	TLK2	Amplification	Sensitivity/Response
1810	civic	Sorafenib	Skin Melanoma	BRAF	D594G	Sensitivity/Response
1811	civic	U0126	Skin Melanoma	BRAF	D594G	Resistance
1812	civic	Sorafenib	Skin Melanoma	BRAF	G469E	Sensitivity/Response
1813	civic	U0126	Skin Melanoma	BRAF	G469E	Resistance
1814	civic	Erlotinib	Pancreatic Adenocarcinoma	EGFR	L747_P753delinsS	Sensitivity/Response
1815	civic	Osimertinib	Pancreatic Adenocarcinoma	EGFR	T790M	Sensitivity/Response
1816	civic	JQ1,Panobinostat	Neuroblastoma	MYCN	Amplification	Sensitivity/Response
1817	civic	Crizotinib	Vagina Sarcoma	ALK	Fusion	Sensitivity/Response
1818	civic	Crizotinib	Epithelioid Inflammatory Myofibroblastic Sarcoma	ALK	Fusion	Sensitivity/Response
1819	civic	Vemurafenib,Cobimetinib	Melanoma	BRAF	V600	Sensitivity/Response
1820	civic	Vemurafenib	Thyroid Gland Anaplastic Carcinoma	BRAF	V600E	Sensitivity/Response
1821	civic	Cetuximab,Encorafenib	Colorectal Cancer	BRAF	V600	Sensitivity/Response
1822	civic	Encorafenib,Cetuximab,Alpelisib	Colorectal Cancer	BRAF	V600	Sensitivity/Response
1823	civic	Meloxicam	Desmoid Tumor	CTNNB1	S45F	Sensitivity/Response
1824	civic	Afatinib	Mucinous Adenocarcinoma	NRG1	Fusion	Sensitivity/Response
1825	civic	Larotrectinib	Sarcoma	NTRK2	STRN::NTRK2	Sensitivity/Response
1826	civic	Larotrectinib	Congenital Fibrosarcoma	NTRK3	ETV6::NTRK3	Sensitivity/Response
1827	civic	Larotrectinib	Sarcoma	NTRK1	LMNA::NTRK1	Sensitivity/Response
1828	civic	Larotrectinib	Sarcoma	NTRK1	TPM3::NTRK1	Sensitivity/Response
1829	civic	Larotrectinib	Sarcoma	NTRK1	PDE4DIP::NTRK1	Sensitivity/Response
1830	civic	Larotrectinib	Congenital Fibrosarcoma	NTRK1	SQSTM1::NTRK1	Sensitivity/Response
1831	civic	Panitumumab,Trametinib,Dabrafenib	Colorectal Cancer	BRAF	V600E	Sensitivity/Response
1832	civic	Trametinib,Panitumumab	Colorectal Adenocarcinoma	BRAF	V600E	Sensitivity/Response
1833	civic	Trastuzumab,Paclitaxel	Salivary Gland Cancer	ERBB2	Overexpression	Sensitivity/Response
1834	civic	Trastuzumab,Capecitabine,Zoledronic Acid	Salivary Gland Cancer	ERBB2	Overexpression	Sensitivity/Response
1835	civic	Osimertinib	Breast Cancer	ERBB2	T798I	Sensitivity/Response
1836	civic	Dabrafenib,Trametinib	Melanoma	BRAF	V600E	Sensitivity/Response
1837	civic	Dabrafenib,Trametinib	Melanoma	BRAF	V600K	Sensitivity/Response
1838	civic	Trametinib,Dabrafenib	Melanoma	BRAF	V600	Sensitivity/Response
1839	civic	Gefitinib,Erlotinib	Lung Non-small Cell Carcinoma	EGFR	G719A	Sensitivity/Response
1840	civic	Erlotinib,Gefitinib	Lung Non-small Cell Carcinoma	EGFR	R705K	Sensitivity/Response
1841	civic	Gefitinib	Lung Adenocarcinoma	EGFR	L858R	Sensitivity/Response
1842	civic	Gefitinib	Lung Adenocarcinoma	EGFR	Exon 19 Deletion	Sensitivity/Response
1843	civic	Gefitinib	Lung Adenocarcinoma	EGFR	Rare Mutation	Sensitivity/Response
1844	civic	Tamoxifen	Estrogen-receptor Positive Breast Cancer	PIK3CA	Mutation	Sensitivity/Response
1845	civic	Dasatinib	Chronic Myeloid Leukemia	ABL1	BCR::ABL T315A	Resistance
1846	civic	Fluorouracil,Cyclophosphamide,Epirubicin,Doxorubicin,Paclitaxel	Breast Cancer	PIK3CA	Mutation	Resistance
1847	civic	Lapatinib,Trastuzumab	Her2-receptor Positive Breast Cancer	PIK3CA	H1047R	Resistance
1848	civic	Dactolisib	Her2-receptor Positive Breast Cancer	PIK3CA	H1047R	Resistance
1849	civic	Imatinib Mesylate,Dasatinib	Chronic Myeloid Leukemia	ABL1	BCR::ABL L248R	Resistance
1850	civic	Lapatinib,Trastuzumab	Her2-receptor Positive Breast Cancer	PIK3CA	E545K	Resistance
1851	civic	Dactolisib	Her2-receptor Positive Breast Cancer	PIK3CA	E545K	Resistance
1852	civic	Dasatinib	Chronic Myeloid Leukemia	ABL1	BCR::ABL V299L	Resistance
1853	civic	Dasatinib	Chronic Myeloid Leukemia	ABL1	BCR::ABL F317I	Resistance
1854	civic	Dasatinib	Chronic Myeloid Leukemia	ABL1	BCR::ABL F317S	Resistance
1855	civic	Dasatinib	Chronic Myeloid Leukemia	ABL1	BCR::ABL Q252H	Resistance
1856	civic	Imatinib Mesylate,Nilotinib	Chronic Myeloid Leukemia	ABL1	BCR::ABL F359C	Resistance
1857	civic	Imatinib Mesylate,Nilotinib	Chronic Myeloid Leukemia	ABL1	BCR::ABL L248V	Resistance
1858	civic	Imatinib Mesylate,Nilotinib	Chronic Myeloid Leukemia	ABL1	BCR::ABL F311L	Resistance
1859	civic	Imatinib Mesylate,Nilotinib	Chronic Myeloid Leukemia	ABL1	BCR::ABL F359C	Resistance
1860	civic	Nilotinib,Imatinib Mesylate	Chronic Myeloid Leukemia	ABL1	BCR::ABL H396P	Resistance
1861	civic	Dasatinib,Imatinib Mesylate	Chronic Myeloid Leukemia	ABL1	BCR::ABL V299L	Resistance
1862	civic	Imatinib Mesylate	Chronic Myeloid Leukemia	ABL1	BCR::ABL M244V	Resistance
1863	civic	Imatinib Mesylate	Chronic Myeloid Leukemia	ABL1	BCR::ABL L248R	Resistance
1864	civic	Imatinib Mesylate	Chronic Myeloid Leukemia	ABL1	BCR::ABL Q252H	Resistance
1865	civic	Dasatinib	Chronic Myeloid Leukemia	ABL1	BCR::ABL V299L	Resistance
1866	civic	Dasatinib	Chronic Myeloid Leukemia	ABL1	BCR::ABL F317C	Resistance
1867	civic	Dasatinib	Chronic Myeloid Leukemia	ABL1	BCR::ABL F317I	Resistance
1868	civic	Imatinib Mesylate	Chronic Myeloid Leukemia	ABL1	BCR::ABL E355G	Resistance
1869	civic	Imatinib Mesylate	Chronic Myeloid Leukemia	ABL1	BCR::ABL F359V	Resistance
1870	civic	Imatinib Mesylate	Chronic Myeloid Leukemia	ABL1	BCR::ABL V379I	Resistance
1871	civic	Imatinib Mesylate	Chronic Myeloid Leukemia	ABL1	BCR::ABL H396R	Resistance
1872	civic	Vemurafenib	Melanoma	AKT1	Overexpression	Resistance
1873	civic	Dabrafenib	Melanoma	AKT1	Q79K	Resistance
1874	civic	Vemurafenib	Melanoma	AKT3	Overexpression	Resistance
1875	civic	Dabrafenib,Vemurafenib	Melanoma	NRAS	Mutation	Resistance
1876	civic	Vemurafenib,Dabrafenib	Melanoma	KRAS	Mutation	Resistance
1877	civic	Vemurafenib	Melanoma	PIK3R2	Overexpression	Resistance
1878	civic	Vemurafenib	Melanoma	PREX2	R172I	Resistance
1879	civic	Vemurafenib	Melanoma	PTEN	Loss	Resistance
1880	civic	Afatinib	Pancreatic Adenocarcinoma	NRG1	Fusion	Sensitivity/Response
1881	civic	Dasatinib	Chronic Myeloid Leukemia	ABL1	BCR::ABL Q252H	Resistance
1882	civic	Vemurafenib	Melanoma	PIK3CA	Amplification	Resistance
1883	civic	Oxaliplatin	Colorectal Cancer	KRAS	G12/G13	Resistance
1884	civic	Irinotecan	Colorectal Cancer	KRAS	G12/G13	Resistance
1885	civic	Bevacizumab	Colorectal Cancer	KRAS	G12/G13	Resistance
1886	civic	Cetuximab	Colorectal Cancer	KRAS	G12/G13	Resistance
1887	civic	Oxaliplatin	Colorectal Cancer	PIK3CA	Mutation	Resistance
1888	civic	Irinotecan	Colorectal Cancer	PIK3CA	Mutation	Resistance
1889	civic	Bevacizumab	Colorectal Cancer	PIK3CA	Mutation	Resistance
1890	civic	Cetuximab	Colorectal Cancer	PIK3CA	Mutation	Resistance
1891	civic	Oxaliplatin	Colorectal Cancer	BRAF	Mutation	Resistance
1892	civic	Irinotecan	Colorectal Cancer	BRAF	Mutation	Resistance
1893	civic	Bevacizumab	Colorectal Cancer	BRAF	Mutation	Resistance
1894	civic	Cetuximab	Colorectal Cancer	BRAF	Mutation	Resistance
1895	civic	Dasatinib	Chronic Myeloid Leukemia	ABL1	BCR::ABL L248V	Resistance
1896	civic	Dasatinib	Chronic Myeloid Leukemia	ABL1	BCR::ABL E459K	Resistance
1897	civic	Dasatinib	Chronic Myeloid Leukemia	ABL1	TKD MUTATION	Resistance
1898	civic	Cetuximab,Panitumumab	Colorectal Cancer	KRAS	G13V	Resistance
1899	civic	Panitumumab,Cetuximab	Colorectal Cancer	KRAS	G12S	Resistance
1900	civic	Cetuximab,Panitumumab	Colorectal Cancer	PTEN	Loss	Resistance
1901	civic	Cetuximab,Panitumumab	Colorectal Cancer	KRAS	G12D	Resistance
1902	civic	Vemurafenib	Melanoma	KRAS	Amplification	Resistance
1903	civic	Cetuximab,Panitumumab	Colorectal Cancer	KRAS	G12A	Resistance
1904	civic	Panitumumab,Cetuximab	Colorectal Cancer	KRAS	G13D	Resistance
1905	civic	Panitumumab,Cetuximab	Colorectal Cancer	KRAS	G13D	Resistance
1906	civic	Cetuximab,Panitumumab	Colorectal Cancer	KRAS	G12V	Resistance
1907	civic	Bosutinib	Chronic Myeloid Leukemia	ABL1	TKD MUTATION	Resistance
1908	civic	Bosutinib	Chronic Myeloid Leukemia	ABL1	P-Loop Mutation	Resistance
1909	civic	Bosutinib	Chronic Myeloid Leukemia	ABL1	Non-P-Loop Mutation	Resistance
1910	civic	Rucaparib	Ovarian Cancer	BRCA1	Mutation	Sensitivity/Response
1911	civic	Nilotinib	Chronic Myeloid Leukemia	ABL1	TKD MUTATION	Resistance
1912	civic	Rucaparib	Ovarian Cancer	BRCA2	Mutation	Sensitivity/Response
1913	civic	Cetuximab,Panitumumab	Colorectal Cancer	PIK3CA	Mutation	Resistance
1914	civic	Panitumumab,Cetuximab	Colorectal Cancer	KRAS	G12/G13	Resistance
1915	civic	Aspirin	Colorectal Cancer	PIK3CA	Mutation	Sensitivity/Response
1916	civic	Imatinib	Lung Non-small Cell Carcinoma	ABL1	R351W	Sensitivity/Response
1917	civic	Regorafenib	Gastrointestinal Stromal Tumor	KIT	Exon 11 Mutation	Sensitivity/Response
1918	civic	Ruxolitinib	Chronic Neutrophilic Leukemia	CSF3R	T618I	Sensitivity/Response
1919	civic	Ruxolitinib	Chronic Neutrophilic Leukemia	CSF3R	T618I	Sensitivity/Response
1920	civic	Larotrectinib	Melanoma	NTRK1	TRIM63::NTRK1	Sensitivity/Response
1921	civic	Larotrectinib	Melanoma	NTRK1	DDR2::NTRK1	Sensitivity/Response
1922	civic	Larotrectinib	Melanoma	NTRK1	GON4L::NTRK1	Sensitivity/Response
1923	civic	Larotrectinib	Acute Myeloid Leukemia	NTRK2	ETV6::NTRK2	Sensitivity/Response
1924	civic	Dabrafenib,Vemurafenib	Melanoma	BRAF	intron 10 rearrangement	Resistance
1925	civic	Vemurafenib,Dabrafenib	Melanoma	BRAF	intron 9 rearrangement	Resistance
1926	civic	Irinotecan	Colorectal Cancer	BRAF	D594K	Resistance
1927	civic	Oxaliplatin	Colorectal Cancer	BRAF	D594K	Resistance
1928	civic	PD173074,AZ12908010,FGFR Inhibitor AZD4547	Myeloid Neoplasm	FGFR3	V555M	Resistance
1929	civic	Infigratinib	Transitional Cell Carcinoma	FGFR3	FGFR3::TACC3	Sensitivity/Response
1930	civic	Dasatinib	Intrahepatic Cholangiocarcinoma	IDH1	R132	Sensitivity/Response
1931	civic	Atezolizumab,Pembrolizumab,Nivolumab	Lung Adenocarcinoma	STK11	Mutation	Resistance
1932	civic	Larotrectinib	Congenital Fibrosarcoma	NTRK3	ETV6::NTRK3	Sensitivity/Response
1933	civic	Larotrectinib	Breast Secretory Carcinoma	NTRK3	ETV6::NTRK3	Sensitivity/Response
1934	civic	Aromatase Inhibitor	Breast Cancer	KMT2C	Loss	Resistance
1935	civic	Larotrectinib	Solid Tumor	NTRK1	Fusion	Sensitivity/Response
1936	civic	Larotrectinib	Solid Tumor	NTRK3	Fusion	Sensitivity/Response
1937	civic	Larotrectinib	Sarcoma	NTRK1	Fusion	Sensitivity/Response
1938	civic	Larotrectinib	B-lymphoblastic Leukemia/lymphoma	NTRK3	ETV6::NTRK3	Sensitivity/Response
1939	civic	Trametinib,Dabrafenib	Melanoma	BRAF	V600	Sensitivity/Response
1940	civic	Trametinib,Dabrafenib	Melanoma	BRAF	V600E	Sensitivity/Response
1941	civic	Trametinib,Dabrafenib	Melanoma	BRAF	V600E	Sensitivity/Response
1942	civic	Dabrafenib,Trametinib	Melanoma	BRAF	V600K	Sensitivity/Response
1943	civic	Vemurafenib,Cobimetinib	Melanoma	BRAF	V600	Sensitivity/Response
1944	civic	Dasatinib	B-lymphoblastic Leukemia/lymphoma	ABL1	ETV6::ABL1	Sensitivity/Response
1945	civic	Nilotinib,Imatinib Mesylate	Chronic Myeloid Leukemia	ABL1	BCR::ABL F359V	Resistance
1946	civic	Nilotinib,Imatinib Mesylate	Chronic Myeloid Leukemia	ABL1	BCR::ABL E255V	Resistance
1947	civic	Dabrafenib,Trametinib	Thyroid Gland Anaplastic Carcinoma	BRAF	V600E	Sensitivity/Response
1948	civic	Imatinib	Childhood B-cell Acute Lymphoblastic Leukemia	PDGFRB	EBF1::PDGFRB	Sensitivity/Response
1949	civic	Imatinib Mesylate	Chronic Myeloid Leukemia	ABL1	C475V	Resistance
1950	civic	Imatinib Mesylate	Chronic Myeloid Leukemia	ABL1	BCR::ABL N336S	Resistance
1951	civic	Imatinib Mesylate	Chronic Myeloid Leukemia	ABL1	BCR::ABL E453A	Resistance
1952	civic	Imatinib Mesylate	Chronic Myeloid Leukemia	ABL1	BCR::ABL L387F	Resistance
1953	civic	Imatinib Mesylate	Chronic Myeloid Leukemia	ABL1	BCR::ABL V299L	Resistance
1954	civic	Imatinib Mesylate	Chronic Myeloid Leukemia	ABL1	BCR::ABL Q300R	Resistance
1955	civic	Imatinib Mesylate	Chronic Myeloid Leukemia	ABL1	BCR::ABL F359I	Resistance
1956	civic	Imatinib Mesylate	Chronic Myeloid Leukemia	ABL1	BCR::ABL F359C	Resistance
1957	civic	Imatinib Mesylate	Chronic Myeloid Leukemia	ABL1	BCR::ABL E255V	Resistance
1958	civic	Imatinib Mesylate	Chronic Myeloid Leukemia	ABL1	BCR::ABL F486S	Resistance
1959	civic	Imatinib Mesylate	Chronic Myeloid Leukemia	ABL1	BCR::ABL H396R	Resistance
1960	civic	Imatinib Mesylate	Chronic Myeloid Leukemia	ABL1	BCR::ABL M244V	Resistance
1961	civic	Imatinib Mesylate	Chronic Myeloid Leukemia	ABL1	BCR::ABL F359V	Resistance
1962	civic	Bosutinib	Chronic Myeloid Leukemia	ABL1	TKD MUTATION	Resistance
1963	civic	Bosutinib	Chronic Myeloid Leukemia	ABL1	P-Loop Mutation	Resistance
1964	civic	Bosutinib	Chronic Myeloid Leukemia	ABL1	Non-P-Loop Mutation	Resistance
1965	civic	Ruxolitinib	B-lymphoblastic Leukemia/lymphoma, BCR-ABL1–like	JAK2	GOLGA5::JAK2	Sensitivity/Response
1966	civic	BET Inhibitor	Alveolar Rhabdomyosarcoma	FOXO1	PAX3::FOXO1	Sensitivity/Response
1967	civic	Olaparib	Malignant Peripheral Nerve Sheath Tumor	PARP1	OVEREXPRESSION	Sensitivity/Response
1968	civic	Birabresib	NUT Midline Carcinoma	BRD4	BRD4::NUTM1	Sensitivity/Response
1969	civic	Imatinib	Myeloid And Lymphoid Neoplasms With Eosinophilia And Abnormalities Of PDGFRA, PDGFRB, And FGFR1	PDGFRA	FIP1L1::PDGFRA T674I	Resistance
1970	civic	Ruxolitinib	Childhood B-cell Acute Lymphoblastic Leukemia	JAK2	F694L	Sensitivity/Response
1971	civic	Erlotinib	Lung Non-small Cell Carcinoma	EGFR	Mutation	Sensitivity/Response
1972	civic	Imatinib	Childhood B-cell Acute Lymphoblastic Leukemia	PDGFRB	EBF1::PDGFRB	Sensitivity/Response
1973	civic	Dasatinib	Chronic Myeloid Leukemia	ABL1	BCR::ABL L248V	Resistance
1974	civic	Dasatinib	Chronic Myeloid Leukemia	ABL1	BCR::ABL E459K	Resistance
1975	civic	Imatinib Mesylate	Chronic Myeloid Leukemia	ABL1	BCR::ABL V379I	Resistance
1976	civic	Imatinib Mesylate	Chronic Myeloid Leukemia	ABL1	BCR::ABL A397P	Resistance
1977	civic	Imatinib Mesylate	Chronic Myeloid Leukemia	ABL1	BCR::ABL F359C	Resistance
1978	civic	Imatinib Mesylate	Chronic Myeloid Leukemia	ABL1	BCR::ABL E355G	Resistance
1979	civic	Imatinib Mesylate	Chronic Myeloid Leukemia	ABL1	BCR::ABL M244V	Resistance
1980	civic	Imatinib Mesylate	Chronic Myeloid Leukemia	ABL1	BCR::ABL F359V	Resistance
1981	civic	Imatinib Mesylate	Chronic Myeloid Leukemia	ABL1	BCR::ABL L248V	Resistance
1982	civic	Imatinib Mesylate	Chronic Myeloid Leukemia	ABL1	BCR::ABL E459K	Resistance
1983	civic	Selpercatinib	Lung Non-small Cell Carcinoma	RET	Fusion	Sensitivity/Response
1984	civic	Selpercatinib	Thyroid Gland Medullary Carcinoma	RET	V804M	Sensitivity/Response
1985	civic	Selpercatinib	Thyroid Gland Papillary Carcinoma	RET	Fusion	Sensitivity/Response
1986	civic	Cetuximab,Panitumumab	Colorectal Cancer	EGFR	V441F	Resistance
1987	civic	Imatinib,Dasatinib	Childhood B-cell Acute Lymphoblastic Leukemia	PDGFRB	EBF1::PDGFRB	Sensitivity/Response
1988	civic	Palbociclib,Abemaciclib	Lung Non-small Cell Carcinoma	SMARCA4	Loss	Sensitivity/Response
1989	civic	Celecoxib,Sulindac,Aspirin	Head And Neck Squamous Cell Carcinoma	PIK3CA	Mutation	Sensitivity/Response
1990	civic	Ibuprofen,Aspirin,Sulindac	Head And Neck Squamous Cell Carcinoma	PIK3CA	Amplification	Sensitivity/Response
1991	civic	Trametinib,Everolimus	Childhood Low-grade Glioma	BRAF	KIAA1549::BRAF	Sensitivity/Response
1992	civic	Vincristine,Dexamethasone,Dasatinib	B-lymphoblastic Leukemia/lymphoma, BCR-ABL1–like	ABL1	NUP214::ABL1	Sensitivity/Response
1993	civic	Dasatinib	B-lymphoblastic Leukemia/lymphoma	ABL1	SNX2::ABL1	Resistance
1994	civic	Pazopanib	Breast Cancer	FGFR1	Amplification	Sensitivity/Response
1995	civic	Imatinib	B-lymphoblastic Leukemia/lymphoma, BCR-ABL1–like	ABL1	RCSD1::ABL1	Sensitivity/Response
1996	civic	Dasatinib	B-lymphoblastic Leukemia/lymphoma, BCR-ABL1–like	ABL1	RCSD1::ABL1	Sensitivity/Response
1997	civic	Dasatinib	B-lymphoblastic Leukemia/lymphoma, BCR-ABL1–like	ABL2	Fusion	Sensitivity/Response
1998	civic	Imatinib	B-lymphoblastic Leukemia/lymphoma	ABL1	SNX2::ABL1	Reduced Sensitivity
1999	civic	Ruxolitinib	B-lymphoblastic Leukemia/lymphoma, BCR-ABL1–like	JAK2	SSBP2::JAK2	Sensitivity/Response
2000	civic	Encorafenib,Binimetinib,Cetuximab	Colorectal Cancer	BRAF	V600E	Sensitivity/Response
2001	civic	Trametinib,Dabrafenib	Biliary Tract Cancer	BRAF	V600E	Sensitivity/Response
2002	civic	Tepotinib	Lung Non-small Cell Carcinoma	MET	Exon 14 Skipping Mutation	Sensitivity/Response
2003	civic	Olaparib	Ovarian Cancer	BRCA1	Mutation	Sensitivity/Response
2004	civic	Olaparib	Ovarian Cancer	BRCA1	Mutation	Sensitivity/Response
2005	civic	Olaparib	Ovarian Cancer	BRCA2	Mutation	Sensitivity/Response
2006	civic	Ivosidenib	Acute Myeloid Leukemia	IDH1	Mutation	Sensitivity/Response
2007	civic	Crizotinib	Lung Non-small Cell Carcinoma	ROS1	Fusion	Sensitivity/Response
2008	civic	Gilteritinib	Acute Myeloid Leukemia	FLT3	Mutation	Sensitivity/Response
2009	civic	Alectinib	Lung Non-small Cell Carcinoma	ALK	Fusion	Sensitivity/Response
2010	civic	Ceritinib	Lung Non-small Cell Carcinoma	ALK	Fusion	Sensitivity/Response
2011	civic	Lorlatinib	Lung Non-small Cell Carcinoma	ALK	Fusion	Sensitivity/Response
2012	civic	Encorafenib,Binimetinib	Melanoma	BRAF	V600	Sensitivity/Response
2013	civic	Sunitinib	Gastrointestinal Stromal Tumor	KIT	V555_V559DEL	Resistance
2014	civic	Sunitinib	Gastrointestinal Stromal Tumor	KIT	K550_K559DEL	Resistance
2015	civic	Dasatinib	B-lymphoblastic Leukemia/lymphoma	ABL1	FOXP1::ABL1	Sensitivity/Response
2016	civic	Palbociclib	Pancreatic Cancer	CDKN2A	Mutation	Sensitivity/Response
2017	civic	Palbociclib	Cholangiocarcinoma	CDKN2A	Mutation	Sensitivity/Response
2018	civic	Pertuzumab,Trastuzumab	Colorectal Cancer	ERBB2	Amplification	Sensitivity/Response
2019	civic	Sorafenib,Temsirolimus,Bevacizumab	Spindle Cell Sarcoma	BRAF	KIAA1549::BRAF	Sensitivity/Response
2020	civic	Fulvestrant,Alpelisib	Breast Cancer	PIK3CA	Mutation	Sensitivity/Response
2021	civic	Icotinib	Lung Adenocarcinoma	EGFR	EGFR::RAD51	Sensitivity/Response
2022	civic	Alpelisib,Fulvestrant	Breast Cancer	PIK3CA	E542K	Sensitivity/Response
2023	civic	Fulvestrant,Alpelisib	Breast Cancer	PIK3CA	H1047X	Sensitivity/Response
2024	civic	Derazantinib	Intrahepatic Cholangiocarcinoma	FGFR2	Fusion	Sensitivity/Response
2025	civic	Cetuximab,Irinotecan,Vemurafenib	Colorectal Cancer	BRAF	V600	Sensitivity/Response
2026	civic	Crizotinib	Anaplastic Large Cell Lymphoma	ALK	Fusion	Sensitivity/Response
2027	civic	Crizotinib	Inflammatory Myofibroblastic Tumor	ALK	Fusion	Sensitivity/Response
2028	civic	Fludarabine,Daunorubicin,Cytarabine,Methotrexate,Imatinib	B-lymphoblastic Leukemia/lymphoma	IKZF1	Deletion	Sensitivity/Response
2029	civic	Ponatinib	Acute Myeloid Leukemia	FLT3	ITD	Sensitivity/Response
2030	civic	Sorafenib,Sunitinib	Acute Myeloid Leukemia	KIT	N822K	Sensitivity/Response
2031	civic	Sorafenib,Sunitinib	Acute Myeloid Leukemia	FGFR1	Fusion	Sensitivity/Response
2032	civic	Sorafenib,Sunitinib	Acute Myeloid Leukemia	PDGFRA	FIP1L1::PDGFRA	Sensitivity/Response
2033	civic	Ponatinib	Acute Myeloid Leukemia	KIT	N822K	Sensitivity/Response
2034	civic	Ponatinib	Acute Myeloid Leukemia	FGFR1	FGFR1OP2::FGFR1	Sensitivity/Response
2035	civic	Sorafenib,Sunitinib	Leukemia	FLT3	ITD	Sensitivity/Response
2036	civic	Olaparib	Pancreatic Adenocarcinoma	BRCA1	Loss-of-function	Sensitivity/Response
2037	civic	Olaparib	Pancreatic Adenocarcinoma	BRCA2	Loss-of-function	Sensitivity/Response
2038	civic	Sunitinib	Gastrointestinal Stromal Tumor	KIT	A502_Y503insAY	Sensitivity/Response
2039	civic	Ponatinib,Imatinib	Gastrointestinal Stromal Tumor	KIT	V560_L576DEL	Sensitivity/Response
2040	civic	Regorafenib,Ponatinib,Imatinib	Gastrointestinal Stromal Tumor	KIT	V560G	Sensitivity/Response
2041	civic	Sunitinib,Ponatinib	Gastrointestinal Stromal Tumor	KIT	K642E	Sensitivity/Response
2042	civic	Ponatinib	Gastrointestinal Stromal Tumor	KIT	D816E	Resistance
2043	civic	Vemurafenib,Sorafenib	Childhood Pilocytic Astrocytoma	BRAF	KIAA1549::BRAF	Resistance
2044	civic	Ponatinib	Gastrointestinal Stromal Tumor	KIT	A829P	Resistance
2045	civic	Imatinib,Sunitinib	Gastrointestinal Stromal Tumor	KIT	N822K	Resistance
2046	civic	Sunitinib,Imatinib	Gastrointestinal Stromal Tumor	KIT	A829P	Resistance
2047	civic	Imatinib	Gastrointestinal Stromal Tumor	KIT	T670I	Resistance
2048	civic	Sunitinib,Ponatinib	Gastrointestinal Stromal Tumor	KIT	T670I	Resistance
2049	civic	Larotrectinib	Congenital Fibrosarcoma	NTRK3	ETV6::NTRK3	Sensitivity/Response
2050	civic	Larotrectinib	Spindle Cell Sarcoma	NTRK1	TPM3::NTRK1	Sensitivity/Response
2051	civic	Larotrectinib	Sarcoma	NTRK1	PDE4DIP::NTRK1	Sensitivity/Response
2052	civic	Entrectinib	Mucosal Melanoma	ALK	Alternative Transcript (ATI)	Sensitivity/Response
2053	civic	Erdafitinib	Transitional Cell Carcinoma	FGFR3	Mutation	Sensitivity/Response
2054	civic	Doxorubicin,Methotrexate	Osteosarcoma	TP53	R273H	Resistance
2055	civic	Palbociclib	Lung Non-small Cell Carcinoma	CDKN2A	Loss	Resistance
2056	civic	Sapanisertib	Lung Squamous Cell Carcinoma	NFE2L2	Mutation	Sensitivity/Response
2057	civic	Ivosidenib	Cholangiocarcinoma	IDH1	Mutation	Sensitivity/Response
2058	civic	Vistusertib	Lung Small Cell Carcinoma	RICTOR	Amplification	Sensitivity/Response
2059	civic	Imatinib	Melanoma	KIT	S628N	Sensitivity/Response
2060	civic	Dasatinib,Imatinib	Cancer	KIT	D816V	Resistance
2061	civic	Alpelisib,Fulvestrant	Breast Cancer	PIK3CA	E545	Sensitivity/Response
2062	civic	Agerafenib	Colorectal Cancer	RET	CCDC6::RET	Sensitivity/Response
2063	civic	Entrectinib	Colorectal Cancer	ALK	CAD::ALK	Sensitivity/Response
2064	civic	Lorlatinib	Glioblastoma	ROS1	GOPC::ROS1	Sensitivity/Response
2065	civic	Selumetinib	Childhood Low-grade Glioma	NF1	Mutation	Sensitivity/Response
2066	civic	Lucitanib	Breast Cancer	FGFR1	Amplification	Sensitivity/Response
2067	civic	Afatinib	Pancreatic Ductal Adenocarcinoma	NRG1	ATP1B1::NRG1	Sensitivity/Response
2068	civic	Afatinib	Pancreatic Ductal Adenocarcinoma	NRG1	APP::NRG1	Sensitivity/Response
2069	civic	Larotrectinib	Solid Tumor	NTRK3	ETV6::NTRK3	Sensitivity/Response
2070	civic	Crizotinib	Head And Neck Cancer	MET	R1004G	Sensitivity/Response
2071	civic	Irinotecan,Panitumumab	Colorectal Cancer	BRAF	G466V	Sensitivity/Response
2072	civic	Vemurafenib	Colorectal Cancer	BRAF	G466V	Sensitivity/Response
2073	civic	Vemurafenib	Solid Tumor	BRAF	G466V	Sensitivity/Response
2074	civic	Vemurafenib	Cancer	BRAF	D594G	Sensitivity/Response
2075	civic	Cisplatin,Gemcitabine	Urinary Bladder Cancer	FGFR3	Mutation	Sensitivity/Response
2076	civic	Vemurafenib	Langerhans Cell Sarcoma	BRAF	V600E	Sensitivity/Response
2077	civic	Anti-PD1 Monoclonal Antibody	Lung Non-small Cell Carcinoma	EGFR	Exon 19 Deletion	Resistance
2078	civic	Anti-PD-L1 Monoclonal Antibody	Lung Non-small Cell Carcinoma	EGFR	Exon 19 Deletion	Resistance
2079	civic	Akt/ERK Inhibitor ONC201	Glioma	H3-3A	K28M	Sensitivity/Response
2080	civic	Osimertinib	Lung Non-small Cell Carcinoma	EGFR	Exon 20 Insertion	Sensitivity/Response
2081	civic	Binimetinib,Cetuximab,Encorafenib	Colorectal Cancer	BRAF	V600E	Sensitivity/Response
2082	civic	BRAF Inhibitor	Melanoma	BRAF	V600D	Sensitivity/Response
2083	civic	BRAF Inhibitor,Mitogen-Activated Protein Kinase Kinase Inhibitor	Melanoma	BRAF	V600D	Sensitivity/Response
2084	civic	BRAF Inhibitor,Mitogen-Activated Protein Kinase Kinase Inhibitor	Melanoma	BRAF	V600_K601>E	Sensitivity/Response
2085	civic	Mitogen-Activated Protein Kinase Kinase Inhibitor,BRAF Inhibitor	Melanoma	BRAF	G469	Sensitivity/Response
2086	civic	BRAF Inhibitor,Mitogen-Activated Protein Kinase Kinase Inhibitor	Melanoma	BRAF	A598V	Sensitivity/Response
2087	civic	Fisogatinib	Hepatocellular Carcinoma	FGF19	Overexpression	Sensitivity/Response
2088	civic	Trastuzumab,Pertuzumab	Cholangiocarcinoma	ERBB2	Amplification	Sensitivity/Response
2089	civic	Crizotinib	Lung Non-small Cell Carcinoma	MET	Exon 14 Skipping Mutation	Sensitivity/Response
2090	civic	Crizotinib	Lung Non-small Cell Carcinoma	MET	Exon 14 Skipping Mutation	Sensitivity/Response
2091	civic	Trastuzumab Deruxtecan	Stomach Cancer	ERBB2	Amplification	Sensitivity/Response
2092	civic	Dasatinib,Imatinib	B-lymphoblastic Leukemia/lymphoma	ABL1	SNX2::ABL1	Resistance
2093	civic	Dabrafenib,Trametinib	Melanoma	BRAF	Amplification	Resistance
2094	civic	Cabozantinib	Thyroid Gland Medullary Carcinoma	RET	M918T	Sensitivity/Response
2095	civic	Temozolomide,Olaparib	Glioblastoma	BRCA2	K3326*	Sensitivity/Response
2096	civic	Gilteritinib	Acute Myeloid Leukemia	FLT3	Mutation	Sensitivity/Response
2097	civic	Trametinib	Pancreatic Cancer	BRAF	N486_P490del	Sensitivity/Response
2098	civic	Trametinib	Cancer	BRAF	D594G	Sensitivity/Response
2099	civic	Trametinib	Transitional Cell Carcinoma	BRAF	NRF1::BRAF	Sensitivity/Response
2100	civic	Axitinib	Chronic Myeloid Leukemia	ABL1	BCR::ABL T315V	Sensitivity/Response
2101	civic	Axitinib	Chronic Myeloid Leukemia	ABL1	BCR::ABL V299L	Sensitivity/Response
2102	civic	Axitinib	Chronic Myeloid Leukemia	ABL1	BCR::ABL T315A	Sensitivity/Response
2103	civic	Axitinib	Chronic Myeloid Leukemia	ABL1	BCR::ABL H396P	Resistance
2104	civic	Axitinib	Chronic Myeloid Leukemia	ABL1	BCR::ABL M244V	Resistance
2105	civic	Axitinib	Chronic Myeloid Leukemia	ABL1	BCR::ABL E279K	Sensitivity/Response
2106	civic	Axitinib	Chronic Myeloid Leukemia	ABL1	BCR::ABL E292L	Resistance
2107	civic	Axitinib	Chronic Myeloid Leukemia	ABL1	BCR::ABL F317R	Resistance
2108	civic	Axitinib	Chronic Myeloid Leukemia	ABL1	BCR::ABL L248R and F359I	Resistance
2109	civic	Axitinib	Chronic Myeloid Leukemia	ABL1	BCR::ABL L248R	Resistance
2110	civic	Ponatinib,Dasatinib	Chronic Myeloid Leukemia	ABL1	BCR::ABL E255K V299L	Sensitivity/Response
2111	civic	Imatinib	B-lymphoblastic Leukemia/lymphoma	ABL1	RCSD1::ABL1	Sensitivity/Response
2112	civic	Leucovorin,Fluorouracil	Head And Neck Squamous Cell Carcinoma	DPYD	EXON 11-19 DELETION	Sensitivity/Response
2113	civic	Crizotinib	Lung Non-small Cell Carcinoma	MET	MET::ATXN7L1	Sensitivity/Response
2114	civic	Crizotinib	Histiocytic And Dendritic Cell Cancer	MET	Exon 14 Skipping Mutation	Sensitivity/Response
2115	civic	Capmatinib	Cancer	MET	Exon 14 Skipping Mutation	Sensitivity/Response
2116	civic	Ribociclib,Dexamethasone	Childhood B-cell Acute Lymphoblastic Leukemia	CDK4	EXPRESSION	Sensitivity/Response
2117	civic	Palbociclib	Glioblastoma Proneural Subtype	CDK6	Overexpression	Sensitivity/Response
2118	civic	Ribociclib,Dexamethasone	Childhood B-cell Acute Lymphoblastic Leukemia	CDK6	EXPRESSION	Sensitivity/Response
2119	civic	Afatinib	Colorectal Cancer	ERBB2	Amplification	Sensitivity/Response
2120	civic	Pazopanib	Adenosquamous Lung Carcinoma	FGFR1	Amplification	Sensitivity/Response
2121	civic	Thioguanine,Mercaptopurine	Childhood Acute Lymphocytic Leukemia	NT5C2	R367Q	Resistance
2122	civic	Thioguanine,Mercaptopurine	Childhood Acute Lymphocytic Leukemia	NT5C2	R238W	Resistance
2123	civic	Mercaptopurine,Thioguanine	Childhood Acute Lymphocytic Leukemia	NT5C2	S445F	Resistance
2124	civic	Doxorubicin,Cytarabine,Prednisolone,Gemcitabine	Childhood Acute Lymphocytic Leukemia	NT5C2	R367Q	Resistance
2125	civic	Prednisolone,Doxorubicin,Cytarabine,Gemcitabine	Childhood Acute Lymphocytic Leukemia	NT5C2	R238W	Resistance
2126	civic	Prednisolone,Cytarabine,Doxorubicin,Gemcitabine	Childhood Acute Lymphocytic Leukemia	NT5C2	S445F	Resistance
2127	civic	Imatinib	Chronic Myeloid Leukemia	ABL1	BCR::ABL D363G	Resistance
2128	civic	Imatinib	Chronic Myeloid Leukemia	ABL1	BCR::ABL E98G	Resistance
2129	civic	Dasatinib	Chronic Myeloid Leukemia	ABL1	BCR::ABL H396R	Resistance
2130	civic	Imatinib	Chronic Myeloid Leukemia	ABL1	BCR::ABL M244V	Resistance
2131	civic	Imatinib	Chronic Myeloid Leukemia	ABL1	BCR::ABL L364I	Resistance
2132	civic	Pazopanib	Head And Neck Squamous Cell Carcinoma	FGFR2	P253R	Sensitivity/Response
2133	civic	Nilotinib,Dasatinib,Bafetinib	Chronic Myeloid Leukemia	ABL1	BCR::ABL	Sensitivity/Response
2134	civic	Nilotinib,Bafetinib	Cancer	ABL1	BCR::ABL T315A	Resistance
2135	civic	Imatinib,Dasatinib	Cancer	ABL1	BCR::ABL T315A	Resistance
2136	civic	Nilotinib,Bafetinib	Cancer	ABL1	BCR::ABL H396P	Resistance
2137	civic	Imatinib	Cancer	ABL1	BCR::ABL H396P	Resistance
2138	civic	Imatinib	Cancer	ABL1	BCR::ABL Y253F	Resistance
2139	civic	Imatinib,Bafetinib	Cancer	ABL1	BCR::ABL Q252H	Resistance
2140	civic	Bafetinib,Imatinib	Cancer	ABL1	BCR::ABL M244V	Resistance
2141	civic	Ruxolitinib	Sarcoma	JAK1	OVEREXPRESSION	Sensitivity/Response
2142	civic	Trametinib	Solid Tumor	BRAF	Non-V600	Sensitivity/Response
2143	civic	Mercaptopurine,Thioguanine	Childhood Acute Lymphocytic Leukemia	NT5C2	R367Q	Resistance
2144	civic	Dasatinib,Bafetinib	Chronic Myeloid Leukemia	LYN	OVEREXPRESSION	Resistance
2145	civic	Nilotinib	Chronic Myeloid Leukemia	LYN	OVEREXPRESSION	Resistance
2146	civic	Mercaptopurine,Thioguanine	B-lymphoblastic Leukemia/lymphoma	PRPS1	T303S	Resistance
2147	civic	Mercaptopurine,Thioguanine	B-lymphoblastic Leukemia/lymphoma	PRPS1	L191F	Resistance
2148	civic	Mercaptopurine,Thioguanine	B-lymphoblastic Leukemia/lymphoma	PRPS1	D183E	Resistance
2149	civic	Thioguanine,Mercaptopurine	B-lymphoblastic Leukemia/lymphoma	PRPS1	K176N	Resistance
2150	civic	Thioguanine,Mercaptopurine	B-lymphoblastic Leukemia/lymphoma	PRPS1	N144S	Resistance
2151	civic	Thioguanine,Mercaptopurine	B-lymphoblastic Leukemia/lymphoma	PRPS1	S103I	Resistance
2152	civic	Thioguanine,Mercaptopurine	B-lymphoblastic Leukemia/lymphoma	PRPS1	S103N	Resistance
2153	civic	Thioguanine,Mercaptopurine	B-lymphoblastic Leukemia/lymphoma	PRPS1	S103T	Resistance
2154	civic	Thioguanine,Mercaptopurine	B-lymphoblastic Leukemia/lymphoma	PRPS1	A190T	Resistance
2155	civic	Cytarabine	B-lymphoblastic Leukemia/lymphoma	PRPS1	N144S	Sensitivity/Response
2156	civic	Cytarabine	B-lymphoblastic Leukemia/lymphoma	PRPS1	L191F	Sensitivity/Response
2157	civic	Mercaptopurine,Lometrexol	B-lymphoblastic Leukemia/lymphoma	PRPS1	A190T	Sensitivity/Response
2158	civic	Thioguanine,Mercaptopurine	B-lymphoblastic Leukemia/lymphoma	PRPS1	D139G	Resistance
2159	civic	Thioguanine,Mercaptopurine	B-lymphoblastic Leukemia/lymphoma	PRPS1	C77S	Resistance
2160	civic	Mercaptopurine,Thioguanine	B-lymphoblastic Leukemia/lymphoma	PRPS1	I72V	Resistance
2161	civic	Mercaptopurine,Thioguanine	B-lymphoblastic Leukemia/lymphoma	PRPS1	V53A	Resistance
2162	civic	Mercaptopurine,Thioguanine	B-lymphoblastic Leukemia/lymphoma	PRPS1	A87T	Resistance
2163	civic	Thioguanine,Mercaptopurine	B-lymphoblastic Leukemia/lymphoma	PRPS1	M115T	Resistance
2164	civic	Methotrexate,Asparaginase,Daunorubicin	B-lymphoblastic Leukemia/lymphoma	PRPS1	L191F	Resistance
2165	civic	Daunorubicin,Methotrexate,Asparaginase,Cytarabine	B-lymphoblastic Leukemia/lymphoma	PRPS1	S103T	Resistance
2166	civic	Asparaginase,Methotrexate,Cytarabine,Daunorubicin	B-lymphoblastic Leukemia/lymphoma	PRPS1	S103N	Resistance
2167	civic	Asparaginase,Cytarabine,Methotrexate,Daunorubicin	B-lymphoblastic Leukemia/lymphoma	PRPS1	K176N	Resistance
2168	civic	Methotrexate,Asparaginase,Daunorubicin,Cytarabine	B-lymphoblastic Leukemia/lymphoma	PRPS1	D183E	Resistance
2169	civic	Methotrexate,Daunorubicin,Cytarabine,Asparaginase	B-lymphoblastic Leukemia/lymphoma	PRPS1	A190T	Resistance
2170	civic	Asparaginase,Cytarabine,Methotrexate,Daunorubicin	B-lymphoblastic Leukemia/lymphoma	PRPS1	T303S	Resistance
2171	civic	Daunorubicin,Methotrexate,Asparaginase	B-lymphoblastic Leukemia/lymphoma	PRPS1	N144S	Resistance
2172	civic	Crizotinib	Lung Non-small Cell Carcinoma	ROS1	Rearrangement	Sensitivity/Response
2173	civic	Dasatinib	Chronic Myeloid Leukemia	ABL1	BCR::ABL E450Q	Resistance
2174	civic	Dasatinib	Chronic Myeloid Leukemia	ABL1	BCR::ABL M244V and L364I	Resistance
2175	civic	Dasatinib	Chronic Myeloid Leukemia	ABL1	BCR::ABL N146S	Resistance
2176	civic	Dasatinib	Chronic Myeloid Leukemia	ABL1	BCR::ABL V298I	Resistance
2177	civic	Dasatinib	Chronic Myeloid Leukemia	ABL1	BCR::ABL S438C	Resistance
2178	civic	Dasatinib	Chronic Myeloid Leukemia	ABL1	BCR::ABL M388L	Resistance
2179	civic	Bazedoxifene	Rhabdomyosarcoma	IL6	Overexpression	Resistance
2180	civic	Sunitinib	Rhabdomyosarcoma	PDGFRA	Overexpression	Sensitivity/Response
2181	civic	Imatinib	B-cell Acute Lymphoblastic Leukemia	PDGFRA	BCR::PDGFRA	Sensitivity/Response
2182	civic	Sunitinib	Dermatofibrosarcoma Protuberans	PDGFB	COL1A1::PDGFB	Sensitivity/Response
2183	civic	Sunitinib	Dermatofibrosarcoma Protuberans	PDGFRB	Overexpression	Sensitivity/Response
2184	civic	Larotrectinib	B-lymphoblastic Leukemia/lymphoma	NTRK3	ETV6::NTRK3	Sensitivity/Response
2185	civic	Entrectinib	Acute Myeloid Leukemia	NTRK3	ETV6::NTRK3	Sensitivity/Response
2186	civic	Dasatinib	Chronic Myeloid Leukemia	ABL1	BCR::ABL F359V	Resistance
2187	civic	PI-103	Breast Cancer	PIK3CA	E542K	Resistance
2188	civic	PI-103	Breast Cancer	PIK3CA	E545K	Resistance
2189	civic	PI-103	Breast Cancer	PIK3CA	H1047L	Sensitivity/Response
2190	civic	PI-103	Her2-receptor Positive Breast Cancer	PIK3CA	K111N	Sensitivity/Response
2191	civic	PI-103	Her2-receptor Positive Breast Cancer	PTEN	Loss	Sensitivity/Response
2192	civic	PI3Ka/Di	Her2-receptor Positive Breast Cancer	PIK3CA	E542K	Sensitivity/Response
2193	civic	PI3Ka/Di	Breast Cancer	PIK3CA	E542K	Sensitivity/Response
2194	civic	PI3Ka/Di	Her2-receptor Positive Breast Cancer	PIK3CA	E545K	Sensitivity/Response
2195	civic	PI3Ka/Di	Breast Cancer	PIK3CA	E545K	Sensitivity/Response
2196	civic	PI3Ka/Di	Breast Cancer	PIK3CA	H1047L	Sensitivity/Response
2197	civic	PI3Ka/Di	Her2-receptor Positive Breast Cancer	PIK3CA	K111N	Sensitivity/Response
2198	civic	PI3Ka/Di	Her2-receptor Positive Breast Cancer	PTEN	Loss	Resistance
2199	civic	Cetuximab	Colorectal Cancer	PIK3CA	V955I	Resistance
2200	civic	Imatinib	Chronic Myeloid Leukemia	ABL1	BCR::ABL E355G	Resistance
2201	civic	Imatinib	Chronic Myeloid Leukemia	ABL1	BCR::ABL F486S	Resistance
2202	civic	Imatinib	Chronic Myeloid Leukemia	ABL1	BCR::ABL E459K	Resistance
2203	civic	Imatinib	Chronic Myeloid Leukemia	ABL1	Double Ph	Resistance
2204	civic	Imatinib	Chronic Myeloid Leukemia	ABL1	P-Loop Mutation	Resistance
2205	civic	Gilteritinib	Cancer	FLT3	D835Y	Sensitivity/Response
2206	civic	Gilteritinib	Acute Myeloid Leukemia	FLT3	D835Y	Sensitivity/Response
2207	civic	Cisplatin,Radiation Ionizing Radiotherapy	Cervical Cancer	PIK3CA	E545K	Resistance
2208	civic	Arsenic Trioxide	Acute Promyelocytic Leukemia	PML	PML::RARA A216V	Resistance
2209	civic	Lapatinib,Trastuzumab,Dactolisib	Her2-receptor Positive Breast Cancer	PIK3CA	K111N	Resistance
2210	civic	Venetoclax	Chronic Lymphocytic Leukemia/small Lymphocytic Lymphoma	BCL2	G101V	Resistance
2211	civic	Imatinib,Chemotherapy	B-lymphoblastic Leukemia/lymphoma, BCR-ABL1–like	PDGFRB	EBF1::PDGFRB	Sensitivity/Response
2212	civic	Trastuzumab	Her2-receptor Positive Breast Cancer	PIK3CA	Amplification	Resistance
2213	civic	Dactolisib,Lapatinib	Her2-receptor Positive Breast Cancer	PIK3CA	Amplification	Sensitivity/Response
2214	civic	Trastuzumab	Her2-receptor Positive Breast Cancer	PTEN	Loss	Resistance
2215	civic	Lapatinib	Her2-receptor Positive Breast Cancer	PTEN	Loss	Resistance
2216	civic	Dactolisib	Her2-receptor Positive Breast Cancer	PTEN	Loss	Resistance
2217	civic	Dactolisib,Lapatinib	Her2-receptor Positive Breast Cancer	PTEN	Loss	Resistance
2218	civic	Trastuzumab,Dactolisib	Her2-receptor Positive Breast Cancer	PTEN	Loss	Resistance
2219	civic	R3Mab	Cancer	FGFR3	R248C	Resistance
2220	civic	FLT3/ABL/Aurora Kinase Inhibitor KW-2449	Acute Myeloid Leukemia	FLT3	Y842C	Resistance
2221	civic	Sorafenib	Acute Myeloid Leukemia	FLT3	Y842C	Resistance
2222	civic	Sunitinib	Acute Myeloid Leukemia	FLT3	Y842C	Resistance
2223	civic	Lestaurtinib	Acute Myeloid Leukemia	FLT3	Y842C	Sensitivity/Response
2224	civic	Midostaurin	Acute Myeloid Leukemia	FLT3	Y842C	Sensitivity/Response
2225	civic	Lestaurtinib	Acute Myeloid Leukemia	FLT3	F691L	Resistance
2226	civic	Midostaurin	Acute Myeloid Leukemia	FLT3	F691L	Resistance
2227	civic	Gilteritinib	Acute Myeloid Leukemia	FLT3	D835I	Sensitivity/Response
2228	civic	Vemurafenib,Akt Inhibitor MK2206	Colorectal Cancer	PIK3CA	H1047R	Sensitivity/Response
2229	civic	Vemurafenib	Colorectal Cancer	KRAS	Exon 2 Mutation	Sensitivity/Response
2230	civic	Venetoclax	Follicular Lymphoma	BCL2	F104I	Resistance
2231	civic	Venetoclax	Follicular Lymphoma	BCL2	F104I	Resistance
2232	civic	Olaparib	Prostate Carcinoma	PALB2	Mutation	Sensitivity/Response
2233	civic	Olaparib	Prostate Carcinoma	ATM	Mutation	Sensitivity/Response
2234	civic	Irinotecan,Vemurafenib,Cetuximab	Colorectal Cancer	BRAF	V600E	Sensitivity/Response
2235	civic	Erlotinib,Vemurafenib	Colorectal Cancer	BRAF	V600E	Sensitivity/Response
2236	civic	Imatinib	Chronic Myeloid Leukemia	ABL1	BCR::ABL Y253F	Resistance
2237	civic	Gilteritinib	Acute Myeloid Leukemia	FLT3	D835H	Sensitivity/Response
2238	civic	Gilteritinib	Acute Myeloid Leukemia	FLT3	D835V	Sensitivity/Response
2239	civic	Trastuzumab Emtansine	Her2-receptor Positive Breast Cancer	PIK3CA	Mutation	Resistance
2240	civic	Trastuzumab	Her2-receptor Positive Breast Cancer	PIK3CA	E545K	Resistance
2241	civic	Trastuzumab	Her2-receptor Positive Breast Cancer	PIK3CA	H1047R	Resistance
2242	civic	Trastuzumab	Her2-receptor Positive Breast Cancer	PIK3CA	C420R	Resistance
2243	civic	Cisplatin	Transitional Cell Carcinoma	FGFR3	S249C	Resistance
2244	civic	Quizartinib	Acute Myeloid Leukemia	FLT3	Y842C	Resistance
2245	civic	Alectinib	Lung Non-small Cell Carcinoma	ALK	Fusion	Sensitivity/Response
2246	civic	Trastuzumab	Her2-receptor Positive Breast Cancer	PIK3CA	K111N	Resistance
2247	civic	Trastuzumab	Her2-receptor Positive Breast Cancer	PIK3CA	I391M	Resistance
2248	civic	Lapatinib,Capecitabine	Her2-receptor Positive Breast Cancer	PIK3CA	Mutation	Resistance
2249	civic	Trastuzumab Emtansine	Her2-receptor Positive Breast Cancer	PTEN	Loss	Resistance
2250	civic	Trastuzumab Emtansine	Her2-receptor Positive Breast Cancer	ERBB3	Overexpression	Resistance
2251	civic	Binimetinib	Ovary Serous Adenocarcinoma	KRAS	Mutation	Sensitivity/Response
2252	civic	Regorafenib	Colorectal Cancer	KRAS	Wildtype	Resistance
2253	civic	Venetoclax	Chronic Lymphocytic Leukemia	BCL2	G101V	Resistance
2254	civic	Olaparib	Prostate Cancer	BRCA2	Mutation	Sensitivity/Response
2255	civic	Capmatinib	Lung Non-small Cell Carcinoma	MET	Exon 14 Skipping Mutation	Sensitivity/Response
2256	civic	Selpercatinib	Lung Non-small Cell Carcinoma	RET	Fusion	Sensitivity/Response
2257	civic	Selpercatinib	Thyroid Gland Medullary Carcinoma	RET	Mutation	Sensitivity/Response
2258	civic	Selpercatinib	Thyroid Gland Cancer	RET	Fusion	Sensitivity/Response
2259	civic	Venetoclax	Acute Myeloid Leukemia	IDH1	Mutation	Sensitivity/Response
2260	civic	Venetoclax	Acute Myeloid Leukemia	IDH2	Mutation	Sensitivity/Response
2261	civic	Larotrectinib	Congenital Fibrosarcoma	NTRK1	SQSTM1::NTRK1	Sensitivity/Response
2262	civic	Crizotinib	Congenital Fibrosarcoma	NTRK1	LMNA::NTRK1	Sensitivity/Response
2263	civic	Entrectinib	Colorectal Cancer	NTRK1	LMNA::NTRK1	Sensitivity/Response
2264	civic	Etoposide,Larotrectinib,Methotrexate	B-lymphoblastic Leukemia/lymphoma	NTRK3	ETV6::NTRK3	Sensitivity/Response
2265	civic	Gilteritinib	Acute Myeloid Leukemia	FLT3	ITD	Sensitivity/Response
2266	civic	Gilteritinib	Acute Myeloid Leukemia	FLT3	ITD	Sensitivity/Response
2267	civic	Larotrectinib	B-lymphoblastic Leukemia/lymphoma	NTRK3	ETV6::NTRK3	Sensitivity/Response
2268	civic	Trametinib	Ovary Serous Adenocarcinoma	NRAS	Q61K	Sensitivity/Response
2269	civic	Selumetinib	Childhood Pilocytic Astrocytoma	BRAF	KIAA1549::BRAF	Sensitivity/Response
2270	civic	Trametinib	Childhood Pilocytic Astrocytoma	BRAF	KIAA1549::BRAF	Sensitivity/Response
2271	civic	Vemurafenib	Thyroid Gland Papillary Carcinoma	BRAF	V600E	Sensitivity/Response
2272	civic	Dasatinib	Cancer	ABL1	BCR::ABL H396P	Sensitivity/Response
2273	civic	Ponatinib,Imatinib,Nilotinib,Dasatinib	B-lymphoblastic Leukemia/lymphoma	ABL1	NUP214::ABL1	Sensitivity/Response
2274	civic	Imatinib,Dasatinib	B-lymphoblastic Leukemia/lymphoma	ABL1	SFPQ::ABL1	Sensitivity/Response
2275	civic	Dasatinib	B-lymphoblastic Leukemia/lymphoma	ABL1	RCSD1::ABL1	Sensitivity/Response
2276	civic	Dasatinib	B-lymphoblastic Leukemia/lymphoma	ABL1	RCSD1::ABL1	Sensitivity/Response
2277	civic	Dasatinib	B-lymphoblastic Leukemia/lymphoma	ABL1	RCSD1::ABL1	Reduced Sensitivity
2278	civic	Dasatinib	B-lymphoblastic Leukemia/lymphoma	ABL1	RCSD1::ABL1	Sensitivity/Response
2279	civic	Tyrosine Kinase Inhibitor	B-lymphoblastic Leukemia/lymphoma, BCR-ABL1–like	ABL1	RCSD1::ABL1	Sensitivity/Response
2280	civic	Imatinib	B-lymphoblastic Leukemia/lymphoma	ABL1	ETV6::ABL1	Sensitivity/Response
2281	civic	Dasatinib	B-lymphoblastic Leukemia/lymphoma, BCR-ABL1–like	ABL1	RANBP2::ABL1	Sensitivity/Response
2282	civic	Ponatinib	B-lymphoblastic Leukemia/lymphoma	ABL1	RCSD1::ABL1	Sensitivity/Response
2283	civic	Osimertinib	Lung Non-small Cell Carcinoma	EGFR	A767_V769dupASV	Sensitivity/Response
2284	civic	Osimertinib	Lung Non-small Cell Carcinoma	EGFR	N771_P772insL	Sensitivity/Response
2285	civic	Osimertinib	Lung Non-small Cell Carcinoma	EGFR	D770_N771insG	Sensitivity/Response
2286	civic	Osimertinib	Lung Non-small Cell Carcinoma	EGFR	S768_D770dup	Sensitivity/Response
2287	civic	Osimertinib	Lung Non-small Cell Carcinoma	EGFR	A763_Y764insFQEA	Sensitivity/Response
2288	civic	Alectinib	Malignant Pleural Mesothelioma	ALK	EML4::ALK	Sensitivity/Response
2289	civic	Fluorouracil,Cisplatin	Cancer	ATRX	Deletion	Sensitivity/Response
2290	civic	Axitinib,Dovitinib,Lenvatinib,Cabozantinib	Colorectal Cancer	KDR	R1032Q	Sensitivity/Response
2291	civic	Imatinib	B-lymphoblastic Leukemia/lymphoma, BCR-ABL1–like	CSF1R	MEF2D::CSF1R	Sensitivity/Response
2292	civic	Tazemetostat	Diffuse Large B-cell Lymphoma	EZH2	Y646H	Sensitivity/Response
2293	civic	Ceritinib	Neuroblastoma	ALK	I1171T	Sensitivity/Response
2294	civic	Sotorasib	Lung Non-small Cell Carcinoma	KRAS	G12C	Sensitivity/Response
2295	civic	Larotrectinib	Gastrointestinal Stromal Tumor	NTRK3	F617L	Resistance
2296	civic	Tipifarnib	Bladder Urothelial Carcinoma	HRAS	Mutation	Sensitivity/Response
2297	civic	Tipifarnib	Head And Neck Squamous Cell Carcinoma	HRAS	Mutation	Sensitivity/Response
2298	civic	Lapatinib	Cancer	ERBB2	V777L	Sensitivity/Response
2299	civic	Tazemetostat	Follicular Lymphoma	EZH2	Activating Mutation	Sensitivity/Response
2300	civic	Lapatinib	Childhood Ependymoma	ERBB2	Amplification	Sensitivity/Response
2301	civic	Encorafenib,Cetuximab	Colorectal Cancer	BRAF	V600E	Sensitivity/Response
2302	civic	Ibrutinib	Diffuse Large B-cell Lymphoma Activated B-cell Type	PIM1	L2V	Resistance
2303	civic	Ibrutinib	Diffuse Large B-cell Lymphoma Activated B-cell Type	PIM1	P81S	Resistance
2304	civic	Ibrutinib	Diffuse Large B-cell Lymphoma Activated B-cell Type	PIM1	S97N	Resistance
2305	civic	Lorlatinib,Alectinib	Lung Non-small Cell Carcinoma	ABCB1	Overexpression	Resistance
2306	civic	Cetuximab	Colorectal Cancer	PIK3CA	K944N	Resistance
2307	civic	Cetuximab	Colorectal Cancer	PIK3CA	F930S	Resistance
2308	civic	Cetuximab	Colorectal Cancer	PIK3CA	V955G	Resistance
2309	civic	Cetuximab	Colorectal Cancer	PIK3CA	K966E	Resistance
2310	civic	Cetuximab	Colorectal Cancer	PIK3CA	L938*	Resistance
2311	civic	Erlotinib	Cancer	EGFR	G598V	Sensitivity/Response
2312	civic	Entrectinib	Cancer	NTRK1	TPM3::NTRK1	Sensitivity/Response
2313	civic	Entrectinib	Cancer	NTRK1	LMNA::NTRK1	Sensitivity/Response
2314	civic	Entrectinib	Cancer	NTRK1	ETV6::NTRK1	Sensitivity/Response
2315	civic	Entrectinib	Cancer	NTRK2	VCL::NTRK2	Sensitivity/Response
2316	civic	Entrectinib	Cancer	NTRK2	AFAP1::NTRK2	Sensitivity/Response
2317	civic	Entrectinib	Cancer	NTRK2	ETV6::NTRK2	Sensitivity/Response
2318	civic	Everolimus	Renal Cell Carcinoma	FLCN	c.1285dupC	Sensitivity/Response
2319	civic	Exemestane,Metformin	Breast Cancer	IGF1R	Overexpression	Sensitivity/Response
2320	civic	Etoposide,Olaparib	Leukemia	SF3B1	K700E	Sensitivity/Response
2321	civic	Trastuzumab Deruxtecan	Lung Non-small Cell Carcinoma	ERBB2	Exon 20 Insertion	Sensitivity/Response
2322	civic	Gemcitabine,Carboplatin	Lung Non-small Cell Carcinoma	ERCC1	Underexpression	Sensitivity/Response
2323	civic	Gemcitabine,Carboplatin	Lung Non-small Cell Carcinoma	RRM1	Underexpression	Sensitivity/Response
2324	civic	Olaparib	Cancer	IDH1	R132C	Sensitivity/Response
2325	civic	Gemcitabine	Pancreatic Adenocarcinoma	SLC29A1	Overexpression	Sensitivity/Response
2326	civic	Platinum Compound	Ovary Epithelial Cancer	ERCC1	Underexpression	Sensitivity/Response
2327	civic	Larotrectinib	Solid Tumor	NTRK1	Amplification	Sensitivity/Response
2328	civic	Sunitinib	Glioblastoma	KIT	EXPRESSION	Sensitivity/Response
2329	civic	Pasireotide	Neuroendocrine Tumor	SSTR5	expression	Sensitivity/Response
2330	civic	Pemigatinib	Pilocytic Astrocytoma	FGFR1	N546K	Sensitivity/Response
2331	civic	Trametinib	Spindle Cell Sarcoma	RAF1	QKI-RAF1	Sensitivity/Response
2332	civic	Alectinib	Pancreatic Acinar Cell Adenocarcinoma	ALK	KANK4::ALK	Sensitivity/Response
2333	civic	R3Mab	Cancer	FGFR3	Overexpression	Sensitivity/Response
2334	civic	R3Mab	Cancer	FGFR3	G370C	Resistance
2335	civic	R3Mab	Cancer	FGFR3	Y373C	Resistance
2336	civic	R3Mab	Cancer	FGFR3	K650E	Resistance
2337	civic	Larotrectinib	Anaplastic Ependymoma	NTRK2	KANK1::NTRK2	Sensitivity/Response
2338	civic	Larotrectinib	Glioblastoma	NTRK2	KANK1::NTRK2	Sensitivity/Response
2339	civic	R-CHOP Regimen	Diffuse Large B-cell Lymphoma	MS4A1	Mutation	Resistance
2340	civic	Larotrectinib	Solid Tumor	NTRK2	Fusion	Sensitivity/Response
2341	civic	Entrectinib	Thyroid Gland Papillary Carcinoma	NTRK3	EML4::NTRK3	Sensitivity/Response
2342	civic	Entrectinib	Lung Non-small Cell Carcinoma	NTRK3	EML4::NTRK3	Sensitivity/Response
2343	civic	Larotrectinib	Congenital Mesoblastic Nephroma	NTRK3	ETV6::NTRK3	Sensitivity/Response
2344	civic	Ivosidenib	Cholangiocarcinoma	IDH1	R132	Sensitivity/Response
2345	civic	Erlotinib	Lung Adenocarcinoma	EGFR	EGFR::RAD51	Sensitivity/Response
2346	civic	Osimertinib	Lung Adenocarcinoma	EGFR	EGFR::RAD51	Sensitivity/Response
2347	civic	Afatinib	Lung Adenocarcinoma	EGFR	KIF5B::EGFR	Sensitivity/Response
2348	civic	CTX-712	Myeloid Neoplasm	SRSF2	P95L	Sensitivity/Response
2349	civic	CTX-712	Myeloid Neoplasm	SRSF2	P95H	Sensitivity/Response
2350	civic	Entrectinib	Lung Adenocarcinoma	NTRK3	EML4::NTRK3	Sensitivity/Response
2351	civic	Larotrectinib	High Grade Glioma	NTRK3	EML4::NTRK3	Sensitivity/Response
2352	civic	Tazemetostat	Follicular Lymphoma	EZH2	Activating Mutation	Sensitivity/Response
2353	civic	Tazemetostat	Diffuse Large B-cell Lymphoma Germinal Center B-cell Type	EZH2	expression	Sensitivity/Response
2354	civic	Brigatinib	Lung Non-small Cell Carcinoma	ALK	Fusion	Sensitivity/Response
2355	civic	Crizotinib	Inflammatory Myofibroblastic Tumor	ALK	Fusion	Sensitivity/Response
2356	civic	Entrectinib	Lung Non-small Cell Carcinoma	ROS1	FUSIONS	Sensitivity/Response
2357	civic	Entrectinib	Solid Tumor	NTRK1	Fusion	Sensitivity/Response
2358	civic	Entrectinib	Solid Tumor	NTRK3	Fusion	Sensitivity/Response
2359	civic	Rucaparib	Ovarian Cancer	BRCA1	Mutation	Sensitivity/Response
2360	civic	Rucaparib	Ovarian Cancer	BRCA2	Mutation	Sensitivity/Response
2361	civic	Rucaparib	Ovarian Cancer	BRCA1	Mutation	Sensitivity/Response
2362	civic	Rucaparib	Ovarian Cancer	BRCA2	Mutation	Sensitivity/Response
2363	civic	Imatinib Mesylate	Systemic Mastocytosis	KIT	D816V	Sensitivity/Response
2364	civic	Olaparib	Her2-receptor Negative Breast Cancer	BRCA1	Loss-of-function	Sensitivity/Response
2365	civic	Olaparib	Her2-receptor Negative Breast Cancer	BRCA2	Loss-of-function	Sensitivity/Response
2366	civic	Olaparib	Prostate Carcinoma	BRCA1	Mutation	Sensitivity/Response
2367	civic	Olaparib	Prostate Carcinoma	CDK12	Mutation	Sensitivity/Response
2368	civic	Olaparib	Prostate Carcinoma	CHEK2	mutation	Sensitivity/Response
2369	civic	Olaparib	Prostate Carcinoma	PPP2R2A	Mutation	Sensitivity/Response
2370	civic	Olaparib	Prostate Carcinoma	RAD54L	Mutation	Sensitivity/Response
2371	civic	Olaparib	Prostate Carcinoma	BRIP1	Mutation	Sensitivity/Response
2372	civic	Olaparib	Prostate Carcinoma	BARD1	Mutation	Sensitivity/Response
2373	civic	Olaparib	Prostate Carcinoma	CHEK1	Mutation	Sensitivity/Response
2374	civic	Olaparib	Prostate Carcinoma	RAD51B	Mutation	Sensitivity/Response
2375	civic	Olaparib	Prostate Carcinoma	RAD51D	Mutation	Sensitivity/Response
2376	civic	Olaparib	Triple-receptor Negative Breast Cancer	BRCA1	Loss-of-function	Sensitivity/Response
2377	civic	Olaparib	Triple-receptor Negative Breast Cancer	BRCA2	Loss-of-function	Sensitivity/Response
2378	civic	Crizotinib	Anaplastic Large Cell Lymphoma	ALK	Fusion	Sensitivity/Response
2379	civic	Entrectinib	Solid Tumor	NTRK2	Fusion	Sensitivity/Response
2380	civic	Pralsetinib	Lung Non-small Cell Carcinoma	RET	Fusion	Sensitivity/Response
